Method for purifying product

By using chao liquor salt buffer and multi-step removal technology during protein purification, the problem of difficult removal of HCP and viral contaminants is solved, improving the purity of proteins and the safety of biological drugs.

CN119032099APending Publication Date: 2024-11-26KO PHARML
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380033420.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-10
Filing Date
2023-02-09
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively remove host cell proteins (HCPs) and viral contaminants during protein purification, affecting the purity and safety of biological drugs.

Method used

Affinity chromatography was washed with buffer containing chaotropic salt, combined with low pH inactivation, detergent inactivation, virus filtration and ultrafiltration steps, HCP and viral contaminants were removed, and further purified by ion exchange chromatography protein.

Benefits of technology

It significantly reduces the level of protein in host cells, improves the purity and safety of proteins, extends the shelf life of biological drugs, and reduces the risk of complications in patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032099A_ABST
    Figure CN119032099A_ABST
Patent Text Reader

Abstract

Embodiments provided herein relate to affinity chromatography purification and isolation of contaminant species from desired molecules and chemical species, including HCPs (host cell proteins). The product can be produced or processed in a method in which the target product is combined with an affinity chromatography matrix. A protein purification system is also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Sequence Listing

[0002] This application is submitted with a sequence listing in electronic format. The sequence listing is provided as a file titled KDIAK.141WO.xml, created on February 8, 2023, and is 843,266 bytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

[0003] Incorporation by reference to any priority application

[0004] This application claims priority to U.S. Provisional Application No. 63 / 267,810, filed on February 10, 2022.

[0005] Any and all applications claiming foreign or domestic priority identified in the Application Data Sheet filed with the present application are incorporated herein by reference pursuant to 37 CFR 1.57. Technical Field

[0006] The present disclosure relates to methods of purifying antibodies and other cellular products. Background Art

[0007] The unit operations involved in processing and purifying molecular species from cell culture include preferential separation of desired and undesired molecular species. Specifically, chromatography and protein A chromatography can preferentially separate certain species based on various molecular binding interactions compared to any given wash or flow-through buffer solution. Optimization of the unit operations in this step can increase the overall purity and percent yield of the desired molecular species while reducing impurities. Summary of the invention

[0008] Provided herein are methods for purifying a product by administering a chaotropic agent.

[0009] Some embodiments provided herein allow to improve product purity and composition by providing a new purification method in the processing steps involved in product purification. In some embodiments, the product can be a protein product. In some embodiments, purification includes chromatography. In some embodiments, chromatography can be protein A or protein G. In some embodiments, chaotropic agents can include one or more of lithium and lithium salts, magnesium and magnesium salts, calcium and calcium salts, and guanidine and guanidine salts.

[0010] Provided herein are methods for purifying protein products using affinity chromatography. Some embodiments provided herein allow for overcoming certain limitations in the prior art by providing new methods for purifying protein products after harvesting cell cultures. In some embodiments, the protein product is an antibody. In some embodiments, the protein product is an anti-VEGF antibody. In some embodiments, the anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate (e.g., KSI-301, KSI-501) or an anti-VEGF protein conjugate comprising a polymer portion that, when administered to a subject, can extend the half-life of the antibody or protein (e.g., ocular half-life, etc.). In some embodiments, provided herein are buffer compositions that can be used to purify protein products.

[0011] In some embodiments, provided herein is a method for purifying a product and reducing impurities from a load fluid comprising a protein and one or more impurities by passing the load fluid through an affinity chromatography matrix, followed by at least one wash solution comprising a chaotropic salt, and collecting the protein using an elution solution.

[0012] In some embodiments, provided herein is a method for separating impurities in an eluate containing a target protein, the method comprising loading the eluate containing the target protein onto an affinity chromatography matrix; and washing the affinity chromatography matrix with one or more buffer solutions, the buffer solution comprising one or more of lithium and lithium salts, magnesium and magnesium salts, calcium and calcium salts, and guanidine and guanidine salts.

[0013] In some embodiments, the present invention provides a method for producing a product using affinity chromatography. The method includes loading an eluate containing a target protein onto an affinity chromatography matrix, then washing the affinity chromatography matrix with a first buffer comprising sodium phosphate and salt, and then washing the affinity chromatography matrix with a second buffer comprising a chaotropic agent.

[0014] In some embodiments, a method for producing a product using affinity chromatography is provided herein. The method comprises loading an eluate containing a target protein onto an affinity chromatography matrix, performing a first wash with a first buffer containing Tris and a salt, and performing a second wash with a second buffer containing Tris and a chaotropic agent, wherein the second buffer chaotropic agent contains a different salt than the first buffer.

[0015] In some embodiments, a method for producing a product is provided herein. The method includes collecting a loading fluid, wherein the loading fluid comprises a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting the bound target protein; and collecting an eluate, wherein the eluate contains the target protein.

[0016] In some embodiments, a method for producing a product is provided herein. The method includes collecting a loading fluid, wherein the loading fluid comprises a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, supplying a buffer solution comprising a chaotropic salt to the affinity chromatography matrix, eluting the bound target protein; and collecting an eluate, wherein the eluate contains the target protein.

[0017] In some embodiments, provided herein is a method of producing a product, the method comprising collecting a conjugated protein, wherein the conjugated protein comprises an antibody bound to a conjugated polymer, loading the conjugated protein onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the conjugated protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting the conjugated protein, and collecting an eluate, wherein the eluate contains the conjugated protein.

[0018] In some embodiments, a method for producing a product is provided herein, the method comprising washing an affinity chromatography matrix bound to a target protein of interest with a buffer comprising a chaotropic salt, then eluting and collecting an eluate, wherein the eluate contains the target protein of interest, and removing viral contaminants from the eluate. In some embodiments of the methods provided herein, removing viral contaminants from the eluate comprises one or more of low pH inactivation, detergent inactivation, polishing chromatography steps, virus filtration (VF), ultrafiltration (UF) and / or diafiltration (DF).

[0019] In some embodiments of the methods provided herein, a method for producing a product is provided, the method comprising washing an affinity chromatography matrix bound to a target protein of interest with a buffer comprising a chaotropic salt, removing the chaotropic salt, eluting and collecting an eluate, wherein the eluate contains the target protein of interest. In some embodiments of the methods provided herein, the eluate is further combined with an acceptable pharmaceutical excipient to form a pharmaceutical composition. In some embodiments of the methods provided herein, a buffer solution is added to the pharmaceutical composition. In some embodiments of the methods provided herein, a preservative solution is added to the pharmaceutical composition. In some embodiments of the methods provided herein, the pharmaceutical composition is further refined for intravitreal injection.

[0020] In some embodiments, a method of treating a product is provided herein. The method includes loading an eluate onto an affinity chromatography matrix. The method also includes washing with a wash buffer comprising a chaotropic salt to collect the eluate, wherein the concentration of the chaotropic salt is increased from a first concentration to a second concentration, wherein the eluate is collected in at least one fraction, wherein the at least one fraction comprises the product of interest.

[0021] In some embodiments, provided herein is a method for producing a product, the method comprising collecting a load fluid, wherein the load fluid comprises a target protein, loading the load fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting and collecting an eluate, wherein the eluate contains the target protein of interest, and removing viral contaminants from the eluate.

[0022] In some embodiments, a method for producing a product is provided herein, the method comprising loading the eluate onto an affinity chromatography matrix, washing with a first wash buffer, washing with a second wash buffer comprising a chaotropic salt, washing with a third wash buffer, wherein the third wash buffer removes the chaotropic salt, eluting with an elution buffer, wherein the eluate is collected, wherein the eluate comprises a protein product. In some embodiments, the first wash buffer comprises 50mM sodium phosphate. In some embodiments, the first wash buffer further comprises 250mM NaCl. In some embodiments, a method is provided herein, wherein the first wash buffer comprises Tris and salt. In some embodiments, a method is provided herein, the method further comprising removing viral contaminants from the eluate.

[0023] In some embodiments, a method is provided herein, wherein the removal of viral contaminants includes one or more of low pH inactivation, detergent inactivation, polishing chromatography steps, virus filtration (VF), ultrafiltration (UF) or diafiltration (DF). In some embodiments, the eluent comprises a protein of interest. In some embodiments, the protein of interest is an antibody. In some embodiments, the antibody is further conjugated to a polymer to form an antibody conjugate. In some embodiments, the antibody conjugate comprises a bispecific antibody. In some embodiments, the bispecific antibody comprises an anti-VEGF and an anti-IL-6 binding portion.

[0024] In some embodiments, the antibody conjugate has the structure of Formula (I):

[0025] wherein each heavy chain of the anti-VEGF-A antibody is represented by the letter H, each light chain of the anti-VEGF-A antibody is represented by the letter L, and the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains. For the purposes of the above structure, PC refers to a structure having the following structure:

[0026] wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

[0027] In some embodiments, provided herein is a method for producing a product, the method comprising recovering a cell culture supernatant, wherein the cell culture supernatant comprises a target protein, then treating the cell culture supernatant into an eluate, wherein the eluate comprises the target protein, then loading the eluate onto an affinity chromatography matrix and washing with a first wash buffer comprising Tris or sodium phosphate, then washing with a second wash buffer comprising a chaotropic salt, eluting with an elution buffer, wherein the eluate is collected, wherein the eluate comprises the protein product, then inactivating viral contaminants present in the eluate with a low pH viral buffer to obtain a virus-inactivated eluate, filtering the virus-inactivated eluate, subjecting the virus-inactivated eluate to at least one round of ion exchange chromatography, and filtering the virus-inactivated eluate to obtain a retentate, wherein the retentate comprises the target protein.

[0028] In some embodiments, the cell culture supernatant is produced using an animal component-free cell culture in a bioreactor. In some embodiments, the cell culture supernatant includes harvesting a cell product from the cell culture. In some embodiments, the cell culture is clarified to remove cells and cell debris. In some embodiments, the eluate comprises a clarified cell culture supernatant.

[0029] In some embodiments, provided herein is a method for purifying a protein using affinity chromatography, the method comprising contacting a loading fluid with a medium, wherein the medium is an affinity chromatography matrix that binds a target protein, then washing the medium with a buffer solution comprising a chaotropic agent, wherein the chaotropic agent is a salt, and contacting the washed medium with an elution solution under conditions suitable for eluting the target protein.

[0030] In some embodiments, provided herein is a method for producing a product, the method comprising applying a solution containing a target protein to an affinity chromatography matrix, washing the affinity chromatography matrix with a first buffer, then washing the affinity chromatography matrix with a second buffer containing a chaotropic agent, then washing the affinity chromatography matrix with a third buffer to remove the chaotropic agent, and then eluting with an elution buffer, wherein the eluate is collected, wherein the eluate contains the protein product.

[0031] In some embodiments, the present invention provides a protein purification system comprising: a column having a first antigen binding protein bound to the column; a phosphate wash buffer comprising sodium phosphate and salt; an intermediate wash buffer comprising tris; a second wash buffer comprising magnesium chloride; and an elution buffer comprising sodium formate.

[0032] In some embodiments, a protein purification system is provided herein, the system comprising: a column having a first antigen binding protein bound to the column; a first tris wash buffer comprising tris and a salt, an intermediate tris wash buffer; a second wash buffer comprising magnesium chloride; and an elution buffer comprising sodium formate. In some embodiments, the column comprises a ligand for affinity chromatography. In some embodiments, the ligand comprises protein A or protein G. In some embodiments, the first wash buffer comprising sodium phosphate and a salt has a pH between 5.5 and 9.5. In some embodiments, the phosphate wash buffer comprising sodium phosphate and a salt comprises about 50mM sodium phosphate. In some embodiments, the phosphate wash buffer comprising sodium phosphate and a salt comprises about 250mM NaCl. In some embodiments, the first tris wash buffer comprises about 50mM Tris. In some embodiments, the first tris wash buffer further comprises about 250mM NaCl. In some embodiments, the intermediate tris wash buffer comprises about 50mM Tris. In some embodiments, the pH of the first tris wash buffer is about 7.2. In some embodiments, the pH of the second wash buffer is about 7.8. In some embodiments, the concentration of magnesium chloride in the second wash buffer is about 2.8 M. In some embodiments, the concentration of sodium formate in the elution buffer comprises 10 mM.

[0033] In some embodiments, described herein is an antibody purification system comprising: a column having a protein A resin bound to an antibody, wherein the antibody comprises a light chain and a heavy chain of at least one of SEQ ID NOs: 91-93, 28-30 and at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262, respectively; a chaotropic wash buffer comprising a chaotropic salt; and an elution buffer comprising sodium formate.

[0034] In some embodiments, the target protein is a bispecific antibody. In some embodiments, the bispecific antibody is specific for VEGF and IL-6. In some embodiments, the target protein is an antibody conjugate. In some embodiments, the affinity chromatography matrix is ​​a protein A chromatography matrix. In some embodiments, the chaotropic agent in the buffer solution comprises one or more of lithium and lithium salts, magnesium and magnesium salts, calcium and calcium salts, and guanidine and guanidine salts. In some embodiments, the concentration of one or more of lithium and lithium salts, magnesium and magnesium salts, calcium and calcium salts, and guanidine and guanidine salts is between 0.05-3.5M. In some embodiments, the buffer solution also comprises tris. In some embodiments, the concentration of tris in the buffer solution is at least 5mM. In some embodiments, the pH of the buffer solution is greater than 5.5. In some embodiments, the eluate also contains viral impurities.

[0035] In some embodiments of the methods described herein, the methods further include removing viral impurities. In some embodiments of the methods described herein, the methods further include inactivating viral impurities. In some embodiments of the methods described herein, the methods further include the step of washing the affinity chromatography matrix loaded with the loading fluid with a pre-wash buffer solution before washing with the buffer solution. In some embodiments of the methods described herein, the methods further include the step of washing the affinity chromatography matrix loaded with the eluent with a post-wash buffer solution after washing with the buffer solution. In some embodiments, the pre-wash buffer solution comprises sodium phosphate. In some embodiments, the pre-wash buffer solution comprises Tris and salt. In some embodiments, the antibody conjugate has a structure of formula (I), wherein each heavy chain of the anti-VEGF-A antibody is represented by the letter H, each light chain of the anti-VEGF-A antibody is represented by the letter L, and the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains, and wherein PC has the following structure:

[0036] wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

[0037] In some embodiments, the antibody conjugate comprises an anti-VEGF antibody conjugate comprising an anti-VEGF-A light chain and an anti-VEGF-A heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDRH1: CDRH1 in SEQ ID NO: 172, CDRH2: CDRH2 in SEQ ID NO: 173, and CDRH3: CDRH3 in SEQ ID NO: 174, and the anti-VEGF-A antibody light chain comprises CDRL1: CDRL1 in SEQ ID NO: 199, CDRL2: CDRL2 in SEQ ID NO: 200, and CDRL3: CDRL3 in SEQ ID NO: 201.

[0038] In some embodiments, the anti-VEGF antibody conjugate comprises: an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bound to a polymer, the polymer comprising an MPC monomer, wherein the sequence of the anti-VEGF-A antibody heavy chain is at least one of SEQ ID Nos: 7-13, 19-27, 89, 90, 256-262, the sequence of the anti-VEGF-A antibody light chain is at least one of SEQ ID Nos: 91-93, 28-30, and wherein the antibody is bound to the polymer at C449.

[0039] In some embodiments, the target protein of interest is produced by cell culture. In some embodiments, the cell culture comprises CHO cells. In some embodiments, the methods described herein further comprise the step of washing the affinity chromatography matrix loaded with the eluent with a post-wash buffer solution after washing with a buffer solution. In some embodiments, the affinity chromatography matrix is ​​washed with a buffer solution to remove nucleic acids, endotoxins, defoamers, or other small molecules other than the target protein of interest. In some embodiments, the affinity chromatography matrix is ​​washed with a buffer solution to remove impurities while keeping the target protein of interest bound to the affinity chromatography matrix. In some embodiments, the affinity chromatography matrix is ​​washed with a buffer solution to remove host cell proteins other than the target protein of interest. In some embodiments, adding a chaotropic agent to the buffer solution will not elute the target protein of interest. In some embodiments of the methods described herein, these methods further comprise one or more of virus inactivation, tangential flow filtration, diafiltration, ultrafiltration, ion exchange chromatography, or virus reduction filtration. In some embodiments, the eluent is produced in a bioreactor using a cell culture without animal components. In some embodiments, the product is a protein of interest. In some embodiments, impurities include host cell protein impurities. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 General schemes of several embodiments for collecting and purifying a protein of interest are described.

[0041] Figure 2 A general protocol for harvesting and purifying a protein of interest is described.

[0042] Figure 3 A general scheme for column chromatography according to embodiments of the present disclosure is described.

[0043] Figure 4 A set of chromatographic curves run in different wash buffer solutions are described.

[0044] Figure 5 A set of chromatographic curves run in different wash buffer solutions are described.

[0045] Figure 6 A set of chromatographic curves run in different wash buffer solutions are described.

[0046] Figure 7 A set of chromatographic curves run in different wash buffer solutions are described.

[0047] Figure 8 is the amino acid sequence of some embodiments of anti-VEGF antibodies.

[0048] Fig. 9 Some embodiments of IL-6-VEGF Trap fusion proteins are depicted. The VEGF Trap domain is located at the N-terminus just before the variable domain (left), or between the Fab region and the hinge region of the antibody (right).

[0049] Fig.10 Depicted is a sequence listing of VEGF_trap_variant_1, VEGF_trap_variant_2, and VEGF_trap_variant_3.

[0050] Fig.11 An embodiment of an anti-IL-6 heavy chain variable region sequence is shown. The CDRs are underlined.

[0051] Fig.12 Various embodiments of VEGF trap sequences are shown. The differences between the sequences are indicated in bold and underlined. Fig.12 Some embodiments of linker (GS) sequence embodiments are further shown. It may be present as a double repeat Gly-Gly-Gly-Gly-Gly-Ser linker (GS).

[0052] Figure 13-14 Some embodiments of heavy chain sequences of anti-IL-6 molecules are shown. The CDRs are underlined. Fig.15 Some embodiments of light chain sequences of anti-IL-6 molecules are shown. CDRs are underlined Fig.16Some embodiments of heavy chain sequences of anti-IL-6 molecules are shown. CDRs are underlined Figures 17A-17B Some embodiments of CDR combinations are shown.

[0053] Fig.18 Some embodiments of VEGFR-Fc sequence variants are shown. The parts that differ between the sequences are indicated in bold and underlined. DETAILED DESCRIPTION

[0054] In some embodiments, provided herein are methods and systems for reducing impurities by using chromatography to preferentially separate desired and undesired molecular species.

[0055] In some embodiments, a method of purifying a product using affinity chromatography is provided. In some embodiments, the method comprises: loading the eluate onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein; and washing the affinity chromatography matrix with a buffer solution comprising a chaotropic agent.

[0056] In some embodiments is a method of purifying a product and reducing impurities from a load fluid comprising a protein and one or more impurities by passing the load fluid through an affinity chromatography matrix, followed by at least one wash solution comprising a chaotropic salt, and collecting the protein using an elution solution.

[0057] In some embodiments, a method for separating impurities in an eluate containing a target protein. In some embodiments, the method comprises loading the eluate containing the target protein onto an affinity chromatography matrix; and washing the affinity chromatography matrix with one or more buffer solutions containing magnesium or a magnesium salt.

[0058] In some embodiments, a method of producing a product using affinity chromatography is provided. In some embodiments, the method comprises loading an eluate containing a target protein onto an affinity chromatography matrix, performing a first wash on the affinity chromatography matrix with a first buffer comprising sodium phosphate and salt, and performing a second wash on the affinity chromatography matrix with a second buffer comprising a chaotropic agent.

[0059] In some embodiments, a method for producing a product using affinity chromatography is provided. In some embodiments, the method comprises loading an eluate containing a target protein onto an affinity chromatography matrix, performing a first wash with a first buffer containing Tris and a salt, and performing a second wash with a second buffer containing Tris and a chaotropic agent, wherein the second buffer chaotropic agent contains a different salt than the first buffer.

[0060] In some embodiments, a method of producing a product. In some embodiments, the method comprises (i) collecting a loading fluid, wherein the loading fluid comprises a target protein, (ii) loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, (iii) washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, (iv) eluting the bound target protein; and (v) collecting an eluate, wherein the eluate contains the target protein.

[0061] In some embodiments, a method of producing a product is provided. In some embodiments, the method comprises collecting a loading fluid, wherein the loading fluid comprises a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, supplying a buffer solution comprising a chaotropic salt to the affinity chromatography matrix, eluting the bound target protein; and collecting an eluate, wherein the eluate comprises the target protein.

[0062] In some embodiments is a method of producing a product. In some embodiments, the method comprises collecting a conjugated protein, wherein the conjugated protein comprises an antibody bound to a conjugated polymer, loading the conjugated protein onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the conjugated protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting the conjugated protein, and collecting an eluate, wherein the eluate contains the conjugated protein.

[0063] In some embodiments, a method of producing a product. In some embodiments, the method comprises washing an affinity chromatography matrix bound to a target protein of interest with a buffer comprising a chaotropic salt, eluting and collecting an eluate, wherein the eluate contains the target protein of interest, and removing viral contaminants from the eluate. In some embodiments, removing viral contaminants from the eluate comprises one or more of low pH inactivation, detergent inactivation, polishing chromatography steps, virus filtration (VF), ultrafiltration (UF) and / or diafiltration (DF).

[0064] In some embodiments, a method of producing a product. In some embodiments, the method comprises washing an affinity chromatography matrix bound to a target protein of interest with a buffer comprising a chaotropic salt, removing the chaotropic salt, eluting and collecting the eluate, wherein the eluate contains the target protein of interest. In some embodiments, the eluate is further combined with an acceptable pharmaceutical excipient to form a pharmaceutical composition. In some embodiments, a buffer solution is added to the pharmaceutical composition. In some embodiments, a preservative solution is added to the pharmaceutical composition. In some embodiments, the pharmaceutical composition is further refined for intravitreal injection.

[0065] In some embodiments, a method of producing a product is provided. In some embodiments, the method comprises collecting a loading fluid, wherein the loading fluid comprises a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting and collecting an eluate, wherein the eluate comprises the target protein of interest, and removing viral contaminants from the eluate.

[0066] In some embodiments, a method for producing a product is provided. In some embodiments, the method comprises loading the eluate onto an affinity chromatography matrix, washing with a first wash buffer, washing with a second wash buffer comprising a chaotropic salt, washing with a third wash buffer, wherein the third wash buffer removes the chaotropic salt, eluting with an elution buffer, wherein the eluate is collected, wherein the eluate comprises a protein product. In some embodiments, the first wash buffer comprises 50 mM sodium phosphate. In some embodiments, the first wash buffer further comprises 250 mM NaCl. In some embodiments, the first wash buffer comprises Tris and salt. In some embodiments, the method further comprises removing viral contaminants from the eluate. In some embodiments, removing viral contaminants comprises: one or more of low pH inactivation, detergent inactivation, polishing chromatography steps, virus filtration (VF), ultrafiltration (UF) or diafiltration (DF). In some embodiments, the eluate comprises a target protein. In some embodiments, the target protein is an antibody. In some embodiments, the antibody is further conjugated to a polymer to form an antibody conjugate. In some embodiments, the antibody conjugate has a structure of formula (I):

[0067] wherein: each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; PC is: wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%. In some embodiments, the antibody conjugate comprises a bispecific antibody. In some embodiments, the bispecific antibody comprises an anti-VEGF and an anti-IL-6 binding portion.

[0068] In some embodiments, the antibody conjugate has the structure of Formula (II):

[0069] wherein: wherein "n." is an integer from 1 to 50, "ni" is an integer from 1 to 50; each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; PC is: wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%. In some embodiments, the antibody conjugate comprises a bispecific antibody. In some embodiments, the bispecific antibody comprises an anti-VEGF and an anti-IL-6 binding portion.

[0070] In some embodiments, it is a method for producing a product. In some embodiments, the method includes recovering a cell culture supernatant, wherein the cell culture supernatant contains a target protein, treating the cell culture supernatant into an eluate, wherein the eluate contains the target protein, loading the eluate into an affinity chromatography matrix, washing with a first wash buffer containing Tris or sodium phosphate, washing with a second wash buffer containing a chaotropic salt, eluting with an elution buffer, wherein the eluate is collected, wherein the eluate contains a protein product, inactivating viral contaminants present in the eluate with a low pH viral buffer to obtain a virus-inactivated eluate, filtering the virus-inactivated eluate, performing at least one round of ion exchange chromatography on the virus-inactivated eluate, and filtering the virus-inactivated eluate to obtain a retentate, wherein the retentate contains the target protein. In some embodiments, the cell culture supernatant is produced using a cell culture without animal components in a bioreactor. In some embodiments, processing the cell culture supernatant includes harvesting a cell product from the cell culture. In some embodiments, the cell culture is clarified to remove cells and cell debris. In some embodiments, the eluate comprises clarified cell culture supernatant.

[0071] In some embodiments is a method of purifying a protein using affinity chromatography. In some embodiments, the method comprises contacting a loading fluid with a medium, wherein the medium is an affinity chromatography matrix that binds a protein of interest, washing the medium with a buffer solution comprising a chaotropic agent, wherein the chaotropic agent is a salt, and contacting the washed medium with an elution solution under conditions suitable for eluting the protein of interest.

[0072] In some embodiments is a method of producing a product. In some embodiments, the method comprises applying a solution containing a protein of interest to an affinity chromatography matrix, washing the affinity chromatography matrix with a first buffer, washing the affinity chromatography matrix with a second buffer containing a chaotropic agent, washing the affinity chromatography matrix with a third buffer to remove the chaotropic agent, eluting with an elution buffer, wherein an eluate is collected, wherein the eluate contains the protein product.

[0073] In some embodiments, a protein purification system is provided. In some embodiments, the system comprises: a column having a first antigen binding protein bound to the column; a phosphate wash buffer comprising sodium phosphate and salt; an intermediate wash buffer comprising tris; a second wash buffer comprising magnesium chloride; and an elution buffer comprising sodium formate.

[0074] In some embodiments, a protein purification system is provided. In some embodiments, the system comprises: a column having a first antigen binding protein bound to the column; a first tris wash buffer comprising tris and a salt; an intermediate tris wash buffer; a second wash buffer comprising magnesium chloride; and an elution buffer comprising sodium formate. In some embodiments, the column comprises a ligand for affinity chromatography. In some embodiments, the ligand comprises protein A or protein G. In some embodiments, the first wash buffer comprising sodium phosphate and a salt has a pH between 5.5 and 9.5. In some embodiments, the phosphate wash buffer comprising sodium phosphate and a salt comprises about 50 mM sodium phosphate. In some embodiments, the phosphate wash buffer comprising sodium phosphate and a salt comprises about 250 mM NaCl. In some embodiments, the first tris wash buffer comprises about 50 mM Tris. In some embodiments, the first tris wash buffer further comprises about 250 mM NaCl. In some embodiments, the intermediate tris wash buffer comprises about 50 mM Tris. In some embodiments, the pH of the first tris wash buffer is about 7.2. In some embodiments, the pH of the second wash buffer is about 7.8. In some embodiments, the concentration of magnesium chloride in the second wash buffer is about 2.8 M. In some embodiments, the concentration of sodium formate in the elution buffer comprises 10 mM.

[0075] In some embodiments, it is an antibody purification system. In some embodiments, the system includes a column having a protein A resin bound to an antibody, wherein the antibody includes a light chain and a heavy chain of at least one of SEQ ID NOs: 91-93, 28-30 and at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262, respectively; a chaotropic wash buffer comprising a chaotropic salt; and an elution buffer comprising sodium formate. In some embodiments, the protein of interest is a bispecific antibody. In some embodiments, the bispecific antibody is specific for VEGF and IL-6. In some embodiments, the bispecific antibody is OG2072. In some embodiments, the protein of interest is an antibody conjugate. In some embodiments, the affinity chromatography matrix is ​​a protein A chromatography matrix. In some embodiments, the chaotropic agent in the buffer solution comprises one or more of lithium, lithium salts, magnesium, magnesium salts, calcium, calcium salts, guanidine and / or guanidine salts. In some embodiments, the concentration of one or more of lithium, lithium salts, magnesium, magnesium salts, calcium, calcium salts, guanidine and / or guanidine salts is between 0.05-3.5M, respectively. In some embodiments, the buffer solution further comprises tris. In some embodiments, the concentration of tris in the buffer solution is at least 5mM. In some embodiments, the pH of the buffer solution is greater than 5.5. In some embodiments, the eluate further contains viral impurities. In some embodiments, the method further comprises removing viral impurities. In some embodiments, the method further comprises inactivating viral impurities. In some embodiments, the method further comprises the step of washing the affinity chromatography matrix loaded with the loading fluid with a pre-wash buffer solution before washing with the buffer solution. In some embodiments, the method further comprises the step of washing the affinity chromatography matrix loaded with the eluate with a post-wash buffer solution after washing with the buffer solution. In some embodiments, the pre-wash buffer solution comprises sodium phosphate. In some embodiments, the pre-wash buffer solution comprises Tris and salt. In some embodiments, the antibody conjugate has the structure of formula (I), wherein: each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; PC is: wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%. In some embodiments, the antibody conjugate comprises an anti-VEGF antibody conjugate comprising an anti-VEGF-A light chain and an anti-VEGF-A heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDRH1: CDRH1 in SEQ ID NO: 172, CDRH2: CDRH2 in SEQ ID NO: 173, and CDRH3: CDRH3 in SEQ ID NO: 174, and the anti-VEGF-A antibody light chain comprises CDRL1: CDRL1 in SEQ ID NO: 199, CDRL2: CDRL2 in SEQ ID NO: 200, and CDRL3: CDRL3 in SEQ ID NO: 201. In some embodiments, the anti-VEGF antibody conjugate comprises: an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bound to a polymer, the polymer comprising an MPC monomer, wherein the sequence of the anti-VEGF-A antibody heavy chain is at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262, the sequence of the anti-VEGF-A antibody light chain is at least one of SEQ ID Nos: 91-93, 28-30, and wherein the antibody is bound to the polymer at C449.

[0076] In some embodiments, the target protein of interest is produced by cell culture. In some embodiments, the cell culture comprises CHO cells. In some embodiments, the method further comprises, after washing with a buffer solution, a step of washing the affinity chromatography matrix loaded with an eluent with a post-wash buffer solution. In some embodiments, the affinity chromatography matrix is ​​washed with a buffer solution to remove nucleic acids, endotoxins, defoamers, or other small molecules other than the target protein of interest. In some embodiments, the affinity chromatography matrix is ​​washed with a buffer solution to remove impurities while keeping the target protein of interest bound to the affinity chromatography matrix. In some embodiments, the affinity chromatography matrix is ​​washed with a buffer solution to remove host cell proteins other than the target protein of interest. In some embodiments, adding a chaotropic agent to the buffer solution will not elute the target protein of interest. In some embodiments, the method further comprises one or more of viral inactivation, tangential flow filtration, diafiltration, ultrafiltration, ion exchange chromatography, or virus reduction filtration. In some embodiments, the eluent is produced in a bioreactor using a cell culture without animal components. In some embodiments, the product is a protein of interest. In some embodiments, impurities include host cell protein impurities. In some embodiments, the first wash buffer comprises 10 mM sodium phosphate. In some embodiments, the first wash buffer comprises phosphate-based species. In some embodiments, the first wash buffer further comprises 50 mM NaCl.

[0077] In some embodiments, it is a method for treating a product. In some embodiments, the method includes loading an eluate onto an affinity chromatography matrix; and washing with a wash buffer comprising a chaotropic salt to collect the eluate, wherein the concentration of the chaotropic salt increases from a first concentration to a second concentration, wherein the eluate is collected in at least one fraction, wherein the at least one fraction contains the product of interest. In some embodiments, the concentration of the chaotropic salt of the first concentration is 0 M, and the concentration of the chaotropic salt of the second concentration is 4.0 M. In some embodiments, the chaotropic salt is one or more of lithium, lithium salts, magnesium, magnesium salts, calcium, calcium salts, guanidine and / or guanidine salts. In some embodiments, the chaotropic salt is selected from magnesium chloride, calcium chloride, lithium chloride and guanidine hydrochloride.

[0078] In some embodiments, the buffer solution further comprises one or more of the following: acetate, citrate, ACES, BES, Bicine, HEPES, MES, MOPS, MOPSO, TAPS, Tricine, Bis-Tris, Bis-Tris propane, Cacodylate, CAPS, CAPSO, CHES, glycine, diglycine, imidazole, PIPES, TEA, or TES.

[0079] In some embodiments, a method comprising a chaotropic agent to dissolve non-specific interactions is used to remove unwanted molecules from a solution. In some embodiments, a chaotropic agent is used as a part of an affinity chromatography step. In some embodiments, a chaotropic agent is used as a part of an ion exchange chromatography step. In some embodiments, a chaotropic agent used as a part of an ion exchange chromatography has a low conductivity, such as urea, alcohol, and detergent. In some embodiments, a method comprising a hydrophobic interaction resin is used to remove unwanted molecules from a solution, wherein the target protein is bound to the resin with a kosmotropic agent and eluted when a gradient of chaotropic salts is applied.

[0080] Although the desired molecular species may be present in significant concentrations, other unwanted molecular species may also be present when collected from cell culture, such as host cell proteins, cell debris, nucleic acids, endotoxins, or other molecules that may compromise the purity of the desired molecular species. Based on different properties related to binding, shape, size, charge, and other physical properties, sorting and purification of various supernatant compositions becomes possible. In some embodiments, purification of the desired molecular species can allow better patient outcomes and fewer complications due to administration of the desired molecular species. In some embodiments, the methods of the present invention can improve efficacy, or reduce the dosage of the desired molecular species.

[0081] In some embodiments, the desired molecular species are collected from blood. In some embodiments, the desired molecular species are collected from plasma. In some embodiments, the desired molecular species are collected from cell culture. In some embodiments, the desired molecular species are collected from animal component-free cell culture. In some embodiments, the desired molecular species are collected from clarified cell culture fluid (CCCF). In some embodiments, the desired molecular species are collected from cell supernatant.

[0082] In some embodiments, the cell culture is bacterial. In some embodiments, the cell culture is Escherichia coli (E.coli). In some embodiments, the cell culture is eukaryotic. In some embodiments, the cell culture is Saccharomyces cerevisiae (S.cerevisiae). In some embodiments, the cell culture is mammalian. In some embodiments, the cell culture is from human cells. In some embodiments, the cell culture is primary tissue. In some embodiments, the cell culture is an established cell line. Non-limiting examples of established cell lines include CHO cells, HeLa cells, mouse 3T3 fibroblasts, HEK293 cells, and KT-3 cells. In some embodiments, the cell culture comprises a mixture of cell types. In some embodiments, the cell culture comprises a single cell type. In some embodiments, the cell culture is an immune cell. In some embodiments, the cell culture is a lymphocyte. In some embodiments, the cell culture is a T cell.

[0083] In some embodiments, the desired molecular species may include an anti-VEGF antibody conjugate comprising a polymer portion that extends the half-life of the antibody when administered to a subject (e.g., KSI-301, KSI-501). In some embodiments, unwanted molecular species may include host cell proteins (HCP). In some embodiments, chromatography can be achieved using a protein A matrix, wherein the application of certain chaotropic agents can effectively elute unwanted molecular species while keeping the desired molecular species bound to the matrix. Therefore, in some embodiments, the methods and systems of the present disclosure can provide a method for purifying cell products harvested from cell cultures. In some embodiments, as cell processing proceeds, the methods of the present invention can obtain higher purity desired molecular species at a lower loss rate. In some embodiments, the methods of the present invention can reduce the level of HCP, thereby reducing complications for patients when the final drug product is administered. In some embodiments, the methods of the present invention can reduce the cost or time associated with purifying cell products.

[0084] Harvesting and processing cell cultures may involve a lot of purification and collection work, because whole cell extracts usually contain not only the desired molecular species, but also unwanted impurities. Multi-stage processing of collected cell cultures allows effective removal of impurities, including host cell proteins (HCPs), product-related impurities, such as high molecular weight (HMW) species and low molecular weight (LMW) species. In the first stage of a multi-stage purification process of a target protein (e.g., an antibody), some processes use affinity chromatography, where the efficiency and purity of the resulting target protein affect all downstream purification processes. In addition, affinity chromatography in downstream processing can be used to concentrate the product, allowing the use of appropriately smaller equipment in subsequent processing steps, which can be used to reduce the cost and time spent in the processing process. Therefore, it is advantageous to optimize the removal of impurities during affinity chromatography without losing or including the concentrated yield of subsequent processing steps.

[0085] In some embodiments, the method includes purifying antibodies and / or proteins. In some embodiments, the method includes optimized wash buffer. In some embodiments, the optimized wash buffer is pH 6.0, pH 6.5, pH 7.0, pH 7.5, pH 8.0, pH 8.5, pH 9.0, or any integer between pH 6.0 and pH 9.0. In some embodiments, the optimized wash buffer is pH 7.0. In some embodiments, the optimized wash buffer is pH 7.2. In some embodiments, the optimized wash buffer is pH 6.0.

[0086] In some embodiments, the optimized wash buffer comprises 5mM, 10mM, 25mM, 50mM, 100mM, 150mM, 200mM, or any integer between 5mM and 200mM sodium phosphate (sodium-phosphate). In some embodiments, the optimized wash buffer comprises 5mM sodium phosphate. In some embodiments, the optimized wash buffer comprises 50mM sodium phosphate.

[0087] In some embodiments, the optimized wash buffer comprises 5mM, 10mM, 25mM, 50mM, 100mM, 150mM, 200mM, or any integer between 5mM and 200mM Tris. In some embodiments, the optimized wash buffer comprises 5mM Tris. In some embodiments, the optimized wash buffer comprises 50mM Tris.

[0088] In some embodiments, the optimized wash buffer comprises 5mM, 10mM, 25mM, 50mM, 100mM, 150mM, 200mM, or any integer between 5mM and 200mM Bis-Tris. In some embodiments, the optimized wash buffer comprises 5mM Bis-Tris. In some embodiments, the optimized wash buffer comprises 50mM Bis-Tris.

[0089] In some embodiments, the optimized wash buffer comprises 50 mM, 100 mM, 250 mM, 500 mM, 750 mM, 1 M, 1.5 M, 2 M, 3 M, or any integer between 50 mM and 3 M NaCl. In some embodiments, the optimized wash buffer comprises 2 M NaCl. In some embodiments, the optimized wash buffer comprises 50 mM NaCl.

[0090] In some embodiments, the optimized wash buffer comprises MgCl2 of 1 M, 1.5 M, 1.65 M, 2 M, 2.8 M, 3 M, 4 M, 5 M, or any integer between 1 M and 5 M. In some embodiments, the optimized wash buffer comprises 2.8 M MgCl2. In some embodiments, the optimized wash buffer comprises 2 M MgCl2.

[0091] In some embodiments, the wash buffer optimized comprises a chaotropic agent. In some embodiments, the wash buffer optimized comprises a chaotropic salt. In some embodiments, the wash buffer optimized comprises a chaotropic cation. In some embodiments, the wash buffer optimized comprises a chaotropic anion. Non-limiting examples of chaotropic cations include guanidine, magnesium, calcium, sodium and lithium. Non-limiting examples of chaotropic anions include chloride, sulfate, acetate, citrate, nitrate and nitrite. In some embodiments, the chaotropic salt is CaCl2, guanidine chloride, lithium acetate, LiCl, MgCl2, MgSO4, NaNO3 or NaCl. In some embodiments, the wash buffer optimized comprises two or more chaotropic salts. In some embodiments, the chaotropic agent is present in the wash buffer optimized with any integer between 0.05M, 0.1M, 0.2M, 0.5M, 1M, 1.5M, 1.65M, 2M, 2.8M, 3M, 4M, 5M, 6M, 7M, 10M or 0.05M to 10M. In some embodiments, the chaotrope is present in the optimized wash buffer at 1 M. In some embodiments, the chaotrope is present in the optimized wash buffer at 2.8 M. In some embodiments, the concentration of the chaotrope present in the optimized wash buffer is optimized for the protein and / or antibody being purified.

[0092] Related

[0093] As described herein, a washing procedure for reducing the HCP level in the eluate of an affinity chromatography step is established, and a range of buffer strength, conductivity, and pH in the buffer is defined. Salts that are capable of reducing the HCP level in the eluate are determined. It is found that the efficiency of the salt in reducing the HCP level is related to its chaotropic strength according to the Hofmeister series. It is also found that the method is applicable to different antibody types and different Fc fusion proteins, so the concepts of the invention disclosed herein are generally applicable to any antibody and / or protein. The technology has also been shown to work with two different protein A affinity chromatography resins.

[0094] The work described herein used different antibodies and antibody-like constructs derived from Chinese Hamster Ovary (CHO) cells. The CHO expression system is the most commonly used system in the biopharmaceutical production industry because it is able to produce complex proteins with post-translational modifications similar to those produced in humans. To date, more than 6,000 CHO HCPs have been identified.

[0095] Downstream processing of mammalian cell culture biopharmaceutical products currently accounts for a large portion of the total production costs. A major challenge in downstream processing is the removal of host cell proteins (HCPs). HCPs are processing-related impurities that may co-purify with the biopharmaceutical product. Downstream processing typically includes a protein A affinity chromatography step followed by additional polishing steps to remove aggregates, product variants, HCPs, and host cell DNA. After the protein A chromatography step, many of the same HCPs are found in the biopharmaceutical industry. This is due to the almost universal use of CHO cells in the industry to produce antibodies and antibody-like constructs, and the use of protein A affinity chromatography steps under very similar conditions. For the latter, the biopharmaceutical is applied to the resin under physiological conditions (neutral pH and physiological salt conditions), the resin is washed with physiological conditions and high sodium chloride concentration buffers, and then an elution step is performed to collect the product. As a result of this platform approach, the affinity chromatography eluate contains many of the same HCPs and similar levels. There are some small differences depending on the type of biopharmaceutical product. In the survey, 69% of companies stated that they had encountered problems with individual HCPs during drug production, which was considered one of the biggest challenges in biomanufacturing. Some HCPs are high risk and can include those with immunogenicity, bioactivity, or enzymatic activity that may degrade the product molecule or excipients used in the formulation. The need to remove HCPs is easy to identify during process development, but minimizing HCP levels is difficult, but important. Some of these high-risk HCPs are lipases, which are enzymes that break down fats and lipids. Lipases can also degrade polysorbates, which are commonly used in formulations, thereby affecting the stability of therapeutic products. Similarly, hydrolases have been found to be the root cause of polysorbate degradation. Such HCPs may then compromise stability and reduce the shelf life of drug products. Polysorbate degradation can also lead to the formation of particles in formulations, creating safety issues. Then, proteases such as serine proteases, cathepsins, and metalloproteases can degrade antibodies, antibody-like constructs, and other proteins. In summary, various HCP species can affect the active ingredients and excipients in biologics. Importantly, HCPs also have the potential to generate immune responses in humans. Unwanted immune responses can be the most serious harm caused by HCPs and can even be fatal. The phospholipase B-like 2 protein is found in lebrikizumab and, based on clinical study data, triggers an immune response in approximately 90% of subjects. Table 5A shows an overview of high / risk HCPs and their potential impact. For all of these reasons, it is critical to reduce HCP levels as much as possible. Some HCPs bind nonspecifically to the product and are then co-purified. Removal of these HCPs is the most challenging. This work focuses on breaking down these nonspecific interactions of the product and HCPs, thereby reducing HCP levels. Characterization of the types of HCPs removed by this method is beyond the scope of this work.Here, the inventors show that by applying a washing step containing a chaotropic salt, the level of HCPs can be significantly reduced. It remains to be seen what type of HCPs are removed.

[0096] definition

[0097] The term "cell" includes cells of prokaryotes and eukaryotes, and may also include bacterial cells, mycobacterial cells, fungal cells, yeast cells, plant cells, insect cells, non-human animal cells, human cells, or cell fusions, such as hybridomas. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is derived from a human, monkey, ape, hamster, rat, or mouse cell. In some embodiments, the cell is a eukaryotic cell and is selected from the following cells: CHO (e.g., CHO K1, DXB-11 CHO, Veggie-CHO), COS (e.g., COS-7), retinal cells, Vero, CV1, kidney (e.g., HEK293, 293EBNA, MSR 293, MDCK, HaK, BHK), HeLa, HepG2, WI38, MRC 5, Colo205, HB 8065, HL-60 (e.g., BHK21), Jurkat, Daudi, A431 (epidermal), CV-1, U937, 3T3, L cells, C127 cells, SP2 / 0, NS-0, MMT 060562, Sertoli cells, BRL 3A cells, HT1080 cells, myeloma cells, tumor cells, and cell lines derived from the above cells. In some embodiments, the cell comprises one or more viral genes.

[0098] As used herein, "affinity chromatography" is a method that exploits specific, reversible interactions between biomolecules to achieve chromatographic separations.

[0099] As used herein, "Protein A chromatography" refers to a specific affinity chromatography method that depends on the affinity of the IgG binding domain of Protein A to the Fc portion of an immunoglobulin molecule. In immunoglobulins, the Fc portion comprises immunoglobulin constant domains CH2 and CH3 or immunoglobulin domains substantially similar to these domains. Protein A is derived from a natural protein from the cell wall of Staphylococcus aureus, and Protein A is produced by recombinant or synthetic methods, and variants of Protein A can retain the ability to bind to the Fc region. Protein A chromatography is typically fixed on a solid support, such as those in a Protein A column. Protein G and Protein L can also be used in a similar manner. In some embodiments, the solid support is a matrix that adheres to Protein A.

[0100] As used herein, the term "affinity chromatography matrix" or "AC matrix" refers to a solid phase medium, typically a gel or resin, which allows separation of biochemical mixtures based on highly specific binding interactions between a protein of interest and the AC matrix (e.g., between a receptor and a ligand, an enzyme and a substrate, or an antigen and an antibody). Thus, the solid phase medium comprises a target to which the protein of interest can reversibly attach, depending on buffer conditions. Non-limiting examples of immobilized or solid phase media that may comprise an AC matrix include gel matrices, such as agarose beads (e.g., commercially available Sepharose matrix), and glass matrices, such as porous glass beads (e.g., commercially available ProSep matrix).

[0101] In some embodiments, the method for isolating the target protein comprises column chromatography. In this method, the AC matrix is ​​formed into a column, and the biochemical mixture containing the target protein flows through the column. The target protein binds to the AC matrix. The column is then washed by flowing a washing solution through the column, and then the target protein is eluted from the column by flowing an elution buffer through the column.

[0102] In some embodiments, the method for isolating the protein of interest comprises membrane chromatography. Membrane chromatography methods rely on an AC matrix designed to fit a membrane sheet, wherein the biochemical mixture containing the protein of interest flows through the membrane. A non-limiting example of membrane chromatography is Sartobind Rapid A from Sartorius. In some embodiments, where the protein of interest is at least about 500 kDa, membrane chromatography is a preferred chromatography method.

[0103] Other affinity chromatography systems that can be used in the present invention include, for example, protein G, protein A / G, and protein L columns, each of which is also a bacterial protein that binds immunoglobulins, with binding properties that have been established in the art. Thus, an AC matrix that is a protein G matrix, a protein A / G matrix, or a protein L matrix can be used to purify antibodies, antibody fragments, or proteins containing an Fc region (e.g., Fc fusion proteins).

[0104] Although the present disclosure is described specifically with respect to purification of antibodies using Protein A, any protein (including fusion proteins) known in the art to selectively bind to a particular AC matrix is ​​suitable for purification using the wash methods described herein.

[0105] As used herein, "chaotropic agent" is a molecule that weakens or interferes with non-covalent forces and increases entropy in a biomolecular system. In some embodiments, lithium chloride, magnesium chloride, calcium chloride and / or guanidine chloride are chaotropic agents. Non-limiting examples of chaotropic agents include butanol, calcium chloride, ethanol, guanidine chloride, lithium perchlorate, lithium acetate, magnesium chloride, phenol, propanol, sodium dodecyl sulfate, thiourea and urea. Chaotropic agents include salts that affect protein solubility. Anions with higher chaotropic properties include, for example, chloride, nitrate, bromide, chlorate, iodide, perchlorate and thiocyanate. Cations with higher chaotropic properties include, for example, lithium, magnesium, calcium and guanidine.

[0106] As used herein, "eluent" or "eluent" refers to the carrier portion of the mobile phase in chromatography. In liquid chromatography, the eluent is the liquid solvent that enters the column, while in gas chromatography, it is the carrier gas. In some embodiments, the eluent refers to the carrier solvent containing antibodies, host cell proteins (HCPs) and other molecules of interest.

[0107] As used herein, "eluate" refers to the analyte material emerging from the chromatography step, including the analyte and solutes that passed through the solid phase. In some embodiments, the eluate specifically refers to the analyte material that is collected for further processing. In some embodiments, the eluate refers to the antibodies collected from the harvested cells, also referred to as the "product eluate". In some embodiments, the eluate refers to the HCP collected from the harvested cells, also referred to as the "wash eluate".

[0108] A "neovascular disorder" is a disorder or disease state characterized by altered, dysregulated or uncontrolled angiogenesis. Examples of neovascular disorders include neoplastic transformation (eg, cancer) and ocular neovascular disorders, including diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion.

[0109] An "ocular neovascular" disorder is a disorder characterized by altered, dysregulated, or uncontrolled angiogenesis in the eye of a patient. Such disorders include retinal vein occlusion, optic disc neovascularization, iris neovascularization, retinal neovascularization, choroidal neovascularization, corneal neovascularization, vitreous neovascularization, glaucoma, pannus, pterygium, macular edema, diabetic retinopathy, diabetic macular edema, vascular retinopathy, retinal degeneration, uveitis, retinal inflammatory diseases, and proliferative vitreoretinopathy.

[0110] The term antibody includes intact antibodies and binding fragments thereof. A binding fragment refers to a molecule other than an intact antibody, which comprises a portion of an intact antibody that binds to an antigen to which the intact antibody binds. Examples of binding fragments include Fv, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. scFv antibodies are described in Houston JS. 1991. Methods in Enzymol. 203: 46-96. In addition, antibody fragments contain single-chain polypeptides having the characteristics of a VH domain, i.e., capable of being assembled with a VL domain, or contain single-chain polypeptides having the characteristics of a VL domain, i.e., capable of being assembled with a VH domain into a functional antigen binding site, thereby providing the antigen binding properties of a full-length antibody.

[0111] Specific binding of an antibody to its target antigen means that at least 10 6 , 10 7 , 10 8 , 10 9 or 10 10 M -1 Specific binding is detectably higher in magnitude and can be distinguished from nonspecific binding occurring on at least one unrelated target. Specific binding can be the result of a bond or a specific spatial fit (e.g., a lock-and-key type) between specific functional groups, whereas nonspecific binding is typically the result of van der Waals forces. However, specific binding does not necessarily mean that the antibody or fusion protein binds to one and only one target.

[0112] The basic antibody structural unit is a tetramer of subunits. Each tetramer includes two pairs of identical polypeptide chains, each pair having one "light chain" (about 25 kDa) and one "heavy chain" (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids that is primarily responsible for antigen recognition. The initial expression of this variable region is linked to a cleavable signal peptide. Variable regions without signal peptides are sometimes referred to as mature variable regions. Thus, for example, a light chain mature variable region refers to a light chain variable region without a light chain signal peptide. However, reference to a variable region does not necessarily mean that a signal sequence is present; in fact, once the antibody or fusion protein is expressed and secreted, the signal sequence is cleaved. A pair of heavy and light chain variable regions defines the binding region of the antibody. The carboxyl-terminal portions of the light and heavy chains define the light and heavy chain constant regions, respectively. The heavy chain constant region is primarily responsible for effector functions. In IgG antibodies, the heavy chain constant region is divided into a CH1 region, a hinge region, a CH2 region, and a CH3 region. The CH1 region is bound to the light chain constant region by disulfide bonds and non-covalent bonds. The hinge region provides flexibility between the binding region and the effector region of the antibody, and also provides a site for intermolecular disulfide bonds between the two heavy chain constant regions of the tetramer subunit. The CH2 and CH3 regions are the main sites for effector function and FcR binding.

[0113] Light chains are divided into κ (kappa) or λ (lambda). Heavy chains are divided into γ (gamma), μ (mu), α (alpha), δ (delta) or ε (epsilon), and the isotypes of antibodies are defined as IgG, IgM, IgA, IgD and IgE, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "J" segment of about 12 or more amino acids, and the heavy chain also includes a "D" segment of about 10 or more amino acids. (See generally Fundamental Immunology (Paul, W., ed., 2nd ed., Raven Press, NY, 1989), Chapter 7) (incorporated by reference in its entirety for all purposes).

[0114] The mature variable region of each light / heavy chain pair forms an antibody binding site. Therefore, a complete antibody has two binding sites, i.e., it is bivalent. In natural antibodies, the binding sites are identical. However, bispecific antibodies in which the two binding sites are different can be prepared (see, e.g., Songsivilai S, Lachmann PC. 1990. Bispecific antibody: a tool for diagnosis and treatment of disease. Clin Exp Immunol. 79: 315-321; Kostelny SA, Cole MS, Tso JY. 1992. Formation of bispecific antibody by the use of leucine zippers. J Immunol. 148: 1547-1553). The variable regions all exhibit the same general structure of a relatively conservative framework region (FR) connected by three hypervariable regions, also referred to as complementary determining regions or CDRs. The CDRs from each pair of two chains are arranged by the framework region and are able to bind to a specific epitope. From N-terminus to C-terminus, both the light chain and the heavy chain contain the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. For convenience, the variable heavy chain CDRs may be referred to as CDR H 1. CDR H 2 and CDR H 3. Variable light chain CDR can be referred to as CDR L 1. CDR L 2 and CDR L3. The amino acid assignments for each domain are consistent with the definitions in Kabat EA et al. 1987 and 1991. Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, MD) or Chothia C, Lesk AM. 1987. Canonical Structures for the Hypervariable Regions of Immunoglobulins. J Mol Biol 196: 901-917; Chothia C et al. 1989. Conformations of Immunoglobulin Hypervariable Regions. Nature 342: 877-883. Kabat also provides a widely used numbering convention (Kabat numbering), in which corresponding residues between different heavy chain variable regions or between different light chain variable regions are assigned the same numbering. Although Kabat numbering can be used for antibody constant regions, EU numbering is more commonly used, as in the present application. Although specific sequences of the exemplary antibodies disclosed herein are provided, it should be understood that after expression of the protein chains, one to several amino acids at the amino or carboxyl termini of the light and / or heavy chains, in particular the C-terminal lysine residue of the heavy chain, may be deleted or derivatized in part or all of the molecule.

[0115] The term "epitope" refers to a site on an antigen that binds to an antibody or an extracellular trap segment. An epitope on a protein can be formed by continuous amino acids or non-continuous amino acids juxtaposed by the tertiary folding of one or more proteins. Epitopes formed by continuous amino acids (also called linear epitopes) are usually retained when exposed to denaturing solvents, while epitopes formed by tertiary folding (also called conformational epitopes) are usually lost when treated with denaturing solvents. Epitopes usually contain at least 3, more commonly at least 5 or 8-10 amino acids in a unique spatial conformation. Methods for determining the spatial conformation of epitopes include, for example, x-ray crystallography and two-dimensional nuclear magnetic resonance. See, for example, Epitope Mapping Protocols, in Methods in Molecular Biology, Vol. 66, edited by Glenn E. Morris (1996).

[0116] Antibodies that recognize the same or overlapping epitopes can be identified in a simple immunoassay showing the ability of one antibody to compete with another antibody for binding to a target antigen. The epitope of an antibody can also be determined by X-ray crystallography of the antibody (or Fab fragment) bound to its antigen to identify the contact residues.

[0117] Alternatively, if all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other antibody, then the two antibodies have the same epitope. If some amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other antibody, then the two antibodies have overlapping epitopes.

[0118] Competition between antibodies is determined by an assay in which the tested antibody inhibits specific binding of a reference antibody to a common antigen (see, e.g., Junghans et al., Cancer Res. 50: 1495, 1990). If an excess of the test antibody (e.g., at least 2x, 5x, 10x, 20x, or 100x) inhibits binding of the reference antibody by at least 50%, the test antibody competes with the reference antibody. In some embodiments, the test antibody inhibits binding of the reference antibody by 75%, 90%, or 99%, as measured in a competitive binding assay. Antibodies identified by competition assays (competing antibodies) include antibodies that bind to the same epitope as the reference antibody, and antibodies that bind to adjacent epitopes that are close enough to the epitope to which the reference antibody binds to produce steric hindrance.

[0119] The term "patient" includes human and other mammalian subjects receiving prophylactic or therapeutic treatment.

[0120] To classify amino acid substitutions as conservative or non-conservative, the amino acids are grouped as follows: Group I (hydrophobic side chains): met, ala, val, leu, ile; Group II (neutral hydrophilic side chains): cys, ser, thr; Group III (acidic side chains): asp, glu; Group IV (basic side chains): asn, gln, his, lys, arg; Group V (residues that affect chain orientation): gly, pro; and Group VI (aromatic side chains): trp, tyr, phe. Conservative substitutions include substitutions between amino acids of the same class. Non-conservative substitutions are replacements of members of one of these classes for members of another class.

[0121] Percent sequence identity is to maximize the comparison antibody sequence by the Kabat coding convention of variable region or the EU coding of constant region and determine.After the comparison, if the test antibody region (for example, the whole mature variable region of heavy chain or light chain) is compared with the same region of reference antibody, then the percentage sequence identity between the test antibody region and the reference antibody region is the number of positions occupied by the same amino acid in the test antibody region and the reference antibody region divided by two regional comparison positions totals (not calculating gaps (gap)), multiplied by 100 to be converted into percentage.Can be by using algorithm (BESTFIT, FASTA and TFASTA in Wisconsin GeneticsSoftware Package Release7.0, Genetics Computer Group, 575Science Dr., Madison, WI) with default gap parameter comparison sequence, or by checking and best comparison (that is, producing the highest sequence similarity percentage ratio on comparison window), determine the sequence identity of other sequences. The percent sequence identity is calculated by comparing two optimally aligned sequences over a comparison window, determining the number of positions where the identical residue occurs in the two sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window (i.e., the window size), and multiplying the result by 100 to yield the percent sequence identity.

[0122] A composition or method "comprising" one or more recited elements may include other elements not specifically recited. For example, a composition comprising an antibody may comprise the antibody alone or in combination with other ingredients.

[0123] The term "antibody-dependent cellular cytotoxicity" or ADCC is a mechanism of inducing cell death that relies on the interaction of antibody-coated target cells (i.e., cells with bound antibodies) with immune cells (also referred to as effector cells) with lytic activity. Such effector cells include natural killer cells, monocytes / macrophages, and neutrophils. ADCC is triggered by the interaction between the Fc region of the antibody bound to the cell and the Fcy receptors (particularly FcγRI and FcγRIII) on immune effector cells (such as neutrophils, macrophages, and natural killer cells). Depending on the type of mediating effector cells, target cells are cleared by phagocytosis or lysis. The death of antibody-coated target cells is a result of effector cell activity.

[0124] The term opsonization, also known as "antibody-dependent cellular phagocytosis" or ADCP, refers to the process by which antibody-coated cells are fully or partially internalized by phagocytic immune cells (eg, macrophages, neutrophils, and dendritic cells) that are bound to the Fc region of immunoglobulins.

[0125] The term "complement-dependent cytotoxicity" or CDC refers to a mechanism of cell death induction in which the Fc effector domain of a target-binding antibody activates a series of enzymatic reactions that ultimately form pores in the target cell membrane. Typically, the antigen-antibody complex (e.g., on an antibody-coated target cell) binds and activates the complement component Clq, which in turn activates the complement cascade, leading to target cell death. Activation of complement may also result in the deposition of complement components on the surface of target cells, promoting ADCC by binding to complement receptors (e.g., CR3) on leukocytes.

[0126] Humanized antibodies are genetically engineered antibodies in which CDRs from non-human "donor" antibodies are transplanted into human "acceptor" antibody sequences (see, e.g., Queen, US 5,530,101 and 5,585,089; Winter, US 5,225,539, Carter, US 6,407,213, Adair, US 5,859,205 6,881,557, Foote, US 6,881,557). The acceptor antibody sequence can be, for example, a mature human antibody sequence, a complex of such a sequence, a consensus sequence of a human antibody sequence, or a germline region sequence. Therefore, a humanized antibody is an antibody having some or all CDRs from a donor antibody completely or substantially and variable region framework sequences and constant regions (if present) completely or substantially from human antibody sequences. Similarly, humanized heavy chain has at least one, two and usually all three CDRs completely or substantially from the heavy chain of donor antibody, and heavy chain variable region framework sequence and heavy chain constant region (if present) substantially from the framework of human heavy chain variable region and constant region sequence.Similarly, humanized light chain has at least one, two and usually all three CDRs completely or substantially from the light chain of donor antibody, and light chain variable region framework sequence and light chain constant region (if present) substantially from the framework of human light chain variable region and constant region sequence.Except nano antibodies and dAbs, humanized antibodies comprise humanized heavy chain and humanized light chain.When at least 85%, 90%, 95% or 100% of the corresponding residues (defined by Kabat) are identical between respective CDRs, the CDRs in humanized antibodies are substantially from the corresponding CDRs in non-human antibodies. The variable region framework sequence of the antibody chain or the constant region of the antibody chain is substantially derived from a human variable region framework sequence or a human constant region, respectively, when at least 85, 90, 95 or 100% of the corresponding residues as defined by Kabat are identical.

[0127] Although humanized antibodies typically incorporate all six CDRs from a mouse antibody (as defined by Kabat), they may also be composed of less than all CDRs (e.g., at least 3, 4, or 5 CDRs from a mouse antibody) (e.g., De Pascalis R, Iwahashi M, Tamura M et al. 2002. Grafting "Abbreviated" Complementary-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody. J Immunol. 169:3076-3084; Vajdos FF, Adams CW, Breece TN, Presta LG, de Vos AM, Sidhu, SS. 2002. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. 320:415–428; Iwahashi et al. 2003. M, Milenic DE, Padlan EA et al. 1999. CDR substitutions of a humanized monoclonal antibody (CC49): Contributions of individual CDRs to antigen binding and immunogenicity. Mol Immunol. 36: 1079-1091; Tamura M, Milenic DE, Iwahashi M et al. 2000. Structural correlates of an anticarcinoma antibody: Identification of specificity-determining regions (SDRs) and development of a minimallyimmunogenic antibody variant by retention of SDRs only. J Immunol. 164:1432-1441).

[0128] Chimeric antibodies are antibodies in which the mature variable regions of the light and heavy chains of non-human antibodies (e.g., mice) are combined with human light and heavy chain constant regions. Such antibodies substantially or completely retain the binding specificity of mouse antibodies and are approximately two-thirds of the human sequence.

[0129] A veneer antibody is a type of humanized antibody that retains some and usually all of the CDRs and some non-human variable region framework residues of a non-human antibody, but replaces other variable region framework residues that may contribute to B- or T-cell epitopes, such as exposed residues with residues from corresponding positions in human antibody sequences (Padlan EA. 1991. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol. 28: 489-98). The result is that the CDRs in the antibody are completely or substantially from non-human antibodies, and the variable region framework of the non-human antibody becomes more human-like by substitution. Human antibodies can be isolated from humans or produced by expression of human immunoglobulin genes (e.g., in transgenic mice, in vitro, or by phage display). Methods for producing human antibodies include L,Pursch E.1983.Human x(mouse xhuman)hybridoma stably producing human antibodies.Hybridoma 2:361-367; U.S. Pat. No. 4,634,664; and the trioma method of Engleman et al., U.S. Pat. No. 4,634,666; the use of transgenic mice containing human immunoglobulin genes (see, e.g., Lonberg et al., WO 93 / 12227 (1993); U.S. Pat. No. 5,877,397, U.S. Pat. No. 5,874,299, U.S. Pat. No. 5,814,318, U.S. Pat. No. 5,789,650, U.S. Pat. No. 5,770,429, U.S. Pat. No. 5,661,016, U.S. Pat. No. 5,633,425, U.S. Pat. No. 5,625,126, U.S. Pat. No. 5,569,825, U.S. Pat. No. 5,545,806, Nature 148, 1547-1553 (1994), Nature Biotechnology 14,826 (1996), Kucherlapati, WO 91 / 10741 (1991), and phage display methods (see, for example, Dower et al., WO 91 / 17271 and McCafferty et al., WO 92 / 01047, US 5,877,218, US 5,871,907, US 5,858,657, US 5,837,242, US 5,733,743 and US 5,565,332.

[0130] "Polymer" refers to a series of monomer groups linked together. A polymer is composed of multiple units of a single monomer (homopolymer) or different monomers (heteropolymer). High MW polymers are prepared from monomers including but not limited to acrylates, methacrylates, acrylamides, methacrylamides, styrene, vinyl pyridine, vinyl pyrrolidone, and vinyl esters such as vinyl acetate. Additional monomers are useful in high MW polymers. When two different monomers are used, the two monomers are referred to as "comonomers," meaning that the different monomers are copolymerized to form a single polymer. The polymer can be linear or branched. When the polymer is branched, each polymer chain is referred to as a "polymer arm." The end of the polymer arm connected to the initiator portion is the proximal end, and the end of the growing chain of the polymer arm is the distal end. At the end of the growing chain of the polymer arm, the polymer arm end group can be a free radical scavenger or another group.

[0131] "Initiator" refers to a compound that can initiate polymerization using a monomer or comonomer. The polymerization can be conventional free radical polymerization or controlled / "living" free radical polymerization, such as atom transfer radical polymerization (ATRP), reversible addition fragmentation termination (RAFT) polymerization or nitroxide-mediated polymerization (NMP). The polymerization can be a "pseudo" controlled polymerization, such as decay transfer. When the initiator is suitable for ATRP, it contains an unstable bond that can be homolytically cleaved to form an initiator fragment I, which is a free radical that can initiate free radical polymerization, and a free radical scavenger I', which reacts with the free radicals of the growing polymer chain to reversibly terminate the polymerization. The free radical scavenger I' is typically a halogen, but can also be an organic moiety, such as a nitrile. In some embodiments, the initiator contains one or more 2-bromoisobutyrate groups as sites for polymerization by ATRP.

[0132] "Chemical linker" refers to a chemical part that connects two groups together, such as a half-life extension part and a protein. The linker can be cleavable or non-cleavable. Cleaved linkers can be hydrolyzable, enzymatically cleavable, pH sensitive, photolabile or disulfide linkers, etc. Other linkers include homobifunctional and heterobifunctional linkers. "Linking group" is a functional group that can form a covalent bond consisting of one or more bonds connected to a bioactive agent. Non-limiting examples include those shown in Table 1 of WO2013059137 (incorporated by reference).

[0133] The term "reactive group" refers to a group that can react with another chemical group to form a covalent bond, i.e., is covalently reactive under appropriate reaction conditions, and generally represents a point of attachment for another substance. A reactive group is a moiety that can chemically react with a functional group on a different moiety to form a covalent bond, such as a maleimide or succinimide ester. Reactive groups generally include nucleophiles, electrophiles, and photoactivated groups.

[0134] "Phosphorylcholine", also known as "PC", refers to the following:

[0135]

[0136] Wherein * indicates the point of attachment. Phosphorylcholine is a zwitterionic group, including salts (such as inner salts) and their protonated and deprotonated forms.

[0137] The "phosphorylcholine-containing polymer" is a polymer containing phosphorylcholine. The "zwitterion-containing polymer" is a polymer containing zwitterions.

[0138] The poly(acryloyloxyethyl phosphorylcholine)-containing polymer refers to a polymer containing 2-(acryloyloxy)ethyl-2-(trimethylammonium)ethyl phosphate (HEA-PC, shown in Example 6 below) as a monomer.

[0139] Poly(methacryloyloxyethylphosphorylcholine)-containing polymers refer to polymers containing 2-(methacryloyloxy)ethyl-2-(trimethylammonium)ethyl phosphate (HEMA-PC or MPC) as a monomer (see below):

[0140]

[0141] As used herein, "MPC" and "HEMA-PC" are interchangeable.

[0142] "Molecular weight" in the context of polymers can be expressed as number average molecular weight, or weight average molecular weight or peak molecular weight. Unless otherwise specified, all molecular weights mentioned herein refer to peak molecular weight. These molecular weight determination values, i.e., number average molecular weight (Mn), weight average molecular weight (Mw) and peak molecular weight (Mp), can be measured using size exclusion chromatography or other liquid chromatography techniques. Other methods for measuring molecular weight values ​​can also be used, such as using end group analysis or measuring colligative properties (such as freezing point depression, boiling point elevation or osmotic pressure) to determine the number average molecular weight, or using light scattering techniques, ultracentrifugation or viscometry to determine the weight average molecular weight. In some embodiments, molecular weight is measured by SEC-MALS (size exclusion chromatography-multi-angle light scattering). In some embodiments, the polymerization reagent is generally polydisperse (i.e., the number average molecular weight and weight average molecular weight of the polymer are not equal), and can have, for example, a low polydispersity value of less than about 1.5, for example, by judging by the PDI value obtained by SEC-MALS measurement. In some embodiments, polydispersity (PDI) is in the range of about 1.4 to about 1.2. In some embodiments, the PDI is less than about 1.15, 1.10, 1.05, or 1.03.

[0143] The phrase "a" or "an" entity refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. Thus, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein.

[0144] "About" refers to the variation that may be seen in measurements made on different instruments, samples, and sample preparations.

[0145] "Protected," "protected form," "protecting group," and "protective group" refer to the presence of a group (i.e., a protecting group) that prevents or blocks reaction of a particular chemically reactive functional group in a molecule under certain reaction conditions. Protecting groups vary depending on the type of chemically reactive group being protected, the reaction conditions used, and the presence of other reactive or protecting groups in the molecule, if any. Suitable protecting groups include, for example, those found in the paper Greene et al., "Protective Groups In Organic Synthesis," 3rd Edition, John Wiley and Sons, Inc., New York, 1999.

[0146] "Alkyl" refers to a straight or branched saturated aliphatic group with an indicated number of carbon atoms. For example, C1-C6 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc. Other alkyls include, but are not limited to, heptyl, octyl, nonyl, decyl, etc. Alkyl can include any number of carbons, such as 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4-6, and 5-6. Alkyl is usually monovalent, but can also be divalent, such as when the alkyl connects two parts together.

[0147] The term "lower" above and below in relation to an organic radical or compound is defined as a compound or radical having up to 7 and including 7 carbon atoms or up to 4 and including 4 carbon atoms, respectively, which may be branched or unbranched and (as unbranched) have one or two carbon atoms.

[0148] "Alkylene" refers to an alkyl group as defined above that is linked to at least two other groups, i.e., a divalent hydrocarbon radical. The two moieties linked to the alkylene group may be linked to the same atom or to different atoms of the alkylene group. For example, a straight chain alkylene group may be a divalent radical -(CH2) n , wherein n is 1, 2, 3, 4, 5 or 6. Alkylene includes, but is not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene and hexylene.

[0149] Substituents for alkyl and heteroalkyl groups (including those groups commonly referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) may be various groups selected from the group consisting of: -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -C02R', -CONR'R", -OC(O)R', -C02 ... )NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NH-C(NH2)=NH, -NR'C(NH2)=NH, -NH-C(NH2)=NR', -S(O)R', -S(O)2R', -S(O)2NR'R", -CN and -NO2, and the number ranges from 0 to (2m'+1), where m' is the total number of carbon atoms in the group. R', R" and R"' each independently represent hydrogen, unsubstituted (C1-C8) alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy, or aryl-(C1-C4) alkyl. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include 1-pyrrolidinyl and 4-morpholinyl. The term "alkyl" includes groups such as haloalkyl (e.g., -CF3 and -CH2CF3) and acyl (e.g., -C(O)CH3, -C(O)CF3, -C(O)CH2OCH3, etc.). In some embodiments, substituted alkyl and heteroalkyl have 1 to 4 substituents. In some embodiments, substituted alkyl and heteroalkyl have 1, 2, or 3 substituents. Exceptions are those perhaloalkyl groups (e.g., pentafluoroethyl, etc.).

[0150] Substituents for alkyl and heteroalkyl groups (including those groups commonly referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) may be one or more of a variety of groups selected from, but not limited to, -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R", -O C(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')=NR"", -NR-C(NR'R")=NR"', -S(O)R', -S(O)2R', -S(O)2NR'R", -NRSO2R', -CN and -NO2, ranging in number from 0 to (2m'+1), where m' is the total number of carbon atoms in the group. R', R", R"' and R"" each independently represent hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted alkyl, alkoxy or thioalkoxy, or arylalkyl. For example, when a compound includes more than one R group, each R group is independently selected, as are each R', R", R"' and R"" group when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include, but are not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one skilled in the art will understand that the term "alkyl" is meant to include groups containing carbon atoms combined with groups other than hydrogen groups, such as haloalkyl groups (e.g., -CF3 and -CH2CF3) and acyl groups (e.g., -C(O)CH3, -C(O)CF3, -C(O)CH2OCH3, etc.).

[0151] "Alkoxy" refers to an alkyl group with an oxygen atom that connects the alkoxy group to the point of attachment or is connected to two carbons of the alkoxy group. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, 2-butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, etc. The alkoxy group can be further substituted with various substituents described herein. For example, the alkoxy group can be substituted with halogen to form a "haloalkoxy" group.

[0152] "Carboxyalkyl" refers to an alkyl group (as defined herein) substituted with a carboxy group. The term "carboxycycloalkyl" refers to a cycloalkyl group (as defined herein) substituted with a carboxy group. The term alkoxyalkyl refers to an alkyl group (as defined herein) substituted with an alkoxy group. As used herein, the term "carboxy" refers to carboxylic acids and their esters.

[0153] "Haloalkyl" refers to an alkyl group as defined above in which some or all of the hydrogen atoms are replaced by halogen atoms. Halogen (halo) means chloro or fluoro, but may also be bromo or iodo. For example, haloalkyl includes trifluoromethyl, fluoromethyl, 1,2,3,4,5-pentafluoro-phenyl, etc. The term "perfluoro" defines a compound or group in which all available hydrogens are replaced by fluorine. For example, perfluorophenyl refers to 1,2,3,4,5-pentafluorophenyl, perfluoromethyl refers to 1,1,1-trifluoromethyl, and perfluoromethoxy refers to 1,1,1-trifluoromethoxy.

[0154] The "fluorine-substituted alkyl group" refers to an alkyl group in which one, part or all of the hydrogen atoms are substituted with fluorine.

[0155] "Cytokines" are members of a group of protein signaling molecules that can participate in cell-cell communication in immune and inflammatory responses. Cytokines are typically small, water-soluble glycoproteins with a mass of approximately 8-35 kDa.

[0156] "Cycloalkyl" refers to a cyclic hydrocarbon group containing about 3 to 12, 3 to 10, or 3 to 7 carbon atoms in the ring. Cycloalkyl includes fused, bridged and spiro ring structures.

[0157] "Intracyclic" refers to an atom or group of atoms that forms part of a cyclic structure.

[0158] "Exocyclic" refers to atoms or groups of atoms that are linked together but do not define a ring structure.

[0159] "Cycloalkyl ether" refers to a 4- or 5-membered cycloalkyl group having 3 or 4 carbon atoms within the ring and 1 oxygen or sulfur atom within the ring (e.g., oxetane, thietane, tetrahydrofuran, tetrahydrothiophene); or a 6- to 7-membered cycloalkyl group having 1 or 2 oxygen or sulfur atoms within the ring (e.g., tetrahydropyran, 1,3-dioxane, 1,4-dioxane, tetrahydrothiopyran, 1,3-dithiane, 1,4-dithiane, 1,4-thioxanone).

[0160] "Alkenyl" refers to a straight or branched hydrocarbon of 2 to 6 carbon atoms having at least one double bond. Examples of alkenyl include, but are not limited to, vinyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl. Alkenyl can also have 2 to 3, 2 to 4, 2 to 5, 3 to 4, 3 to 5, 3 to 6, 4 to 5, 4 to 6, and 5 to 6 carbons. Alkenyl is usually monovalent, but can also be divalent, such as when an alkenyl connects two parts together.

[0161] "Alkenylene" refers to an alkenyl group, i.e., a divalent hydrocarbon group, connected to at least two other groups as defined above. The two moieties connected to the alkenylene group may be connected to the same atom or different atoms of the alkenylene group. Alkenylene groups include, but are not limited to, vinylene, propenylene, isopropenylene, butenylene, isobutenylene, secondary butenylene, pentenylene, and hexenylene.

[0162] "Alkynyl" refers to a straight or branched hydrocarbon of 2 to 6 carbon atoms having at least one triple bond. Examples of alkynyl include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, isobutynyl, sec-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentenyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, or 1,3,5-hexatriynyl. Alkynyl can also have 2 to 3, 2 to 4, 2 to 5, 3 to 4, 3 to 5, 3 to 6, 4 to 5, 4 to 6, and 5 to 6 carbons. Alkynyl is typically monovalent, but can also be divalent, such as when an alkynyl connects two moieties together.

[0163] "Alkynylidene" refers to an alkynyl group as defined above, i.e., a divalent hydrocarbon group, connected to at least two other groups. The two parts connected to the alkynylene group can be connected to the same atom or different atoms of the alkynylene group. Alkynylidene groups include, but are not limited to, ethynylene, propynylene, butynylene, secondary butynylene, pentynylene, and hexynylene.

[0164] "Cycloalkyl" refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic assembly containing 3 to 12 ring atoms, or the number of atoms indicated. Monocyclic rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Bicyclic and polycyclic rings include, for example, norbornane, decalin, and adamantane. For example, C 3-8 Cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl and norbornane.

[0165] "Cycloalkylene" refers to a cycloalkylene group, i.e. a divalent hydrocarbon group, that is, a group connected to at least two other groups as defined above. The two parts connected to the cycloalkylene group can be connected to the same atom or different atoms of the cycloalkylene group. Cycloalkylene groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and cyclooctylene.

[0166] "Heterocycloalkyl" refers to a ring system having 3 to about 20 ring members and 1 to about 5 heteroatoms such as N, O, and S. Additional heteroatoms may also be useful, including but not limited to B, Al, Si, and P. The heteroatoms may also be oxidized, such as but not limited to -S(O)- and -S(O)2-. For example, heterocycles include but are not limited to tetrahydrofuranyl, tetrahydrothienyl, morpholinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, piperidinyl, indolinyl, quinuclidinyl, and 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl.

[0167] "Heterocycloalkylene" refers to a heterocycloalkyl group as defined above linked to at least two other groups. The two moieties linked to the heterocycloalkylene group may be linked to the same atom or different atoms of the heterocycloalkylene group.

[0168] "Aryl" refers to a monocyclic or fused bicyclic, tricyclic or larger aromatic ring assembly containing 6 to 16 ring carbon atoms. For example, aryl can be phenyl, benzyl or naphthyl. "Arylene" refers to a divalent group derived from aryl. Aryl can be mono-, di- or tri-substituted by one, two or three groups selected from alkyl, alkoxy, aryl, hydroxyl, halogen, cyano, amino, aminoalkyl, trifluoromethyl, alkylenedioxy and oxy-C2-C3-alkylene; all of which are optionally further substituted, for example as defined above; or 1- or 2-naphthyl; or 1- or 2-phenanthrenyl. Alkynedioxy is a divalent substituent attached to two adjacent carbon atoms of phenyl, such as methylenedioxy or ethylenedioxy. Oxo-C2-C3-alkylene is also a divalent substituent attached to two adjacent carbon atoms of phenyl, such as oxyethylene or oxypropylene. An example of oxy-C2-C3-alkylenephenyl is 2,3-dihydrobenzofuran-5-yl.

[0169] In some embodiments, aryl is naphthyl, phenyl or phenyl mono- or di-substituted by alkoxy, phenyl, halogen, alkyl or trifluoromethyl, especially phenyl or phenyl mono- or di-substituted by alkoxy, halogen or trifluoromethyl, especially phenyl.

[0170] Examples of the substituted phenyl group as R include 4-chlorobenz-1-yl, 3,4-dichlorobenz-1-yl, 4-methoxybenz-1-yl, 4-methylbenz-1-yl, 4-aminomethylbenz-1-yl, 4-methoxyethylaminomethylbenz-1-yl, 4-hydroxyethylaminomethylbenz-1-yl, 4-hydroxyethyl-(methyl)-aminomethylbenz-1-yl, 3-aminomethylbenz-1-yl, 4-N-acetylaminomethylbenz-1-yl, 4-aminobenz-1-yl, 3-aminobenz-1-yl, 2-aminobenz-1-yl, 4-phenylbenz-1-yl, 4-methoxyethylaminomethylbenz-1-yl, 4-hydroxyethylaminomethylbenz-1-yl, 4-hydroxyethyl-(methyl)-aminomethylbenz-1-yl, 3-aminomethylbenz-1-yl, 4-N-acetylaminomethylbenz-1-yl, (Imidazol-1-yl)-phenyl, 4-(imidazol-1-ylmethyl)-benz-1-yl, 4-(morpholin-1-yl)-benz-1-yl, 4-(morpholin-1-ylmethyl)-benz-1-yl, 4-(2-methoxyethylaminomethyl)-benz-1-yl and 4-(pyrrolidin-1-ylmethyl)-benz-1-yl, 4-(thiophenyl)-benz-1-yl, 4-(3-thiophenyl)-benz-1-yl, 4-(4-methylpiperazin-1-yl)-benz-1-yl, and 4-(piperidinyl)-phenyl and 4-(pyridinyl)-phenyl are optionally substituted on the heterocycle.

[0171] "Arylene" refers to an aryl group as defined above connected to at least two other groups. The two moieties connected to the arylene group are connected to different atoms of the arylene group. Arylene groups include, but are not limited to, phenylene.

[0172] "Aryleneoxy" refers to an arylene group as defined above wherein one of the moieties attached to the arylene group is attached through an oxygen atom. Aryleneoxy groups include, but are not limited to, phenyleneoxy.

[0173] Similarly, the substituents for the aryl and heteroaryl groups are different and are selected from: -halogen, -OR', -OC(O)R', -NR'R", -SR', -R', -CN, -NO2, -CO2R', -CONR'R", -C(O)R', -OC(O)NR'R", -NR"C(O)R', -NR"C(O)2R', -NR'-C(O)NR"R"', -NH-C(NH2)=NH, -NR'C(NH2)=NH, -NH-C(N H2)=NR', -S(O)R', -S(O)2R', -S(O)2NR'R", -N3, -CH(Ph)2, perfluoro(C1-C4)alkoxy and perfluoro(C1-C4)alkyl, ranging from zero to the total number of open valences on the aromatic ring system; wherein R', R" and R'" are independently selected from hydrogen, (C1-C8)alkyl and heteroalkyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-(C1-C4)alkyl and (unsubstituted aryl)oxy-(C1-C4)alkyl.

[0174] Two substituents on adjacent atoms of an aryl or heteroaryl ring may be optionally replaced by groups of the formula -TC(O)-(CH2)q -U-substituent, wherein T and U are independently -NH-, -O-, -CH2- or a single bond, and q is an integer from 0 to 2. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally substituted with a -U-substituent of the formula -A-(CH2) r -B-, wherein A and B are independently -CH2-, -O-, -NH-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'- or a single bond, and r is an integer from 1 to 3. One of the single bonds of the new ring thus formed may be optionally replaced by a double bond. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally replaced by a substituent of the formula -(CH2) s -X-(CH2) t -substituted with a substituent, wherein s and t are independently integers from 0 to 3, and X is -O-, -NR'-, -S-, -S(O)-, -S(O)2- or -S(O)2NR'-. The substituent R' in -NR'- and -S(O)2NR'- is selected from hydrogen or unsubstituted (C1-C6) alkyl.

[0175] "Heteroaryl" refers to a monocyclic or fused bicyclic or tricyclic aromatic ring assembly containing 5 to 16 ring atoms, wherein 1 to 4 ring atoms are heteroatoms, each heteroatom being N, O or S. For example, heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolyl, isoquinolyl, benzothienyl, benzofuranyl, furanyl, pyrrolyl, thiazolyl, benzothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl or any other group substituted, for example, by alkyl, nitro or halogen, especially monosubstituted or disubstituted. Pyridyl represents 2-, 3- or 4-pyridyl, advantageously 2- or 3-pyridyl. Thienyl represents 2- or 3-thienyl. In some embodiments, quinolyl represents 2-, 3- or 4-quinolyl. In some embodiments, isoquinolyl represents 1-, 3- or 4-isoquinolyl. In some embodiments, benzopyranyl and benzothiopyranyl can represent 3-benzopyranyl or 3-benzothiopyranyl, respectively. In some embodiments, thiazolyl can represent 2- or 4-thiazolyl. In some embodiments, triazolyl can be 1-, 2- or 5-(1,2,4-triazolyl). In some embodiments, tetrazolyl can be 5-tetrazolyl.

[0176] In some embodiments, heteroaryl is pyridyl, indolyl, quinolyl, pyrrolyl, thiazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, furanyl, benzothiazolyl, benzofuranyl, isoquinolyl, benzothienyl, oxazolyl, indazolyl, or any substituted group, especially a mono- or di-substituted group.

[0177] The term "heteroalkyl" refers to an alkyl group having 1 to 3 heteroatoms such as N, O and S. Other heteroatoms may also be useful, including but not limited to B, Al, Si and P. The heteroatoms may also be oxidized, such as but not limited to -S(O)- and -S(O)2-. For example, heteroalkyl groups may include ethers, thioethers, alkylamines and alkylthiols.

[0178] The term "heteroalkylene" refers to a heteroalkyl group as defined above linked to at least two other groups. The two moieties linked to the heteroalkylene group may be linked to the same atom or different atoms of the heteroalkylene group.

[0179] "Electrophile" refers to an ion or an atom or collection of atoms, which may be ionic, having an electrophilic center, i.e., an electron-seeking center, capable of reacting with a nucleophile. An electrophile (or electrophile) is a reagent that forms a bond with its reaction partner (nucleophile) by accepting two bonding electrons from the reaction partner.

[0180] "Nucleophile" refers to an ion or an atom or collection of atoms, which may be ionic, having a nucleophilic center, i.e., a center that seeks an electrophilic center or is capable of reacting with an electrophile. A nucleophile (or nucleophile) is a reagent that forms a bond with its reaction partner (electropophile) by donating two bonding electrons. "Nucleophilic group" refers to a nucleophile after reaction with a reactive group. Non-limiting examples include amino, hydroxyl, alkoxy, haloalkoxy, etc.

[0181] "Maleimido" refers to a pyrrole-2,5-dione-1-yl group having the following structure:

[0182] It forms an -S-maleimido group having the following structure when reacted with a thiol group (e.g., a thioalkyl group):

[0183] Wherein "·" indicates the connection point of the maleimide group, Represents the point of attachment of the sulfur atom of the thiol to the remainder of the original thiol-containing group.

[0184] For purposes of this disclosure, "naturally occurring amino acids" found in proteins and polypeptides are L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamine, L-glutamic acid, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine and / or L-valine. "Non-naturally occurring amino acids" found in proteins are any amino acids other than those referred to as naturally occurring amino acids. Non-naturally occurring amino acids include, but are not limited to, the D isomers of naturally occurring amino acids, and mixtures of the D and L isomers of naturally occurring amino acids. Other amino acids, such as N-α-methyl amino acids (e.g., sarcosine), 4-hydroxyproline, desmosine, isodesmosine, 5-hydroxylysine, ε-N-methyllysine, 3-methylhistidine, although found in naturally occurring proteins, are considered non-naturally occurring amino acids found in proteins for the purposes of this disclosure because they are typically incorporated by means other than ribosomal translation of mRNA.

[0185] "Linear," with respect to polymer geometry, structure, or overall structure, refers to polymers having a single polymer arm.

[0186] In terms of the geometry, structure or overall structure of the polymer, "branching" refers to a polymer with 2 or more polymer "arms" extending from a core structure contained in an initiator. Initiators can be used for atom transfer radical polymerization (ATRP) reactions. Branched polymers may have 2 polymer chains (arms), 3 polymer arms, 4 polymer arms, 5 polymer arms, 6 polymer arms, 7 polymer arms, 8 polymer arms, 9 polymer arms or more. Each polymer arm extends from a polymer starting site. Each polymer starting site can become a site for polymer chain growth by adding monomers. For example, but not limited to, using ATRP, the polymer initiation site on the initiator is typically an organic halide that undergoes a reversible redox process catalyzed by a transition metal compound (e.g., cuprous halide). In some embodiments, the halide is bromine.

[0187] "Pharmaceutically acceptable excipients" refer to excipients that can be included in the composition without causing significant adverse toxicological effects to patients and that are approved or approved by the FDA for therapeutic use, particularly for use in humans. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, saline solution, lactated Ringer's solution, standard sucrose, standard glucose, and the like.

[0188] The therapeutic protein is administered in an effective regimen, which refers to a dose, route of administration, and frequency of administration that delays onset, reduces severity, inhibits further deterioration, and / or improves at least one sign or symptom of the disease. If the patient already has a disease, the regimen may be referred to as a therapeutically effective regimen. If the patient is at high risk of the disease relative to the general population but has not yet developed symptoms, the regimen may be referred to as a preventive effective regimen. In some cases, the therapeutic or preventive effect of a single patient relative to historical controls or past experience of the same patient may be observed. In other cases, the therapeutic or preventive effect may be demonstrated in a treated patient population relative to a control population of untreated patients in preclinical or clinical trials.

[0189] The "biological half-life" of a substance is a pharmacokinetic parameter that describes the time required for half of the substance to be eliminated from a tissue or an organism after its introduction.

[0190] "OG1786" is a 9-arm initiator for polymer synthesis, which describes the salt form of OG1786 with trifluoroacetic acid. OG1786 can be used as other salts or as the free base.

[0191] "OG1801" is a polymer (by Mn or Mp) of approximately (+ / - 15%) 750 kDa prepared using OG1786 as initiator for ATRP synthesis using monomeric HEMA-PC.

[0192] "OG1802" is OG1801 with added maleimide functional groups, wherein each of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is an integer (positive) (from 0 to about 3000) so that the total molecular weight of the polymer is (Mw) 750,000 ± 15% Daltons.

[0193] Multi-angle light scattering (MALS) is a technique for analyzing macromolecules in which a laser is shone on the molecule and the oscillating electric field of the light induces oscillating dipoles within the molecule. The oscillating dipoles reradiate light, which can be measured with a MALS detector, such as the Wyatt miniDawn TREOS. The intensity of the radiated light depends on the size of the dipole induced in the macromolecule, which in turn is proportional to the polarizability of the macromolecule, the larger the induced dipole, the greater the intensity of the scattered light. Therefore, in order to analyze the scattering of such macromolecular solutions, their polarizability relative to the surrounding medium (e.g. solvent) should be known. This can be determined by measuring the dn / dc (=Δn / Δc) value using a Wyatt Optilab T-rEX differential refractometer, measuring the change in the solution refractive index n with the change in molecular concentration Δc Δn. The two molar mass parameters used in MALS determinations are the number average molecular weight (Mn) and the weight average molecular weight (Mw), where the polydispersity index (PDI) is equal to Mw divided by Mn. SEC also allows another average molecular weight determination of the peak molecular weight, Mp, which is defined as the molecular weight of the highest peak in SEC.

[0194] PDI is used as a measure of the width of the molecular weight distribution of polymers and bioconjugates derived from the conjugation of discrete proteins (e.g., OG1950) with polydisperse biopolymers (e.g., OG1802). For a protein sample, its polydispersity is close to 1.0, since it is a product of translation, and each protein molecule in solution is expected to have nearly the same length and molar mass. In contrast, due to the polydispersity of biopolymers, polymer chains of varying lengths are synthesized during the polymerization process, and therefore it is very important to determine the PDI of a sample as one of the quality attributes of its narrow molecular weight distribution.

[0195] Size Exclusion Chromatography (SEC) is a chromatographic technique in which molecules in solution are separated by their size. An aqueous solution is typically used to transport the sample through a column filled with resins of various pore sizes. The resin is expected to be inert to the analytes as they pass through the column, and the analytes are separated from each other based on their unique size and the pore size characteristics of the selected column.

[0196] Combining SEC with MALS or SEC / MALS provides an accurate distribution of molar mass and size (rms radius) compared to relying on a set of SEC calibration standards. This approach has many advantages over traditional column calibration methods. Since light scattering and concentration are measured for each eluting fraction, molar mass and size can be determined independent of elution position. This is particularly relevant for species with non-spherical macromolecules, such as biopolymers (OG1802) or bioconjugates (e.g. KSI-301, KSI-501); these substances do not typically elute in the manner described by a set of column calibration standards.

[0197] In some embodiments, SEC / MALS analysis includes a Waters HPLC system with an Alliance 2695 solvent delivery module and a Waters 2996 Photodiole array detector equipped with a Shodex SEC-HPLC column (7.8x300 mm). This is connected online with a Wyatt miniDawn TREOS and a Wyatt Optilab T-rEX differential refractometer. Waters' Empower software can be used to control the Waters HPLC system, and Wyatt's ASTRAV 6.1.7.16 software can be used to obtain MALS data from the Wyatt miniDawn TREOS, dn / dc data from the T-rEX detector, and mass recovery data using the A280 absorbance signal of the Waters 2996 Photodiole array detector. SEC can be performed at a speed of 1 ml / min in 1xPBS pH 7.4, and after sample injection, MALS and RI signals can be analyzed by ASTRA software to determine absolute molar mass (Mp, Mw, Mn) and polydispersity index (PDI). In addition, the calculations included the input dn / dc values ​​for the polymer and protein, which were 0.142 and 0.183, respectively. For the KSI-301 dn / dc value, the dn / dc was calculated based on the weighted MW of the polymer and protein, which was approximately 0.148, using the following formula:

[0198] Conjugate dn / dc = 0.142x [Mw polymer / (Mw polymer + Mw protein)] + 0.183x [Mw protein / (Mw polymer + Mw protein)]

[0199] The polymer Mw of OG1802 is 800 kDa, and the protein Mw of OG1950 is 146 kDa.

[0200] "KSI-301" is a bioconjugate of a recombinant mammalian cell expressed full-length humanized anti-VEGF monoclonal antibody covalently conjugated to a branched high molecular weight biopolymer based on phosphorylcholine. In some embodiments, KSI-301 is provided in a preservative-free sterile aqueous solution in a disposable glass vial at a concentration of 50 mg / ml (based on antibody mass). Figure 8The amino acid sequence of the antibody portion of KSI-301 is shown. KSI-301 is an anti-vascular endothelial growth factor (VEGF) biopharmaceutical with extended ocular half-life. KSI-301 is a bioconjugate of two intermediates: (1) OG1950 antibody intermediate, a recombinant, full-length humanized anti-huVEGF monoclonal antibody, and (2) OG1802 biopolymer intermediate, a phosphorylcholine biopolymer. The addition of OG1802, an inert biopolymer, increases the size of the biologic, thereby prolonging the ocular pharmacokinetics (PK) of KSI-301 beyond that of currently approved anti-huVEGF-A therapeutics. Nonclinical studies of KSI-301 have shown that it binds appropriately to huVEGF-A with high affinity and then inhibits the binding of huVEGF-A to huVEGF receptors 1 and 2 (huVEGFR). This in turn abrogates huVEGF-A-mediated functions.

[0201] In some embodiments, the molecule to be administered in any one or more of the methods provided herein is any one of the molecules disclosed in U.S. Patent Publication No. 2017 / 0190766, which is incorporated herein by reference in its entirety.

[0202] Figure 8 The amino acid sequence of the antibody portion of KSI-301 with the terminal lysine removed is shown. Terminal lysine removal is a post-translational modification in antibodies. The lysine residue at the C-terminus of the heavy chain of the recombinant IgG is removed (usually to a large extent) by carboxypeptidases endogenous to the CHO host cells during cell culture. For all antibody sequences described herein, although specific sequences of the exemplary antibodies disclosed herein (which may be longer) are provided, it should be understood that after expression of the protein chain, one to several amino acids at the amino or carboxyl terminus of the light and / or heavy chain, in particular the C-terminal lysine residue of the heavy chain, may be deleted or derivatized in part or all of the molecule. Therefore, in some embodiments, any antibody sequence provided herein may be modified by this lysine fragment, which may include, for example Figure 8 A modified version of the shown (one or more underlined residues are removed). In some embodiments, Figure 8 In some embodiments, lysine is removed from the heavy chain. In some embodiments, GK is removed. In some embodiments, PGK is removed. In some embodiments, SPGK is removed. As will be appreciated by those skilled in the art, in a population of molecules, lysine fragments can vary and are not complete. Thus, for example, 90, 95, 98, 99, or 100% of the molecules may have one or more fragment versions, while 10, 5, 2, 1, or as low as 0% may be full length (including any range defined between any two of the foregoing values). Thus, as used herein, KSI-301 comprises Figure 8Any and all options for heavy chain variants in.

[0203] As used herein, whenever an "anti-VEGF antibody" or "anti-VEGF antibody conjugate" is mentioned, anti-VEGF proteins, such as anti-VEGF fusion proteins (e.g., aflibercept) are also contemplated. Thus, as disclosed herein, whenever an "anti-VEGF antibody conjugate" is mentioned, an anti-VEGF protein (e.g., aflibercept) covalently bound to a phosphorylcholine-containing biopolymer (e.g., OG1802) disclosed herein is also contemplated. In various embodiments disclosed herein, any reference to an anti-VEGF antibody conjugate therapy also contemplates an anti-VEGF protein (e.g., aflibercept) conjugate therapy. In various embodiments of the methods of treating an eye disease disclosed herein, any reference to an anti-VEGF antibody conjugate also contemplates an aflibercept biopolymer conjugate.

[0204] Purification methods

[0205] In some embodiments, a method for purifying a product is provided. The method comprises washing the bound protein product with a chaotropic agent and then collecting the bound protein. The method may also comprise additional upstream and downstream purification processes.

[0206] In some embodiments, a method for purifying a product using affinity chromatography is provided. The method comprises loading an eluate onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to a target protein; and washing the affinity chromatography matrix with a buffer solution containing a chaotropic agent.

[0207] In some embodiments, the target protein is produced by cell culture. In some embodiments, the cell culture is a CHO cell. In some embodiments, the protein of interest is a bispecific antibody. In some embodiments, the bispecific antibody is specific for VEGF and IL-6. In some embodiments, the bispecific antibody is OG2072. In some embodiments, the protein of interest is an antibody conjugate. In some embodiments, the affinity chromatography matrix is ​​a protein A chromatography matrix.

[0208] In some embodiments, the chaotrope in the buffer solution comprises one or more of lithium and lithium salts, magnesium and magnesium salts, calcium and calcium salts, and guanidine and guanidine salts.

[0209] In some embodiments, the concentration of the magnesium salt is between 2-3.5 M. In some embodiments, the concentration is about 2.8 M MgCl2.

[0210] In some embodiments, the concentration of the magnesium salt is 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, or 3.5 M, or any value between the foregoing ranges.

[0211] In some embodiments, the concentration of the calcium salt is between 1-3 M. In some embodiments, the concentration is about 2.0 M CaCl2.

[0212] In some embodiments, the concentration of the calcium salt is: 1, 1.5, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.7 or 3 M, or any value between the foregoing ranges.

[0213] In some embodiments, the concentration of the guanidine salt is between 0.05-3 M. In some embodiments, the concentration is about 1.0 M guanidine hydrochloride.

[0214] In some embodiments, the concentration of the guanidine salt is 0.05, 0.075, 0.1, 0.2, 0.25, 0.5, 0.75, 1, 1.5, 1.75, 2, 2.5, 2.75, or 3 M, or any value in between the foregoing ranges.

[0215] In some embodiments, the buffer solution further comprises tris.

[0216] In some embodiments, the concentration of tris in the buffer solution is at least 5 mM.

[0217] In some embodiments, the concentration of tris in the buffer solution is at least 10 mM.

[0218] In some embodiments, the concentration of tris in the buffer solution is at least: 25 mM, 30 mM, 35 mM, 40 mM, 50 mM, or a value greater than 50 mM.

[0219] In some embodiments, the pH of the buffer solution is greater than 5.5.

[0220] In some embodiments, the present invention provides a method for purifying a product and reducing impurities from a loading fluid comprising a protein and one or more impurities. The method comprises passing the loading fluid through an affinity chromatography matrix, followed by passing through at least one washing solution comprising a chaotropic salt, and collecting the protein using an elution solution.

[0221] In some embodiments, the present invention provides a method for separating impurities in an eluate containing a target protein. The method includes loading the eluate containing the target protein onto an affinity chromatography matrix; and washing the affinity chromatography matrix with one or more buffer solutions, the buffer solution including one or more of lithium and lithium salts, magnesium and magnesium salts, calcium and calcium salts, and guanidine and guanidine salts.

[0222] In some embodiments, a method for separating impurities in an eluate containing a target protein is provided herein. The method includes loading the eluate containing the target protein onto an affinity chromatography matrix; and washing the affinity chromatography matrix with one or more buffer solutions, the buffer solution including one or more of lithium and lithium salts, magnesium and magnesium salts, calcium and calcium salts, and guanidine and guanidine salts. In some embodiments, the method further includes the step of washing the affinity chromatography matrix loaded with the eluate with a post-wash buffer solution after washing with the buffer solution. In some embodiments, washing the affinity chromatography matrix with a buffer solution removes nucleic acids, endotoxins, defoamers, other molecules, or other small molecules other than the target protein of interest. In some embodiments, washing the affinity chromatography matrix with a buffer solution removes impurities while keeping the target protein of interest bound to the affinity chromatography matrix. In some embodiments, washing the affinity chromatography matrix with a buffer solution removes host cell proteins other than the target protein of interest. In some embodiments, adding a chaotropic agent to the buffer solution does not elute the target protein of interest. In some embodiments, the method further includes one or more of viral inactivation, tangential flow filtration, diafiltration, ultrafiltration, ion exchange chromatography, or viral reduction filtration. In some embodiments, the eluate is produced in a bioreactor using a cell culture without animal components. In some embodiments, the product is a purified protein of interest. In some embodiments, impurities include host cell protein (HCP) impurities. In some embodiments, the eluate also includes viral impurities. In some embodiments, the method also includes removing viral impurities. In some embodiments, the method also includes the step of washing the affinity chromatography matrix loaded with the loading fluid with a pre-wash buffer solution before washing with a buffer solution. In some embodiments, the method also includes washing the affinity chromatography matrix loaded with the eluate with a post-wash buffer solution after washing with a buffer solution. In some embodiments, the pre-wash buffer solution includes sodium phosphate. In some embodiments, the pre-wash buffer solution includes tris and salt. In some embodiments of the method, the antibody conjugate comprises an anti-VEGF antibody conjugate comprising an anti-VEGF-A light chain and an anti-VEGF-A heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDRH1: CDRH1 in SEQ ID NO: 172, CDRH2: CDRH2 in SEQ ID NO: 173, and CDRH3: CDRH3 in SEQ ID NO: 174, and the anti-VEGF-A antibody light chain comprises CDRL1: CDRL1 in SEQ ID NO: 199, CDRL2: CDRL2 in SEQ ID NO: 200, and CDRL3: CDRL3 in SEQ ID NO: 201.In some embodiments of the methods provided herein, the anti-VEGF antibody conjugate comprises: an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bound to a polymer, the polymer comprising an MPC monomer, wherein the sequence of the anti-VEGF-A antibody heavy chain is at least one of SEQ ID Nos: 7-13, 19-27, 89, 90, 256-262, the sequence of the anti-VEGF-A antibody light chain is at least one of SEQ ID Nos: 91-93, 28-30, and wherein the antibody is bound to the polymer at C449.

[0223] In some embodiments, a method for producing a product using affinity chromatography is provided, the method comprising loading an eluate containing a target protein onto an affinity chromatography matrix; and washing the affinity chromatography matrix with one or more buffer solutions, the buffer solution comprising one or more of lithium and lithium salts, magnesium and magnesium salts, calcium and calcium salts, and guanidine and guanidine salts.

[0224] In some embodiments, a method for treating a product is provided. The method includes loading an eluent onto an affinity chromatography matrix. In some embodiments, the method also includes washing with a wash buffer comprising a chaotropic salt to collect the eluate, wherein the concentration of the chaotropic salt increases from a first concentration to a second concentration, wherein the eluate is collected in at least one fraction, wherein the at least one fraction comprises the product of interest. In some embodiments, the method also includes wherein the concentration of the chaotropic salt of the first concentration is 0 M, and wherein the concentration of the chaotropic salt of the second concentration is 4.0 M. In some embodiments, the chaotropic salt is based on magnesium. In some embodiments, the chaotropic salt is MgCl2.

[0225] In some embodiments, a method for producing a product using affinity chromatography is provided, the method comprising loading an eluate containing a target protein onto an affinity chromatography matrix, performing a first wash on the affinity chromatography matrix with a first buffer comprising sodium phosphate and salt, and performing a second wash on the affinity chromatography matrix with a second buffer comprising a chaotropic agent.

[0226] In some embodiments, a method for producing a product using affinity chromatography is provided. The method comprises loading an eluate containing a target protein onto an affinity chromatography matrix, performing a first wash with a first buffer containing Tris and a salt, and performing a second wash with a second buffer containing Tris and a chaotropic agent, wherein the second buffer chaotropic agent contains a different salt than the first buffer.

[0227] In some embodiments, a method for producing a product is provided. The method includes collecting a loading fluid, wherein the loading fluid contains a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, then washing the affinity chromatography matrix with a buffer solution containing a chaotropic salt to elute the bound target protein; and collecting an eluate, wherein the eluate contains the target protein.

[0228] In some embodiments, a method for producing a product is provided, which includes collecting a loading fluid, wherein the loading fluid contains a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, supplying a buffer solution containing a chaotropic salt to the affinity chromatography matrix, eluting the bound target protein, and collecting an eluate, wherein the eluate contains the target protein.

[0229] In some embodiments, a method of producing a product is provided, the method comprising collecting a conjugated protein, wherein the conjugated protein comprises an antibody bound to a conjugated polymer, loading the conjugated protein onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the conjugated protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting the conjugated protein, and collecting an eluate, wherein the eluate contains the conjugated protein.

[0230] In some embodiments, a method for producing a product is provided, which comprises washing an affinity chromatography matrix bound to a target protein of interest with a buffer containing a chaotropic salt, eluting and collecting an eluate, wherein the eluate contains the target protein of interest, and removing viral contaminants from the eluate.

[0231] In some embodiments, removing viral contaminants from the eluate comprises one or more of low pH inactivation, detergent inactivation, a polishing chromatography step, viral filtration, ultrafiltration, and / or diafiltration.

[0232] In some embodiments, a method for producing a product is provided, comprising washing an affinity chromatography matrix bound to a target protein with a buffer containing a chaotropic salt, removing the chaotropic salt, eluting and collecting an eluate, wherein the eluate contains the target protein.

[0233] In some embodiments, the eluate is further combined with an acceptable pharmaceutical excipient to form a pharmaceutical composition. In some embodiments, a buffer solution is added to the pharmaceutical composition. In some embodiments, a preservative solution is added to the pharmaceutical composition. In some embodiments, the pharmaceutical composition is further refined for intravitreal injection.

[0234] In some embodiments, a method for producing a product is provided, comprising collecting a loading fluid, wherein the loading fluid comprises a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting and collecting an eluate, wherein the eluate comprises the target protein, and removing viral contaminants from the eluate.

[0235] In some embodiments, a method for producing a product is provided. The method includes collecting a loading fluid, wherein the loading fluid contains a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, washing the affinity chromatography matrix with a buffer solution containing a chaotropic salt, eluting the bound target protein; and collecting an eluate, wherein the eluate contains the target protein.

[0236] In some embodiments, a method for producing a product is provided, which includes collecting a loading fluid, wherein the loading fluid contains a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, supplying a buffer solution containing a chaotropic salt to the affinity chromatography matrix, eluting the bound target protein, and collecting an eluate, wherein the eluate contains the target protein.

[0237] In some embodiments, a method of producing a product is provided, the method comprising collecting a conjugated protein, wherein the conjugated protein comprises an antibody bound to a conjugated polymer, loading the conjugated protein onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the conjugated protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting the conjugated protein, and collecting an eluate, wherein the eluate contains the conjugated protein.

[0238] In some embodiments, a method for producing a product is provided, which comprises washing an affinity chromatography matrix bound to a target protein of interest with a buffer containing a chaotropic salt, eluting and collecting an eluate, wherein the eluate contains the target protein of interest, and removing viral contaminants from the eluate.

[0239] The method may also include, wherein removing viral contaminants from the eluate includes one or more of low pH inactivation, detergent inactivation, polishing chromatography steps, viral filtration (VF), ultrafiltration (UF) and / or diafiltration (DF). The method may also include, wherein the eluate is further combined with an acceptable pharmaceutical excipient to form a pharmaceutical composition. The method may also include, wherein a buffer solution is added to the pharmaceutical composition. The method may also include, wherein a preservative solution is added to the pharmaceutical composition. The method may also include, wherein the pharmaceutical composition is further refined for intravitreal injection.

[0240] In some embodiments, a method for producing a product is provided, which comprises washing an affinity chromatography matrix bound to a target protein with a buffer containing a chaotropic salt, removing the chaotropic salt, eluting and collecting an eluate, wherein the eluate contains the target protein.

[0241] In some embodiments, a method for producing a product is provided, comprising collecting a loading fluid, wherein the loading fluid comprises a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting and collecting an eluate, wherein the eluate comprises the target protein, and removing viral contaminants from the eluate.

[0242] In some embodiments, a method of producing a product is provided, the method comprising loading an eluate onto an affinity chromatography matrix, washing with a first wash buffer, washing with a second wash buffer comprising a chaotropic salt, washing with a third wash buffer, wherein the third wash buffer removes the chaotropic salt, eluting with an elution buffer, wherein the eluate is collected, wherein the eluate comprises a protein product.

[0243] The method may also include, wherein the first wash buffer comprises 50mM sodium phosphate. The method may also include, wherein the first wash buffer further comprises 250mM NaCl. The method may also include, wherein the first wash buffer comprises Tris and salt. The method may also include removing viral contaminants from the eluate. The method may also include, wherein the removal of viral contaminants comprises: one or more of low pH inactivation, detergent inactivation, polishing chromatography steps, virus filtration (VF), ultrafiltration (UF) or diafiltration (DF). The method may also include, wherein the eluate comprises a target protein. The method may also include, wherein the target protein is an antibody. The method may also include, wherein the antibody is further conjugated to a polymer to form an antibody conjugate. The method may also include, wherein the antibody conjugate comprises a bispecific antibody. The method may also include, wherein the bispecific antibody comprises an anti-VEGF and an anti-IL-6 binding portion.

[0244] The method can also include, wherein the first washing buffer comprises the sodium phosphate of any integer between 10,50,100,150,200mM or 10 to 200mM.The method can also include, wherein the first washing buffer comprises the kind based on phosphate.The method can also include, wherein the first washing buffer also comprises the NaCl of any integer between 25,50,100,150,200 or 25 to 200mM.The method can also include, wherein the concentration of the chaotropic salt of the first concentration is 0M, and wherein the concentration of the chaotropic salt of the second concentration is 4.0M.The method can also include, wherein the chaotropic salt is based on magnesium.The method can also include, wherein the chaotropic salt is MgCl 2.

[0245] In some embodiments, the antibody conjugate comprises a protein construct comprising an antagonist IL-6 antibody fused to a VEGF trap, wherein the antibody comprises an isolated antagonist IL-6 antibody or a fragment thereof. In some embodiments, the bispecific antibody comprises a VEGF-anti-IL-6 dual inhibitor, wherein the VEGFR-anti-IL-6 dual inhibitor comprises an anti-IL-6 antibody or a fragment thereof and a trap antibody fusion of an anti-VEGF trap (VEGFR1 / 2), wherein the dual inhibitor comprises at least one point mutation with a VEGFR sequence to reduce cleavage of the VEGFR protein, wherein the antibody comprises an antigen binding fragment (Fab) region, a hinge region, and a crystallizable fragment (Fc) region, wherein the anti-VEGF trap is located at the N-terminus of the antibody heavy chain, wherein the heavy chain comprises IL-6 VH, or is located between the Fab and hinge regions. In some embodiments, the antibody conjugate comprises an antibody conjugate comprising (1) an anti-VEGF-A antibody and (2) a polymer containing phosphorylcholine, wherein the polymer is covalently bound to the antibody at a cysteine ​​outside the variable region of the antibody, wherein the cysteine ​​has been added by recombinant DNA technology. In some embodiments, the antibody conjugate comprises an isolated antagonist antibody that specifically binds complement factor D (CFD) and directly inhibits the proteolytic activity of CFD.

[0246] In some embodiments, the antibody conjugate has the structure of Formula (I):

[0247]

[0248] wherein each heavy chain of the antibody is represented by the letter H, and each light chain of the anti-CFD antibody is represented by the letter L; the polymer is bound to the antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains;

[0249] PC is wherein the curved line represents the point of attachment to the rest of the polymer, wherein X = a) OR, wherein R = H, methyl, ethyl, propyl, isopropyl, b) H, or c) any halide, including Br; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8, and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8, and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8, and n9 is 2500 plus or minus 15%. In some embodiments, the sum of n1, n2, n3, n4, n5, n6, n7, n8, and n9 is from about 1500 to about 3500 plus or minus about 10% to about 20%.

[0250] Some embodiments provide any of the following substances or compositions (including pharmaceutical compositions) comprising anti-CFD antibodies, the anti-CFD antibodies having partial light chain sequences and partial heavy chain sequences as can be seen in Tables 1A, 1B, 1C, 1D and / or 1E, or variants thereof. In Table 1A, the underlined sequences are some embodiments of CDR sequences provided herein. In some embodiments, compositions disclosed herein include antibodies having partial or complete light chain sequences and partial or complete heavy chain sequences from any of the options provided in Tables 1A, 1B, 1C, 1D and / or 1E, or variants thereof. In some embodiments, antibodies (or their binding fragments) may include any one or more CDRs provided in Tables 1A, 1B, 1C, 1D and / or 1E. In some embodiments, antibodies (or their binding fragments) may include any three or more CDRs provided in Tables 1A, 1B, 1C, 1D and / or 1E. In some embodiments, antibodies (or their binding fragments) may include any six CDRs provided in Tables 1A, 1B, 1C, 1D and / or 1E. The CDR sequences of the various constructs can also be found in Tables 1A, 1B, 1C, 1D and / or 1E.

[0251] Table 1A: Variable region sequences of anti-CFD antagonist monoclonal antibodies (CDRs are underlined).

[0252]

[0253]

[0254]

[0255]

[0256]

[0257]

[0258] Table 1B: CDRs of anti-CFD antagonist monoclonal antibodies based on extensive CDR definition

[0259]

[0260]

[0261]

[0262]

[0263] Table 1C: Heavy and light chain variable sequences of 88 mouse anti-CFD antibodies with underlined CDRs.

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270]

[0271]

[0272]

[0273]

[0274]

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281]

[0282] Table 1D: Variable region sequences of variant humanized CFD antagonist antibodies based on CDR definition

[0283]

[0284]

[0285] Table 1D (continued): CDR (simplified CDR definition sequence)

[0286]

[0287]

[0288] Table 1E: Amino acid sequences of final heavy and light chain candidates and their variants (KCD119 variant sequences; CDR Implementation Schemes are underlined. )

[0289]

[0290]

[0291] The methods described herein may also include, wherein the anti-VEGF-A antibody conjugate has the structure:

[0292]

[0293] Wherein: each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; PC is wherein the curved line represents the point of attachment to the rest of the polymer, wherein X = a) OR, wherein R = H, methyl, ethyl, propyl, isopropyl, b) H, or c) any halide, including Br; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

[0294] In some embodiments, the anti-VEGF A heavy chain comprises CDRH1: i.e., CDRH1 in SEQ ID NO: 172, CDRH2: i.e., CDRH2 in SEQ ID NO: 173, and CDRH3: i.e., CDRH3 in SEQ ID NO: 174, position 221 is T, and the anti-VEGF-A light chain comprises CDRL1: i.e., CDRL1 in SEQ ID NO: 199, CDRL2: i.e., CDRL2 in SEQ ID NO: 200, and CDRL3: i.e., CDRL3 in SEQ ID NO: 201, and Kabat position 4 is L. Optionally, the anti-VEGF A heavy chain isotype is human IgG1. Optionally, the sequence of the anti-VEGF-A heavy chain is at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262, and the sequence of the anti-VEGF-A antibody light chain is at least one of SEQ ID Nos: 91-93, 28-30. In some embodiments, the antibody that binds to VEGF-A comprises CDRH1, i.e., CDRH1 in SEQ ID NO: 172; CDRH2, i.e., CDRH2 in SEQ ID NO: 173; CDRH3, i.e., CDRH3 in SEQ ID NO: 174; CDRL1, i.e., CDRL1 in SEQ ID NO: 199; CDRL2, i.e., CDRL2 in SEQ ID NO: 200; CDRL3, i.e., CDRL3 in SEQ ID NO: 201; at least one of the following mutations (EU numbering): L234A, L235A, and G237A; and at least one of the following mutations (EU numbering): Q347C or L443C.

[0295] The methods described herein may also include wherein the anti-IL-6 antibody conjugate has the following structure: wherein: each heavy chain of the anti-IL-6 antibody is represented by the letter H, each light chain of the anti-IL-6 antibody is represented by the letter L, the polymer is bound to the anti-IL-6 antibody (and / or Ab-Trap) via the sulfhydryl group of C443 (EU numbering), and the binding is depicted on one of the heavy chains; PC is,

[0296] wherein the curved line represents the point of attachment to the rest of the polymer; wherein X=a) OR, wherein R=H, methyl, ethyl, propyl, isopropyl, b) H, c) any halide, including Br; and n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different, such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%. In some embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000. In some embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 500. In some embodiments, X=OR, wherein R is a sugar, an aminoalkyl, a mono-, poly- or unsubstituted variant of the following residues: a saturated C1-C 24 Alkyl, unsaturated C2-C 24 Alkenyl or C2-C 24 Alkynyl, acyl, acyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkyloxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxygen sulfonyl, carboxyl, cyano and haloalkyl (including polyhaloalkyl), -CO-O-R7, carbonyl-CCO-R7, -CO-NR8R9, -(CH2) n -COOR7, -CO-(CH) n -COOR7, -(CH2) n -NR8R9, ester, alkoxycarbonyl, aryloxycarbonyl, wherein n is an integer from 1 to 6, wherein each of R7, R8 and R9 is independently selected from the group consisting of: hydrogen atom, halogen atom, monosubstituted, polysubstituted or unsubstituted variants of the following residues: saturated C1-C 24 Alkyl, unsaturated C2-C 24 Alkenyl or C2-C 24 Alkynyl, acyl, acyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkyloxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxyl, cyano and haloalkyl (including polyhaloalkyl), 5-membered ring and 6-membered ring.

[0297] In some embodiments, the anti-IL-6 antibody, or as otherwise used herein, "IL-6 antibody-VEGF Trap fusion", "IL-6 antibody-VEGF Trap", "Ab IL-6-VEGF Trap", "anti-IL-6-VEGF Trap", "VEGFR-anti-IL6", "VEGFR-anti-IL-6", "VEGF Trap-anti-IL6 antibody fusion (TAF)", "VEGF Trap-IL6", "VEGFRIL-6", "IL6-VEGFR" or similar terms or reverse terms (e.g., "VEGF Trap-IL-6Ab", "VEGF Trap-IL-6 antibody fusion", etc.) refers to a fusion between an IL-6 antibody and a VEGF Trap. Fig. 9 Embodiments are depicted in . When used generally, the order of the two terms can be interchanged. When used specifically, the order of the two terms indicates the relative position of the components in the construct. The term "Ab-Trap", "IL-6Ab-VEGF Trap", "Ab IL-6VEGF Trap" or "Ab IL-6-Trap" or "anti-IL-6VEGF Trap", "Trap-Ab", anti-IL-6-VEGFR, anti-IL6-VEGFR or other similar terms or reverse terms (e.g., "VEGF Trap-IL-6Ab", "VEGF Trap-IL-6 antibody fusion", etc.) indicates the arrangement of Ab fused to the relevant domain of VEGF binding protein, thereby providing VEGF trap. As described above, this part of the VEGF binding protein is a part that prevents VEGF from binding to the VEGF receptor. As described herein, the arrangement (sequencing) of the Trap and antibody parts can vary. Therefore, unless otherwise explicitly stated or the context indicates otherwise, the phrases used herein about Ab-Trap (or Il-6 / VEGF Trap, etc.) fusions represent all disclosed embodiments of antibody and Trap positioning. Therefore, unless otherwise indicated, the phrase Ab-Trap (or Il-6 / VEGF Trap, etc.) means Fig. 9 The implementation on the left, and Fig. 9 The implementation on the right side of the figure, and Fig. 9Thus, for convenience, general language is expressed as disclosing all three options. If a direction is specifically indicated, it may be indicated, for example, by stating an "arrangement" that may be one of the following: Trap-Ab, Trap IL-6Ab, VEGF Trap Ab IL-6, VEGF Trap Ab IL-6. Similarly, it will be understood that some of the disclosed embodiments are context-specific molecular orientations or arrangements, which are indicated by the context of the embodiments. For all discussions of fusion proteins provided herein, both arrangements (optional and combined) are explicitly contemplated. In addition, it will be understood that when used in the context of fusion proteins, due to the ordering, the phrase IL-6Ab includes two options, where the antibodies are continuous ( Fig. 9 left-hand side), and where TRAP is located “inside” the Ab ( Fig. 9 Likewise, the term "Ab" or "antibody," when used in the context of a fusion protein (or other similar terminology), includes all three options ( Fig. 9 Left hand side, Fig. 9 Right-hand side, and two options) unless otherwise indicated. In some embodiments, VEGF Trap is fused to IL-6 in one of the following ways: fused to the N-terminus of the heavy chain comprising IL-6VH; or between the hinge region and the CH1 domain of the heavy chain comprising IL-6VH. When the names of Ab, antibody, "anti" or other similar terms are used in the names to represent antibodies or fragments thereof, there is no difference between these names. There is no difference between the names of "Il-6" or "IL6" or "IL-6". As used herein, when referring to fusion constructs with IL-6, the terms "VEGF", "VEGFR", "VEGF Trap", "VEGFR Trap" are used interchangeably. When used separately from the IL-6 fusion arrangement, these terms can have different meanings, which will depend on the context of the terms in question.

[0298] In some embodiments, the antibody can be connected or fused to the VEGF Trap sequence. In some embodiments, the Trap sequence can be shown in Table 2A. In some embodiments, the sequence is at least 80% identical to the sequence shown in Table 2A, for example, at least 80, 85, 90, 95, 96, 97, 98, 99% identical to the sequence shown in 2A. In some embodiments, any VEGF Trap molecule in U.S. Publication No. 20150376271 can be used herein. In some embodiments, the VEGF Trap sequence is fused to IL-6 in one of the following ways: fused to the N-terminus of the heavy chain comprising IL-6VH ( Fig. 9 left side), or between the hinge region and after the CH1 domain of the heavy chain containing IL-6 VH ( Fig. 9Right side). Unless otherwise stated, for the embodiments provided herein in which any Ab-Trap fusion is discussed, two optional options and two options together are considered. In some embodiments, the term "Trap" refers to a full-length extracellular region or any portion thereof, or a combination of portions from different VEGF receptors, which can antagonize signaling between at least one VEGF and VEGFR. Preferably, the extracellular trap segment includes at least one domain from one of VEGFR-1, -2 or -3, more preferably at least two continuous domains, such as D2 and D3. Optionally, the extracellular domain includes at least one domain from at least two different VEGFRs. The preferred extracellular domain comprises D2 of VEGFR-1 and D3 of VEGFR-2 or consists essentially of D2 of VEGFR-1 and D3 of VEGFR-2.

[0299] Table 2A: VEGFR1, domain 2 and VEGFR2, domain 3 fusion sequences.

[0300]

[0301] In some embodiments, the IL-6Ab VEGF Trap construct may have any sequence provided in Table 2B or 2B-1. In some embodiments, the construct may be at least identical to a sequence in Table 2B or 2B-1, e.g., 80, 85, 90, 95, 96, 97, 98, 99 or more. In some embodiments, the fusion protein may conform to those percentages, except that the antibody IL-6 domain does not include one or more CDRs in Table 1E. In some embodiments, the fusion protein is a protein comprising Figure 5 In some embodiments, the sequences can be directly fused to each other. In some embodiments, one or more flexible linker sequences or portions can be used. The linker sequence can be located between the Ab sequence and the VEGF Trap sequence. The length of these sequences can be 5 to 30 amino acids. In some embodiments, the linker sequence can include G and S in a ratio of about 4: 1. In some embodiments, the linker includes the following sequence: GGGGSGGGGS (SEQ ID NO: 748). In some embodiments, any flexible linker can be used. In some embodiments, the Fc portion of IL-6Ab is IgG1.

[0302] Table 2B: Heavy and light chain sequences of dual inhibitor molecules. CDRs are underlined in the heavy and light chains. The VEGFtrap sequence is in black bold and the Gly-Ser linker is in italics.

[0303]

[0304]

[0305]

[0306]

[0307]

[0308]

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317] Table 2B-1:

[0318]

[0319] Table 2C: Anti-IL-6 heavy chain variable region sequences. CDRs are underlined.

[0320]

[0321]

[0322] Table 2D: Anti-IL-6 light chain variable region sequences. CDRs are underlined.

[0323]

[0324] In some embodiments, the antibody has one or more (or any) of the following CDRs: Table 2E (which includes Table 2E1, Table 2E2, and / or Table 2E3).

[0325] Table 2E1

[0326]

[0327] Table 2E2

[0328]

[0329] Table 2E3

[0330]

[0331]

[0332] In some embodiments, the IL-6 antagonist antibody comprises three CDRs of any one of the heavy chain variable regions shown in Tables 2C, 2D, 2E1, 2E2 and / or 2E3. In some embodiments, the antibody comprises three CDRs of any one of the light chain variable regions shown in Tables 2C, 2D, 2E1, 2E2 and / or 2E3. In some embodiments, the antibody comprises three CDRs of any one of the heavy chain variable regions shown in Table 2C, and three CDRs of any one of the light chain variable regions shown in Table 2D. In some embodiments, the CDRs are one or more specified in Table 3 (including Tables 3A and / or 3B) or Table 4 (including Tables 4A and / or 4B) below:

[0333] Table 3A: Anti-IL-6 heavy chain CDR sequences.

[0334]

[0335]

[0336] Table 3B: Anti-IL-6 heavy chain CDR sequences.

[0337]

[0338] Table 4A: Anti-IL-6 light chain CDR sequences.

[0339]

[0340]

[0341] Table 4B: Anti-IL-6 light chain CDR sequences.

[0342] CDR1 CDR2 CDR3 SASISVSYLY SEQ ID NO.199) DDSSLAS SEQ ID NO.200) QQWSGYPYT (SEQ ID NO. 201) SASISVSYLY SEQ ID NO.202) DASSLAS SEQ ID NO.203) QQWSGYPYT (SEQ ID NO. 204) SASISVSYLY SEQ ID NO.205) DDSNLAS (SEQ ID NO. 206) QQWSGYPYT (SEQ ID NO. 207)

[0343] In some embodiments, the antibody for binding to IL-6 may be an antibody comprising one or more sequences in Tables 2C, 2D, 2E1, 2E2, 2E3, 3A, 3B, 4A and / or 4B. In some embodiments, the antibody for binding to IL-6 may be an antibody comprising three or more sequences in Tables 2C, 2D, 2E1, 2E2, 2E3, 3A, 3B, 4A and / or 4B. In some embodiments, the antibody for binding to IL-6 may be an antibody comprising six sequences in any one of Tables 2C, 2D, 2E1, 2E2, 2E3, 3A, 3B, 4A and / or 4B. In some embodiments, the antibody that binds to IL-6 may be an antibody that competes for binding with an antibody comprising six designated CDRs in any one of Tables 2C, 2D, 2E1, 2E2, 2E3, 3A, 3B, 4A and / or 4B.

[0344] The methods described herein may also include, wherein the antibody conjugate has a structure of Formula (I), wherein each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; PC is: wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

[0345] In some embodiments, a method for producing a product is provided. The method includes recovering a cell culture supernatant, wherein the cell culture supernatant comprises a target protein, treating the cell culture supernatant into an eluate, wherein the eluate comprises the target protein, loading the eluate onto an affinity chromatography matrix, washing with a first wash buffer comprising Tris or sodium phosphate, washing with a second wash buffer comprising a chaotropic salt, eluting with an elution buffer, wherein the eluate is collected, wherein the eluate comprises the protein product, inactivating viral contaminants present in the eluate with a low pH viral buffer to obtain a virus-inactivated eluate, filtering the virus-inactivated eluate, subjecting the virus-inactivated eluate to at least one round of ion exchange chromatography, and filtering the virus-inactivated eluate to obtain a retentate, wherein the retentate comprises the target protein.

[0346] In some embodiments, the method may also include, wherein the cell culture supernatant is produced using a cell culture without animal components in a bioreactor. The method may also include, wherein processing the cell culture supernatant includes harvesting a cell product from the cell culture. The method may also include, wherein the cell culture is clarified to remove cells and cell debris. The method may also include, wherein the eluent comprises a clarified cell culture supernatant. A method for purifying a protein using affinity chromatography, the method comprising contacting a loading fluid with a medium, wherein the medium is an affinity chromatography matrix that binds a target protein, washing the medium with a buffer solution comprising a chaotropic agent, wherein the chaotropic agent is a salt, and contacting the washed medium with an elution solution under conditions suitable for eluting the target protein.

[0347] In some embodiments, a method for producing a product is provided. The method comprises applying a solution containing a target protein to an affinity chromatography matrix, washing the affinity chromatography matrix with a first buffer, washing the affinity chromatography matrix with a second buffer containing a chaotropic agent, washing the affinity chromatography matrix with a third buffer to remove the chaotropic agent, eluting with an elution buffer, wherein an eluate is collected, wherein the eluate contains the protein product.

[0348] In some embodiments, a protein purification system is provided. The system includes: a column having a first antigen-binding protein bound to the column; a phosphate wash buffer comprising sodium phosphate and salt; an intermediate wash buffer comprising tris; a second wash buffer comprising magnesium chloride; and an elution buffer comprising sodium formate.

[0349] In some embodiments, a protein purification system is provided. The system includes: a column having a first antigen-binding protein bound to the column; a first tris wash buffer comprising tris and salt; an intermediate tris wash buffer; a second wash buffer comprising magnesium chloride; and an elution buffer comprising sodium formate.

[0350] In some embodiments, the system may also include, wherein the column comprises a ligand for affinity chromatography. The system may also include, wherein the ligand comprises protein A or protein G. The system may also include, wherein the first wash buffer comprising sodium phosphate and salt has a pH between 5.5 and 9.5. The system may also include, wherein the phosphate wash buffer comprising sodium phosphate and salt comprises about 50mM sodium phosphate. The system may also include, wherein the phosphate wash buffer comprising sodium phosphate and salt comprises about 250mM NaCl. The system may also include, wherein the first tris wash buffer comprises about 50mM Tris. The system may also include, wherein the first tris wash buffer also comprises about 250mM NaCl. The system may also include, wherein the intermediate tris wash buffer comprises about 50mM Tris. The system may also include, wherein the pH of the first tris wash buffer is about 7.2. The system may also include, wherein the pH of the second wash buffer is about 7.8. The system may also include, wherein the concentration of magnesium chloride in the second wash buffer is about 2.8M. The system can also include, wherein the concentration of sodium formate in the elution buffer comprises 10 mM.

[0351] In some embodiments, a protein purification system is provided. The system comprises a column having a protein A resin bound to an antibody, wherein the antibody comprises a light chain and a heavy chain of SEQ ID: 2 and SEQ ID 1, respectively, a chaotropic wash buffer comprising a chaotropic salt, and an elution buffer comprising sodium formate.

[0352] The methods described herein may also include, wherein the protein of interest is a bispecific antibody. The methods described herein may also include, wherein the bispecific antibody is specific for VEGF and IL-6. The methods described herein may also include, wherein the protein of interest is an antibody conjugate. The methods described herein may also include, wherein the affinity chromatography matrix is ​​a protein A chromatography matrix. The methods described herein may also include, wherein the chaotropic agent in the buffer solution comprises a magnesium salt. The methods described herein may also include, wherein the concentration of the magnesium salt is between 1.5-3.5M. The methods described herein may also include, wherein the chaotropic agent in the buffer solution comprises a calcium salt. The methods described herein may also include, wherein the concentration of the calcium salt is between 1-3M. The methods described herein may also include, wherein the chaotropic agent in the buffer solution comprises a guanidine salt. The methods described herein may also include, wherein the concentration of the guanidine salt is between 0.05-3M.

[0353] The methods described herein may also include, wherein the buffer solution also contains tris. The methods described herein may also include, wherein the concentration of tris in the buffer solution is at least 5 mM. The methods described herein may also include, wherein the pH of the buffer solution is greater than 5.5. The methods described herein may also include, wherein the eluate also contains viral impurities. The methods described herein may also include removing viral impurities. The methods described herein may also include inactivating viral impurities. The methods described herein may also include, before washing with the buffer solution, washing the affinity chromatography matrix loaded with the loading fluid with a pre-wash buffer solution. The methods described herein may also include, after washing with the buffer solution, washing the affinity chromatography matrix loaded with the eluate with a post-wash buffer solution. The methods described herein may also include, wherein the pre-wash buffer solution contains sodium phosphate. The methods described herein may also include, wherein the pre-wash buffer solution contains Tris and salt.

[0354] The methods described herein may also include, wherein the antibody conjugate has a structure of Formula (I),

[0355] wherein: each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; PC is:

[0356] wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

[0357] The method described herein may also include, wherein the antibody conjugate comprises an anti-VEGF antibody conjugate comprising an anti-VEGF-A light chain and an anti-VEGF-A heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDRH1: CDRH1 in SEQ ID NO: 172, CDRH2: CDRH2 in SEQ ID NO: 173, and CDRH3: CDRH3 in SEQ ID NO: 174, and the anti-VEGF-A antibody light chain comprises CDRL1: CDRL1 in SEQ ID NO: 199, CDRL2: CDRL2 in SEQ ID NO: 200, and CDRL3: CDRL3 in SEQ ID NO: 201. The methods described herein may also include, wherein the anti-VEGF antibody conjugate comprises: an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bound to a polymer, the polymer comprising an MPC monomer, wherein the sequence of the anti-VEGF-A antibody heavy chain is at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262, the sequence of the anti-VEGF-A antibody light chain is at least one of SEQ ID NOs: 91-93, 28-30, and wherein the antibody is bound to the polymer at C449. The methods described herein may also include, wherein the target protein of interest is produced by cell culture. The methods described herein may also include, wherein the cell culture comprises CHO cells. The methods described herein may also include, after washing with a buffer solution, the step of washing the affinity chromatography matrix loaded with the eluate with a post-wash buffer solution. The methods described herein may also include washing the affinity chromatography matrix with a buffer solution to remove nucleic acids, endotoxins, defoaming agents, or other small molecules other than the target protein of interest. The methods described herein may also include washing the affinity chromatography matrix with a buffer solution to remove impurities while keeping the target protein of interest bound to the affinity chromatography matrix. The methods described herein may also include washing the affinity chromatography matrix with a buffer solution to remove host cell proteins other than the target protein of interest. The methods described herein may also include, wherein the addition of a chaotropic agent to the buffer solution does not elute the target protein of interest. The methods described herein may also include one or more of viral inactivation, tangential flow filtration, diafiltration, ultrafiltration, ion exchange chromatography, or viral reduction filtration. The methods described herein may also include, wherein the eluent is produced using a cell culture without animal components in a bioreactor. The methods described herein may also include, wherein the product is the target protein. The methods described herein may also include, wherein the impurities include host cell protein impurities.

[0358] As disclosed herein, the purification method of the present disclosure effectively removes impurities, such as host cell proteins (HCP). As described in detail in the embodiments, the method effectively reduces the HCP in the washing eluate while achieving a high percentage yield of the target protein and a high concentration of the target protein. For example, in various embodiments, the method described herein results in a percentage yield of the target protein greater than 80%, greater than 81%, greater than 82%, greater than 83%, greater than 84%, greater than 85%, greater than 86%, greater than 87%, greater than 88%, greater than 89%, greater than 90%, greater than 91%, greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater than 99%.

[0359] As disclosed herein, the purification method of the present disclosure effectively removes impurities from the purification method based on affinity chromatography. In some embodiments, the purification method based on chromatography includes a method based on the specific macromolecular binding interaction between the analyte in the mobile phase and the ligand in the stationary phase. In some embodiments, the method effectively reduces the impurities in the washing eluate while achieving a high percentage yield of the target species. In some embodiments, the method effectively reduces the impurities in the washing eluate while achieving a high concentration of the target species. For example, in various embodiments, the method described herein results in a percentage yield of the target species greater than 80%, greater than 81%, greater than 82%, greater than 83%, greater than 84%, greater than 85%, greater than 86%, greater than 87%, greater than 88%, greater than 89%, greater than 90%, greater than 91%, greater than 92%, greater than 93%, greater than 94%, greater than 95%, greater than 96%, greater than 97%, greater than 98% or greater than 99%.

[0360] As disclosed herein, the purification methods of the present disclosure effectively remove impurities from samples containing monoclonal antibodies (mAbs). In some embodiments, the residues comprising mAb can be changed or engineered to change the overall antibody form or structure. In some embodiments, the residues comprising mAb can be changed or engineered to adjust the binding efficacy to a binding partner. In some embodiments, the residues comprising mAb can be changed or engineered to adjust the binding efficacy of an antigen binding site. In some embodiments, the residues comprising mAb can be changed or engineered to adjust the conjugation efficacy. In some embodiments, the changed residues can be engineered cysteine. In some embodiments, the monoclonal antibody comprises a specific binding domain, including a domain specific for VEGF. In some embodiments, the specific binding domain comprises one or more extracellular components of one or more VEGF receptors. In some embodiments, the binding domain also comprises an Fc portion.

[0361] Table 5 lists common types of high-risk HCPs that may be present and can be removed by this method. The table also includes possible downstream effects on the drug product of the formulation. Without this technology, some HCP species become difficult to remove due to the physicochemical properties close to other desired molecular species. In some embodiments, any one or more embodiments provided herein can be used to remove any one or more substances in Table 5. In some embodiments, the target product is selected from one or more substances in Table 5. In some embodiments, the target protein is selected from one or more substances in Table 5. HCPs that are difficult to remove can be classified as proteins with a molecular weight greater than 15kDa and / or a pI between 7.3 and 9.3.

[0362] Table 5: Common types of HCPA

[0363]

[0364]

[0365]

[0366]

[0367] about Figure 1 , discloses a process 100 for purifying the OG2072 antibody from an animal component-free cell culture process. The process includes three chromatography steps, two TFF (tangential flow filtration) steps, and low pH virus inactivation. First, the clarified cell supernatant is collected 110. Next, the clarified cell supernatant is subjected to affinity chromatography 120. The output eluate collected during the affinity chromatography is then subjected to low pH virus inactivation 130, followed by intermediate filtration 140. Further rounds of chromatography are then performed, including anion exchange chromatography 150, followed by cation exchange chromatography 160. This is followed by virus reduction filtration 170 and final ultrafiltration / diafiltration 180.

[0368] Low pH virus inactivation may include holding the solution at pH 3.5 for 240 minutes and then neutralizing to pH 7. Low pH virus inactivation may alternatively include holding at pH 3.5 for 60 minutes and then neutralizing to pH 5.5, 6 or 6.5. MabSelectSuRe LX affinity chromatography (MSS LX) may be followed by a virus inactivation / neutralization step, followed by a first TFF (TFF1) to condition the antibody for Sartobind Q anion exchange chromatography (AEX chromatography). POROS XS cation exchange chromatography (CEX chromatography) and virus reduction filtration (Planova 20N) are then performed. POROS XS includes binding at 10 mM sodium phosphate, pH 5, 40 mM NaCl, plus acetate (<15 mS / cm) as a supplement, followed by a gradient elution of 10 CV from 50 mM sodium acetate, pH 6, 10 mM NaCl to 50 mM sodium acetate, pH 6, 300 mM NaCl. During POROS XS chromatography containing 50 mM sodium acetate, pH 5, and 150 mM NaCl, additional washes may be performed followed by increasing the NaCl to 165, 180, 195, or 210 mM. A gradient may be applied to the POROS XS column step to provide a gradient from 150 mM NaCl to 400 mM NaCl at pH 5 in 10 CV with a 30 cm bed height, or from 50 mM NaCl to 350 mM NaCl at pH 6 in 12 CV with a 30 cm bed height. Prior to gradient elution, a washing step may be performed, comprising: 2CV of 50 mM sodium acetate, pH 5.0, 10 mM NaCl, followed by 5CV of 18.8 mM sodium phosphate, pH 7.0, 22.5 mM NaCl, followed by 3CV of 50 mM sodium acetate, pH 5.0, 10 mM NaCl, followed by 2CV of 50 mM sodium acetate, pH 6.0, 10 mM NaCl. Finally, a second TFF (TFF2) is performed to formulate the antibody and obtain an antibody intermediate.

[0369] Figure 2 A process 200 for purifying a biomolecule is shown. First, a cell culture is grown and cultured using a fermentation process 210. The cell culture is then collected at harvest 220 to produce a clarified cell concentrate. The clarified cell concentrate is then purified using affinity chromatography and viral inactivation / neutralization 230, the output of which is a product retentate. The collected product retentate is then subjected to tangential flow filtration 240, followed by anion exchange chromatography 250 and cation exchange chromatography 260 in sequence. The treated product retentate is then subjected to virus reduction filtration 270, where a second tangential flow filtration 280 is then performed to produce a purified product.

[0370] about Figure 3 , developed a scheme to evaluate the reduction fold of measurable HCP species to evaluate the yield and purity of the desired molecular species. A process 300 of column purification of OG2072 antibodies from a cell culture process without animal components is disclosed. The process includes balancing 310, followed by loading 320 columns with clarified cell culture fluid (CCCF). The column is then treated with a series of washes, which include wash 1 330, followed by wash 2 340, wash 3 350 and wash 4 360. Wash 2 340 may include sub-washes 340A, 340B and 340C. After wash 4 360, elution 370 is performed, whereby post elution buffer 380 is run on the column to regenerate the resin. The process includes equilibration 310 of a protein A column with 50 mM sodium phosphate and 250 mM NaCl at pH 7, followed by a loading 320 step where the column is loaded with clarified cell culture fluid (CCCF), followed by a series of washes 330-360 including a first wash 330 with 50 mM sodium phosphate and 250 mM NaCl at pH 7. Wash 2 340 can include various wash buffers and conditions as described in Table 6C. Wash 3 350 includes a wash with 50 mM sodium phosphate and 2 M NaCl at pH 7, while wash 4 360 includes a wash with 50 mM sodium phosphate, 250 mM NaCl at pH 7. Elution 370 is accomplished with 10 mM sodium formate at pH 3.5, and post elution is performed by passing 100 mM citric acid through the column at pH 2.1.

[0371] In some embodiments, Figure 8 , 11 Any one or more of the specific amino acid sequences in any one or more of -16 can be substituted into the corresponding structure of any other embodiment provided herein, or exchanged with any other sequence provided herein. In some embodiments, the construct is a VEGFR-anti-IL-6 configuration, and it includes a linker (e.g., Fig.12 , sequence 2A), linked to a heavy chain IL-6 sequence (e.g., Fig.13 , sequence 3A or 3B), linked to a light chain sequence (e.g., Fig.15 , sequence 4A) of sequences 1A-1D ( Fig.12 ) is a combination of one of the following. In some embodiments, any one of sequences 1A-1D ( Fig.12 ), can be combined with a connector ( Fig.12 and heavy chain anti-IL-6 sequence ( Figure 13-14 , sequence 3A-3I), and binds to the light chain anti-IL-6 sequence ( Fig.15, sequences 4A-4C) are combined. In some embodiments, any other corresponding sequence of any specific construct unit provided herein can be substituted into or replace any of these units.

[0372] In some embodiments, any anti-IL-6 antibody construct is contemplated for use as a composition, component, or therapy, including, for example, those in Tables 2C, 2D, 2E, 0.3, and / or 0.4, and the embodiments provided herein. Figure 8 , 11 -Those in 16.

[0373] In some embodiments, the fusion protein comprises a mutation at position 94 in the VEGF Trap sequence, at position 95 in the VEGF Trap sequence, or at T94I and H951 in the VEGF Trap sequence.

[0374] In some embodiments, a VEGFR-anti-IL-6 dual inhibitor is provided. The VEGFR-anti-IL-6 dual inhibitor comprises a trap antibody fusion of an anti-IL-6 antibody and a VEGF (VEGFR1 / 2) trap, wherein the dual inhibitor comprises at least one point mutation within the VEGFR sequence to reduce the cleavage of the VEGFR sequence. In some embodiments, the VEGFR-anti-IL-6 dual inhibitor has a molecular weight of 1.0 MDa.

[0375] In some embodiments, the dual VEGR-anti-IL-6 inhibitor provides treatment for inflammatory retinal diseases.

[0376] In some embodiments, the VEGFR-anti-IL-6 dual inhibitor comprises a constant heavy region, a constant light region, an antigen binding fragment region, a crystallizable fragment (Fc) region, a vascular endothelial growth factor receptor (VEGFR) region, a variable heavy region, a variable light region, and a CDR region.

[0377] In some embodiments, the anti-IL-6 heavy chain variable region sequence may be selected from Fig.11 SEQ ID NO: 7, 8, 9, 10, 11, 12 or 13.

[0378] In some embodiments, the VEGF trap sequence may be selected from Fig.12 At least one of SEQ ID NO: 14, 15, 16 or 17.

[0379] In some embodiments of the VEGR-anti-IL-6 dual inhibitor, the heavy chain sequence of the anti-IL-6 molecule can be selected from Figure 13-14 At least one of SEQ ID NO: 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27.

[0380] In some embodiments of the dual VEGFR-anti-IL-6 inhibitor, the light chain sequence of the anti-IL-6 molecule comprises Fig.15 At least 1, 2 or 3 light chain CDRs of at least one of SEQ ID NOs: 28, 29 or 30.

[0381] In some embodiments of the dual VEGFR-anti-IL-6 inhibitor, the heavy chain sequence of the anti-IL-6 molecule comprises Fig.16 at least 1, 2 or 3 heavy chain CDRs of at least one of 5A, 5B, 5C, 5D, 5E, 5F, 5G, 5H or 51.

[0382] In some embodiments, the dual VEGFR-anti-IL-6 inhibitor comprises Fig.18 A VEGFR-Fc sequence of at least one of SEQ ID NO: 85, 86, 87 or 88.

[0383] In some embodiments, the dual VEGFR-anti-IL-6 inhibitor comprises Figure 11-18 One or more sequences in .

[0384] In some embodiments, the VEGFR-anti-IL-6 dual inhibitor comprises IL-6 VH, IL-6 VL, IL-6 Fc, VEGFTrap and a linker. In some embodiments, the IL-6 VH comprises from Fig.16 or the IL6 VH sequence of 13-14. In some embodiments, the IL-6 VL comprises a sequence from Fig.15 In some embodiments, the Fc comprises a sequence of the IL6 VL sequence from Fig.16 In some embodiments, the VEGF Trap comprises a sequence from the VEGF trap sequence.

[0385] In some embodiments, a protein construct is provided, comprising: at least 3 heavy chain CDRs; at least 3 light chain CDRs; a VEGF trap sequence; and a linker sequence, wherein each sequence is selected from Figure 11-18 sequence in .

[0386] In some embodiments, a fusion protein is provided, comprising: IL-6VH, IL-6VL, IL-6Fc, VEGFTrap, and wherein the fusion protein alters HUVEC proliferation. In some embodiments, each sequence is selected from Figure 11-18 sequence in .

[0387] In other embodiments, the methods of the invention result in a reduction in the percentage of HCP contaminants in the eluate of at least about a 2-fold reduction, at least about a 3-fold reduction, at least about a 4-fold reduction, at least about a 5-fold reduction, at least about a 6-fold reduction, at least about a 7-fold reduction, at least about an 8-fold reduction, at least about a 9-fold reduction, at least about a 10-fold reduction, at least about a 15-fold reduction, or at least about a 20-fold reduction.

[0388] Thus, in one aspect, the present disclosure provides a method for producing a purified protein (e.g., an antibody, an antibody fragment, or a protein comprising an Fc region (e.g., an Fc fusion protein)) using an affinity chromatography (AC) matrix to which a target protein is bound, the method comprising washing the AC matrix with a washing solution comprising magnesium chloride or an equivalent chaotropic agent. In some embodiments, the pH of the washing solution comprising magnesium chloride is about 7.8, the pH being about 6, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.9, about 8, about 8.1, about 8.2, about 8.3, about 8.4, about 8.5, about 8.6, about 8.7, about 8.8, about 8.9, about 9, before eluting the target protein from the AC matrix. In some embodiments, the wash solution comprises about 1 M, about 1.1 M, about 1.2 M, about 1.3 M, about 1.4 M, about 1.5 M, about 1.6 M, about 1.7 M, about 1.8 M, about 1.9 M, about 2 M, about 2.1 M, about 2.2 M, about 2.3 M, about 2.4 M, about 2.5 M, about 2.6 M, about 2.7 M, about 2.8 M, about 2.9 M, about 3 M, about 3.1 M, about 3.2 M, about 3.3 M, about 3.4 M, about 3.5 M, about 3.6 M, about 3.7 M, about 3.8 M, about 3.9 M, about 4 M, about 4.1 M, about 4.2 M, or more than 4.2 M magnesium chloride.

[0389] Antibody conjugates

[0390] Anti-VEGF antibodies (including anti-VEGF proteins, such as aflibercept) and conjugates thereof are provided herein. In some embodiments, the antibody itself is different from other anti-VEGF agents and provides results superior to other anti-VEGF agents. In some embodiments, the anti-VEGF antibody conjugates show surprising advantages over other antibodies and / or superior expected activities over other antibody conjugates.

[0391] In some embodiments, the anti-VEGF antibody conjugate is KSI-301, which is an antibody conjugate comprising:

[0392] (1) anti-VEGF-A antibodies; and

[0393] (2) a polymer containing phosphorylcholine, wherein the polymer is covalently bound to an anti-VEGF-A antibody at a cysteine ​​outside a variable region of the anti-VEGF-A antibody, and wherein the cysteine ​​replaces a non-cysteine ​​amino acid occurring at the same position in the sequence, wherein the anti-VEGF-A antibody comprises a light chain and a heavy chain, the heavy chain comprising an Fc region, wherein the cysteine ​​is in the Fc region of the heavy chain, wherein the sequence of the heavy chain is at least one of SEQ ID NO: 270, and wherein the sequence of the light chain comprises at least one of SEQ ID NO: 275 (or its sequence in Figure 8 ), wherein the antibody conjugate has the structure of Formula (I),

[0394] wherein: each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; wherein the polymer is bound to the anti-VEGF-A antibody via a sulfhydryl group at C443 according to EU numbering, the binding being depicted on one of the heavy chains; wherein PC is wherein the curved line represents the point of attachment to the rest of the polymer; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

[0395] Historically, conjugating molecules to proteins usually results in a reduction in the binding interaction of proteins with their intended targets. In some embodiments of the present disclosure, when conjugated to a position outside the active site, a reduction at the same level as expected is not necessarily observed. The evidence provided herein shows an effect contrary to expectation. In some embodiments, it is not intended to be limited by theory, and conjugates may be superior to single antibodies. For example, the interaction of a ligand and its specific receptor is usually driven by the stereospecific interaction of a ligand and a receptor, which is guided by the interaction of the hydrophilic amino acids on the ligand and the hydrophilic amino acids on the receptor, and water molecules are at the forefront and center in these interactions. At the same time, this hydrophilic stereospecificity is further enhanced by de-emphasizing and / or suppressing nonspecific hydrophobic interactions, which may usually be mediated / produced by hydrophobic-hydrophobic amino acids.

[0396] In some embodiments, an anti-VEGF antibody conjugate is provided that is capable of blocking at least 90% of the interaction between a VEGF ligand ("VEGFL") and a VEGF receptor ("VEGFR"). For example, it can block at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or effectively all interactions between VEGFR and VEGFL. In some embodiments, the blockade noted occurs at saturating concentrations. In some embodiments, an anti-VEGF antibody conjugate is provided that blocks at least 95% of the interaction between a VEGF ligand and a VEGF receptor. An example of such a blocking advantage is that an anti-VEGF antibody bioconjugate (the antibody conjugate provided herein, e.g., KSI-301) is superior to (ranibizumab) or In fact, this result was unexpected because, although adding a polymer to an antibody (to form an antibody conjugate) could be expected to have some or no adverse effect on the binding / activity of the antibody, it was unexpected that it would actually enhance the blocking ability of the antibody in this way.

[0397] In some embodiments, the antibody or its conjugate inhibits at least 70, 80, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% activity and / or interaction between VEGFR and VEGFL. In some embodiments, the IC50 value can be 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100 nM or less than any one or more of the aforementioned values. In some embodiments, KD can be 2*10^-13, 1*10^-13, 1*10^-12, 1*10^-11, 1*10^-10M or less than any one of the aforementioned values. In some embodiments, the IC50 value can be 1, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, or less than any of the foregoing values.

[0398] In some embodiments, an anti-VEGF antibody is provided that blocks at least 90% of the interaction between a VEGF ligand and a VEGF receptor. For example, it can block at least 91, 92, 93, 94, 95, 96, 97, 98, 99, or effectively all interactions between VEGFR and VEGFL. An example of such a blocking advantage is that OG1950 (and the antibodies provided herein) is more effective than (ranibizumab) or (bevacizumab) had a higher degree of blocking ability.

[0399] In some embodiments, other antibodies, such as (ranibizumab) or (bevacizumab), can be conjugated to one or more polymers described herein by one or more methods described herein. In some embodiments, any antibody or fragment thereof can be conjugated to one or more polymers described herein by one or more methods described herein.

[0400] In some embodiments, the antibody comprises a heavy chain amino acid variable region and a light chain amino acid variable region, the heavy chain amino acid variable region comprises at least one of SEQ ID NO: 7-13, 19-27, 89, 90, 256-262, and the light chain amino acid variable region comprises at least one of SEQ ID NO: 91-93, 28-30. In some embodiments, the antibody is conjugated to one or more polymers provided herein. In some embodiments, the conjugated antibody is at least 90% identical to at least one of SEQ ID NO: 7-13, 19-27, 89, 90, 256-262 and / or SEQ ID NO: 91-93, 28-30. In some embodiments, the antibody comprises 6 CDRs within at least one of SEQ ID NO: 7-13, 19-27, 89, 90, 256-262 and SEQ ID NO: 91-93, 28-30, and a point mutation of L443C (EU numbering, or 449C). In some embodiments, the conjugated antibody is at least 90% identical to at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262 and / or at least one of SEQ ID NOs: 91-93, 28-30, and includes the following mutations: L234A, L235A, and G237A (EU numbering), and at least one of the following mutations: Q347C (EU numbering) or L443C (EU numbering).

[0401] In some embodiments, an antibody that binds to VEGF-A is provided. The antibody comprises: CDRH1, i.e., CDRH1 in SEQ ID NO: 172; CDRH2, i.e., CDRH2 in SEQ ID NO: 173; CDRH3, i.e., CDRH3 in SEQ ID NO: 174; CDRL1, i.e., CDRL1 in SEQ ID NO: 199; CDRL2, i.e., CDRL2 in SEQ ID NO: 200; CDRL3, i.e., CDRL3 in SEQ ID NO: 201; at least one of the following mutations (EU numbering): L234A, L235A, and G237A; and at least one of the following mutations (EU numbering): Q347C or L443C.

[0402] As will be appreciated by those of skill in the art, based on the present description, any antibody provided herein may be conjugated to any polymer provided herein, and / or any antibody provided herein may have added cysteines such that it allows site-specific conjugation to a polymer.

[0403] "VEGF" or "vascular endothelial growth factor" is a human vascular endothelial growth factor that affects angiogenesis or the angiogenic process. In particular, the term VEGF refers to any member of the class of growth factors that (i) binds to a VEGF receptor, such as VEGFR-1 (Flt-1), VEGFR-2 (KDR / Flk-1), or VEGFR-3 (FLT-4); (ii) activates tyrosine kinase activity associated with the VEGF receptor; and (iii) thereby affects angiogenesis or the angiogenic process.

[0404] The VEGF factor family consists of five related glycoproteins: VEGF-A (also known as VPE), -B, -C, -D and PGF (placental growth factor). Of these, VEGF-A is the most well-studied and is the target of anti-angiogenic therapy. Ferrara et al., (2003) Nat. Med. 9:669-676. VEGF-A exists in a variety of different isoforms, which are generated by alternative splicing and proteolysis: VEGF-A 206 , VEGF-A 189 , VEGF-A 165 and VEGF-A 121 The isoforms differ in their ability to bind heparin and a non-signaling binding protein called neuropilin. All isoforms are biologically active as dimers.

[0405] The various effects of VEGF are mediated by the binding of VEGF, such as VEGF-A (P15692), -B (P49766), -C (P49767) and -D (q43915) to receptor tyrosine kinases (RTKs). The VEGF family receptors belong to class V RTKs, each of which carries 7 Ig-like domains in the extracellular domain (ECD). In humans, VEGF binds to three types of RTKs: VEGFR-1 (Flt-1) (P17948), VEGFR-2 (KDR, Flk-1) (P935968) and VEGFR-3 (Flt-4) (P35916). Unless otherwise indicated in the context, the VEGF referred to refers to any one of VEGF-A, -B, -C, -D and PGF, in the form of any natural isoform or natural variant or an induced variant having at least 90, 95, 98 or 99% or 100% sequence identity with the natural form. In some embodiments, such VEGF is human VEGF. Likewise, reference to VEGFR refers to any of VEGR-1, R-2 or R-3, including any natural isoform or natural variant or induced variant having at least 90, 95, 98 or 99% or 100% sequence identity with the native sequence.

[0406] VEGF antagonist therapy has been approved for the treatment of certain cancers and wet AMD. Bevacizumab (AVASTIN, Genentech / Roche) is a humanized mouse monoclonal antibody that binds and neutralizes human VEGF, particularly all isoforms of VEGF-A and biologically active proteolytic fragments of VEGF-A. See, e.g., Ferrara N, Hillan KJ, Gerber HP, Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3(5): 391-400. Bevacizumab has been approved for the treatment of certain cancers.

[0407] Bevacizumab variable light chain CDR is CDR L 1:SASQDISNYLN(SEQ ID NO:749), CDR L 2: FTSSLHS (SEQ ID NO: 750) and CDRs L 3:QQYSTVPWT (SEQ ID NO: 751). Bevacizumab variable heavy chain CDR is CDR H 1:GYTFTNYGMN (SEQ ID NO:752), CDR H2: WINTYTGEPTYAADFKR (SEQ ID NO:753) and CDR H 3: YPHYYGSSHWYFDV (SEQ ID NO: 755). CDRs are defined by Kabat, but CDRH1 uses the Kabat / Chothia composite definition. In some embodiments, cysteine ​​can be added to the bevacizumab sequence, and the antibody (and / or variants including the 6 CDRs of bevacizumab) can be conjugated to any one or more polymers provided herein. In some embodiments, bevacizumab or ranibizumab CDRs can be used in the compositions and methods provided herein.

[0408] Another anti-VEGF molecule derived from the same mouse monoclonal antibody as bevacizumab has been approved for the treatment of wet AMD: ranibizumab ( (Ranizumab), Genentech / Roche). Ranibizumab is an antibody fragment or Fab. Ranibizumab was produced by affinity maturation of the variable heavy and light chains of bevacizumab. In some embodiments, cysteine ​​can be added to the ranibizumab sequence, and the antibody (and / or variants comprising the six CDRs of ranibizumab) can be conjugated to any one or more polymers provided herein.

[0409] The CDRs of ranibizumab are the same as those of bevacizumab, except that improvements have been added after affinity maturation: the variable light chain CDRs of ranibizumab are CDRs L 1:SASQDISNYLN(SEQ ID NO:749), CDR L 2: FTSSLHS (SEQ ID NO: 750) and CDRs L 3:QQYSTVPWT (SEQ ID NO: 751). The variable heavy chain CDR of ranibizumab is CDR H 1:GYDFTHYGMN (SEQ ID NO:754), CDR H 2: WINTYTGEPTYAADFKR (SEQ ID NO:753) and CDR H 3:YPYYYGTSHWYFDV (SEQ ID NO:756).

[0410] In some embodiments, an antibody conjugate is provided with an anti-VEGF-A antibody, which is conjugated to a polymer containing phosphorylcholine at a cysteine ​​outside the variable region of the antibody, wherein the cysteine ​​has been added by recombinant DNA technology. In some embodiments, the polymer is conjugated to a single cysteine. In some embodiments, "added by recombinant DNA technology" means that a cysteine ​​residue replaces a non-cysteine ​​amino acid that appears at the same position in a known or existing antibody or consensus antibody sequence. Thus, for example, when the antibody is IgG1 and the heavy chain has a leucine at EU position 443, the leucine is replaced by cysteine ​​(L443C, EU numbering, or 449C) by recombinant DNA technology. Accordingly, the native IgG1 sequence is Q (glutamine) at EU position 347, and Q is replaced by cysteine ​​by recombinant DNA technology to produce Q347C.

[0411] In some embodiments, the anti-VEGF-A antibody comprises a light chain and a heavy chain, wherein the heavy chain has an Fc region. In some embodiments, the cysteine ​​is in the Fc region, and the anti-VEGF-A antibody is immunoglobulin G (IgG). In some embodiments, the anti-VEGF-A heavy chain has CDRs H 1:GYDFTHYGMN (SEQ ID NO:754), CDR H 2: WINTYTGEPTYAADFKR (SEQID NO:753) and CDR H 3: YPYYYGTSHWYFDV (SEQ ID NO: 756), and position 221 is T, the anti-VEGF-A light chain has CDR L 1:SASQDISNYLN(SEQ ID NO:749), CDR L 2: FTSSLHS (SEQ ID NO: 750) and CDRs L 3: QQYSTVPWT (SEQ ID NO: 751), and Kabat position 4 is L.

[0412] In some embodiments, the anti-VEGF-A heavy chain isotype is IgG1. In some embodiments, the IgG1 constant domain has one or more mutations relative to the IgG1 constant domain to modulate effector function. In some embodiments, the effector function mutation is one or more of the following: (EU numbering) E233X, L234X, L235X, G236X, G237X, A327X, A330X, and P331X, wherein X is any natural or unnatural amino acid. In some embodiments, the mutation is selected from the group consisting of (EU numbering): E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S. In some embodiments, the antibody conjugate has the following mutations (EU numbering): L234A, L235A, and G237A.

[0413] In some embodiments, the cysteine ​​residue is in the anti-VEGF-A heavy chain and is Q347C (EU numbering) or L443C (EU numbering). In some embodiments, the cysteine ​​residue is L443C (EU numbering, or 449C). In some embodiments, the sequence of the anti-VEGF-A heavy chain is SEQ ID NO: 7-13, 19-27, 89, 90, 256-262, and the light chain sequence includes at least one of SEQ ID NO: 91-93, 28-30.

[0414] In some embodiments, the phosphorylcholine-containing polymer comprises a 2-(methacryloyloxyethyl)-2'-(trimethylammonium)ethyl phosphate (MPC) monomer as described below:

[0415] Such that the polymer comprises the following repeating units:

[0416]

[0417] Where n is an integer from 1 to 3000, and the wavy lines represent the connection points between monomer units in the polymer.

[0418] In some embodiments, the polymer has three or more arms, or is synthesized with an initiator comprising 3 or more polymer initiation sites. In some embodiments, the polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 arms, or is synthesized with an initiator comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 polymer initiation sites. More preferably, the polymer has 3, 6 or 9 arms, or is synthesized with an initiator comprising 3, 6 or 9 polymer initiation sites. In some embodiments, the polymer has 9 arms, or is synthesized with an initiator comprising 9 polymer initiation sites.

[0419] In some embodiments, the molecular weight of the added polymer is between about 300,000 and about 1,750,000 Da (SEC-MALs). In some embodiments, the molecular weight of the polymer is between about 500,000 and about 1,000,000 Da. In some embodiments, the molecular weight of the polymer is between about 600,000 and about 900,000 Da. In some embodiments, the molecular weight of the polymer is between about 750,000 and about 850,000 Da. In some embodiments, the molecular weight of the polymer is between about 800,000 and about 850,000 Da. In some embodiments, the molecular weight of the polymer is between about 750,000 and about 800,000 Da.

[0420] In some embodiments, any of the antibodies described herein can be further conjugated to a polymer to form a bioconjugate. The molecular weight of the bioconjugate (generally, SEC-MALs) can be between about 350,000 and 2,000,000 Daltons, for example, between about 450,000 and 1,900,000 Daltons, between about 550,000 and 1,800,000 Daltons, between about 650,000 and 1,700,000 Daltons, between about 750,000 and 1,600,000 Daltons, between about 850,000 and 1,500,000 Daltons, between about 1000,000 and 1500,000 Daltons, between about 1500,000 and 1,600,000 Daltons, between about 1000,000 and 15 ... Between about 900,000 and 1,400,000 Daltons, between about 950,000 and 1,300,000 Daltons, between about 900,000 and 1,000,000 Daltons, between about 1,000,000 and 1,300,000 Daltons, between about 850,000 and 1,300,000 Daltons, between about 850,000 and 1,000,000 Daltons, and between about 1,000,000 and 1,200,000 Daltons.

[0421] In some embodiments, the antibody conjugate is purified. In some embodiments, the polymer is polydisperse in the antibody conjugate, i.e., the polymer PDI is not 1.0. In some embodiments, the PDI is less than 1.5. In some embodiments, the PDI is less than 1.4. In some embodiments, the PDI is less than 1.3. In some embodiments, the PDI is less than 1.2. In some embodiments, the PDI is less than 1.1.

[0422] In some embodiments, the antibody conjugate has an anti-VEGF-A immunoglobulin G (IgG) bound to a polymer, the polymer comprising an MPC monomer, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO: 7-13, 19-27, 89, 90, 256-262, the light chain sequence includes at least one of SEQ ID NO: 91-93, 28-30, and wherein the antibody is bound to the polymer only at C449. In some embodiments, the polymer has 9 arms and a molecular weight between about 600,000 and about 1,000,000 Da.

[0423] In some embodiments, the antibody conjugate has anti-VEGF-A immunoglobulin G (IgG) bound to a polymer, the polymer comprising an MPC monomer, wherein the sequence of the anti-VEGF-A heavy chain is SEQ ID NO. 7-13, 19-27, 89, 90, 256-262, the sequence of the anti-VEGF-A light chain is SEQ ID NO. 91-93, 28-30, and wherein the antibody is bound to the polymer only at C443 (EU numbering, or 449C). In some embodiments, the polymer has 9 arms and a molecular weight between about 600,000 and about 1,000,000 Da.

[0424] In some embodiments, the antibody conjugate has the structure of Formula (I),

[0425]

[0426] wherein: each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; wherein the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C449, the binding being depicted on one of the heavy chains; wherein PC is, wherein the curved line represents the point of attachment to the rest of the polymer; wherein X is a) -OR, wherein R is H, methyl, ethyl, propyl or isopropyl, b) -H, c) any halogen, including -Br, -Cl or -I, d) -SCN, or e) -NCS; and wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%. In some embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000. In some embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 500. In some embodiments, X is -OR, wherein R is a sugar, an aminoalkyl group, a mono-, poly- or unsubstituted variant of: a saturated C1-C24 Alkyl, unsaturated C2-C 24 Alkenyl or C2-C 24 Alkynyl, acyl, acyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkyloxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxygen sulfonyl, carboxyl, cyano and haloalkyl (including polyhaloalkyl), -CO-O-R7, carbonyl-CCO-R7, -CO-NR8R9, -(CH2) n -COOR7, -CO-(CH) n -COOR7, -(CH2) n -NR8R9, ester, alkoxycarbonyl, aryloxycarbonyl, wherein n is an integer from 1 to 6, wherein each of R7, R8 and R9 is independently selected from the group consisting of: hydrogen atom, halogen atom, monosubstituted, polysubstituted or unsubstituted variants of the following residues: saturated C1-C 24 Alkyl, unsaturated C2-C 24 Alkenyl or C2-C 24 Alkynyl, acyl, acyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkyloxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxysulfonyl, carboxyl, cyano and haloalkyl (including polyhaloalkyl), 5-membered ring and 6-membered ring.

[0427] In some embodiments, the antibody conjugate has the structure of Formula (I),

[0428]

[0429] wherein: each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; wherein the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering, or 449C), which is depicted on one of the heavy chains; wherein PC is, wherein the curved line represents the point of attachment to the rest of the polymer; wherein X is a) -OR, wherein R is H, methyl, ethyl, propyl or isopropyl, b) -H, c) any halogen, including Br, -Cl or -I, d) -SCN, or e) -NCS; and wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%. In some embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000. In some embodiments, n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 500. In some embodiments, X is -OR, wherein R is a sugar, an aminoalkyl group, a mono-, poly- or unsubstituted variant of: a saturated C1-C 24 Alkyl, unsaturated C2-C 24 Alkenyl or C2-C 24 Alkynyl, acyl, acyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkyloxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxygen sulfonyl, carboxyl, cyano and haloalkyl (including polyhaloalkyl), -CO-O-R7, carbonyl-CCO-R7, -CO-NR8R9, -(CH2) n -COOR7, -CO-(CH) n -COOR7, -(CH2) n -NR8R9, ester, alkoxycarbonyl, aryloxycarbonyl, wherein n is an integer from 1 to 6, wherein each of R7, R8 and R9 is independently selected from the group consisting of: hydrogen atom, halogen atom, monosubstituted, polysubstituted or unsubstituted variants of the following residues: saturated C1-C 24 Alkyl, unsaturated C2-C 24 Alkenyl or C2-C 24 Alkynyl, acyl, acyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, cycloalkyl, cycloalkenyl, alkoxy, cycloalkyloxy, aryl, heteroaryl, arylalkoxycarbonyl, alkoxycarbonylacyl, amino, aminocarbonyl, aminocarbonyloxy, nitro, azido, phenyl, hydroxy, alkylthio, arylthio, oxygen sulfonyl, carboxyl, cyano and halogenated alkyl (including polyhalogenated alkyl), 5-membered ring and 6-membered ring. In some embodiments, the construct is named KSI-301.

[0430] In some embodiments, the antibody conjugate is present in a liquid formulation. In some embodiments, the antibody conjugate is combined with a pharmaceutically acceptable carrier. In some embodiments, any of the methods provided herein can use the following pharmaceutical formulations: a) 12.5 mM sodium phosphate buffer, pH 6.5, containing 0.025% (w / w) polysorbate 20, at a concentration of 50 mg / mL (based on the mass of the antibody), equivalent to a total mass of 324 mg / mL of the antibody-biopolymer conjugate, including 50 mg / mLOG1950 antibody intermediate and 274 mg / mL OG1802 biopolymer intermediate, b) 10-15 mM sodium phosphate buffer, pH 6.5, containing 0.01-0.5% (w / w) polysorbate 20, at a concentration of about 50 mg / mL (based on the mass of the antibody), equivalent to a total mass of about 324 mg / mL of the antibody-biopolymer conjugate, c) 12.5 mM sodium phosphate buffer, pH 6.5, containing optionally 0.025% (w / w) polysorbate 20 6.5, with a concentration of 50 mg / mL (based on the mass of the antibody), equivalent to a total mass of 324 mg / mL of the antibody-biopolymer conjugate, including 50 mg / mL OG1950 antibody intermediate and 274 mg / mL OG1802 biopolymer intermediate, d) sodium phosphate buffer containing polysorbate 20, pH 6.5, with a concentration of 50 mg / mL (based on the mass of the antibody), equivalent to a total mass of about 324 mg / mL of the antibody-biopolymer conjugate, including about 50 mg / mL OG1950 antibody intermediate and about 274 mg / mL OG1802 biopolymer intermediate, e) 10-15 mM sodium phosphate buffer containing 0.01-0.5% (w / w) polysorbate 20, pH 6.5, at a concentration of about 40-55 mg / mL (based on the mass of the antibody), equivalent to about 259-356 mg / mL of the total mass of the antibody-biopolymer conjugate, f) 10-15 mM sodium phosphate buffer, pH 6.5 containing 0.01-0.5% (w / w) polysorbate 20, at a concentration of about 45-52.5 mg / mL (based on the mass of the antibody), equivalent to about 292-340 mg / mL of the total mass of the antibody-biopolymer conjugate, or g) 10-15 mM sodium phosphate buffer, pH 6.5 containing 0.01-0.5% (w / w) polysorbate 20, at a concentration of about 40-55 mg / mL (based on the mass of the antibody), equivalent to about 259-356 mg / mL of the total mass of the antibody-biopolymer conjugate. In any of these formulations, the antibody can be used Figure 8 The VH and VL in (or 1, 2, 3, 4, 5 or all 6 CDRs in these VH and / or VL sequences), for example OG1950 (e.g., SEQ ID Nos: 1, 15-18 and 2).

[0431] In some embodiments, an anti-VEGF-A antibody is provided. The heavy chain of the anti-VEGF-A antibody has at least the following CDR sequence: CDR H 1: CDRH1, CDR in SEQ ID NO: 172 H 2: CDRH2 and CDR in SEQ ID NO: 173 H 3: i.e., CDRH3 in SEQ ID NO: 174. In some embodiments, the anti-VEGF-A heavy chain has those CDRs and additionally has a threonine (T) at position 221. In some embodiments, the anti-VEGF-A light chain has at least the following CDRs: CDR L 1: CDRL1, CDR in SEQ ID NO: 199 L 2: CDRL2 and CDR in SEQ ID NO: 200 L 3: i.e., CDRL3 in SEQ ID NO: 201. In some embodiments, the anti-VEGF-A antibody has those CDRs and additionally has a leucine (L) at Kabat position 4. In some embodiments, the isotype of the anti-VEGF-A antibody heavy chain is IgG1 and has CH1, hinge, CH2, and CH3 domains. In some embodiments, the light chain isotype is κ. In some embodiments, the anti-VEGF antibody conjugate (e.g., KSI-301) construct will have one or more of these CDRs.

[0432] In some embodiments, the IgG1 domain of the anti-VEGF-A antibody has one or more mutations to modulate effector function, such as ADCC, ADCP, and CDC. In some embodiments, the IgG1 mutation reduces effector function. In some embodiments, the amino acids used for effector function mutations include (EU numbering) E233X, L234X, L235X, G236X, G237X, G236X, D270X, K322X, A327X, P329X, A330X, A330X, P331X, and P331X, wherein X is any natural or unnatural amino acid. In some embodiments, the mutation includes one or more of the following: E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S (EU numbering). In some embodiments, the anti-VEGF-A heavy chain has the following mutations (EU numbering): L234A, L235A, and G237A. In some embodiments, the number of effector function mutations relative to the native human IgG1 sequence does not exceed 10. In some embodiments, the number of effector function mutations relative to the native human IgG1 sequence does not exceed 5, 4, 3, 2, or 1. In some embodiments, the antibody has reduced Fcγ binding and / or complement C1q binding, such that the antibody has reduced ability to produce effector function. This is particularly advantageous for ocular indications / disorders.

[0433] In some embodiments, the anti-VEGF-A antibody comprises one or more of the following amino acid mutations: L234A, L235A, G237A (EU numbering), and L443C (EU numbering, or 449C).

[0434] In some embodiments, the anti-VEGF-A antibody is human immunoglobulin G (IgG1) or a portion thereof.

[0435] In some embodiments, the VEGF-A antibody comprises a heavy chain constant domain comprising one or more mutations that reduce immune-mediated effector function.

[0436] In some embodiments, an anti-VEGF-A antibody is provided. The anti-VEGF antibody comprises a heavy chain comprising a CDR comprising the CDRH1 sequence of SEQ ID NO: 172 H 1. CDR containing the CDRH2 sequence in SEQ ID NO: 173 H 2. CDR containing the CDRH3 sequence in SEQ ID NO: 174 H 3. CDR containing the CDRL1 sequence in SEQ ID NO: 199 L 1. CDR containing the CDRL2 sequence in SEQ ID NO: 200L 2 and a CDR containing the CDRL3 sequence in SEQ ID NO: 201 L 3.

[0437] Alternatively, the IgG domain may be IgG2, IgG3 or IgG4 or a complex in which the constant region is formed by more than one of these isotypes (e.g., a CH1 region from IgG2 or IgG4, a hinge region, a CH2 region, and a CH3 region from IgG1). These domains may comprise mutations to reduce and / or modulate the effector function of one or more EU positions mentioned in IgG1. Relative to human IgG1 and IgG3, the effector function of human IgG2 and IgG4 is reduced.

[0438] The anti-VEGF-A heavy chain has a cysteine ​​residue added as a mutation by recombinant DNA technology, which can be used to conjugate a half-life extension moiety. In some embodiments, the mutation is (EU numbering) Q347C (EU numbering) and / or L443C (EU numbering, or 449C). In some embodiments, the mutation is L443C (EU numbering, or 449C). In some embodiments, the stoichiometric ratio of antibody to polymer is 1:1; in other words, the conjugate has one antibody molecule conjugated to one polymer molecule.

[0439] The half-life of anti-VEGF-A antibodies can be extended by attaching a "half-life extending moiety" or "half-life extending group". Half-life extending moieties include peptides and proteins and various polymers, which can be expressed in-frame with the biopharmaceutical under study (or chemically conjugated as appropriate), and polymers that can be attached or conjugated to one or more amino acid side chains or terminal functional groups (e.g., -SH, -OH, -COOH, -CONH2, -NH2) or one or more N- and / or O-glycan structures. Half-life extending moieties are generally used to increase the in vivo circulation half-life of biopharmaceuticals.

[0440] Examples of peptide / protein half-life extending moieties include Fc fusions (Capon DJ, Chamow SM, Mordenti J et al. Designing CD4 immunoadhesions for AIDS therapy. Nature. 1989. 337: 525-31), human serum albumin (HAS) fusions (Yeh P, Landais D, Lemaitre M et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. Proc Natl Acad Sci USA. 1992. 89: 1904-08), carboxyl-terminal peptide (CTP) fusions (Fares FA, Suganuma N. Nishimori K et al. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci USA.1992.89:4304-08), non-precise repeat peptide sequence (XTEN) gene fusion (Schellenberger V, Wang CW, Geething NC et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol.2009.27:1186-90), elastin-like peptide (ELPylation) (MCpherson DT, Morrow C, Minehan DS et al. Production and purification of a recombinantelastomeric polypeptide, G (VPGVG19-VPGV, from Escheriachia coli. Biotechnol Prog.1992.8:347-52), human transferrin fusion (Prior CP, Lai CH, Sadehghi H et al. Modified transferrin fusion proteins. Patent WO2004 / 020405.2004), proline-alanine-serine (PASylation) (Skerra A, Theobald I, Schlapsky M. Biological active proteins having increased in vivo and / or in vitro stability. Patent WO2008 / 155134A1.2008), amino acid homopolymer (HAPylation) (Schlapschy M, Theobald I, Mack H et al. Fusion of arecombinant antibody fragment with a homo-amino acid polymer: effects on biophysical properties and prolonged plasma half-life. Protein Eng Des Sel. 2007.20:273-84) and gelatin-like protein (GLK) fusion (Huang YS, Wen XF, Zaro JL et al. Engineering a pharmacologically superior form of granulocyte-colony-stimulating-factor by fusion with gelatin-like protein polymer. Eur J. PharmBiopharm. 2010.72:435-41). .

[0441] Examples of polymeric half-life extending moieties include polyethylene glycol (PEG), branched PEG, (Warwick Effect Polymers; Coventry, UK), polysialic acid (PSA), starch, hydroxyethyl starch (HES), hydroxyalkyl starch (HAS), carbohydrates, polysaccharides, pullulan, chitosan, hyaluronic acid, chondroitin sulfate, dermatan sulfate, dextran, carboxymethyl dextran, polyalkylene oxide (PAO), polyalkylene glycol (PAG), polypropylene glycol (PPG), polyoxazoline, polyacryloylmorpholine, polyvinyl alcohol (PVA), polycarboxylates, polyvinylpyrrolidone, polyphosphazene, polyoxazoline, polyethylene-co-maleic anhydride, polystyrene-co-maleic anhydride, poly(1-hydroxymethylethylene hydroxymethylformaldehyde) (PHF), zwitterionic polymers, phosphorylcholine-containing polymers, and MPC-containing polymers, poly(Gly x -Ser y ), Hyaluronic acid (HA), Heparosan polymers (HEP), Fleximers, Dextran and Polysialic acid (PSA).

[0442] In one embodiment, the half-life extending moiety can be conjugated to the antibody through the free amino groups of the protein using N-hydroxysuccinimide (NHS) esters. Targeted amine binding agents can react randomly with the ε-amine group of lysine, the α-amine group of the N-terminal amino acid, and the δ-amine group of histidine.

[0443] However, the anti-VEGF-A antibodies disclosed herein have many amine groups available for polymer conjugation. Therefore, conjugation of polymers to free amino groups may negatively affect the ability of the antibody protein to bind VEGF.

[0444] In some embodiments, the half-life extending moiety is conjugated to one or more free SH groups using any suitable thiol-reactive chemistry, including but not limited to maleimide chemistry, or conjugating a polymer hydrazide or polymer amine to the carbohydrate portion of the antibody after prior oxidation. In some embodiments, maleimide conjugation is used. In some embodiments, conjugation occurs on a cysteine ​​that occurs naturally or is introduced by genetic engineering.

[0445] In some embodiments, the polymer is covalently linked to a cysteine ​​residue introduced into an anti-VEGF-A antibody by site-directed mutagenesis. In some embodiments, the cysteine ​​residue is used in the Fc portion of the antibody. In some embodiments, sites for introducing cysteine ​​residues into the Fc region are provided in WO 2013 / 093809, US 7,521,541, WO 2008 / 020827, US 8,008,453, US 8,455,622, and US2012 / 0213705, which are incorporated herein by reference for all purposes. In some embodiments, the cysteine ​​mutations are Q347C (EU numbering) and L443C, referring to human IgG heavy chains numbered by EU.

[0446] In some embodiments, a conjugate of an antibody and a high MW polymer used as a half-life extender is provided. In some embodiments, a conjugate comprising an antibody conjugated to a zwitterionic polymer is provided, wherein the polymer is formed by one or more monomeric units, and wherein at least one monomeric unit has a zwitterionic group. In some embodiments, the zwitterionic group is phosphorylcholine.

[0447] In some embodiments, one of the monomer units is HEMA-PC. In some embodiments, the polymer is synthesized from a single monomer, which is HEMA-PC.

[0448] In some embodiments, some antibody conjugates have 2, 3 or more polymer arms, wherein the monomer is HEMA-PC. In some embodiments, the conjugates have 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 polymer arms, wherein the monomer is HEMA-PC. In some embodiments, the conjugates have 3, 6 or 9 arms. In some embodiments, the conjugates have 9 arms.

[0449] In some embodiments, the polymer-antibody conjugate has a polymer portion with a molecular weight between 100,000 and 1,500,000Da. In some embodiments, the conjugate has a polymer portion with a molecular weight between 500,000 and 1,000,000Da. In some embodiments, the conjugate has a polymer portion with a molecular weight between 600,000 and 800,000Da. In some embodiments, the conjugate has a polymer portion with a molecular weight between 600,000 and 850,000Da and with 9 arms. When the molecular weight of an antibody conjugated to a given polymer is given, the molecular weight will be the sum of the molecular weight of the protein (including any carbohydrate moieties associated therewith) and the polymer molecular weight.

[0450] In some embodiments, an anti-VEGF-A antibody having a HEMA-PC polymer is provided, the polymer having a molecular weight between about 100 kDa and 1650 kDa as measured by Mw. In some embodiments, the molecular weight of the polymer as measured by Mw is between about 500 kDa and 1000 kDa. In some embodiments, the molecular weight of the polymer as measured by Mw is between about 600 kDa and about 900 kDa. In some embodiments, the molecular weight of the polymer as measured by Mw is 750 kDa plus or minus 15%.

[0451] In some embodiments, the polymer is made of an initiator suitable for ATRP with one or more polymer initiation sites. In some embodiments, the polymer initiation site has a 2-bromoisobutyrate site. In some embodiments, the initiator has 3 or more polymer initiation sites. In some embodiments, the initiator has 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 polymer initiation sites. In some embodiments, the initiator has 3, 6 or 9 polymer initiation sites. In some embodiments, the initiator has 9 polymer initiation sites. In some embodiments, the initiator is OG1786.

[0452] Anti-VEGF-A antibodies can be produced by recombinant expression, including (i) generating recombinant DNA by genetic engineering, (ii) introducing the recombinant DNA into prokaryotic or eukaryotic cells by, for example, but not limited to, transfection, electroporation or microinjection, (iii) culturing the transformed cells, (iv) expressing the antibody, e.g., constitutively or inducibly, and (v) isolating the antibody, e.g., from the culture medium or by harvesting the transformed cells, so as to (vi) obtain a purified antibody.

[0453] Anti-VEGF-A antibodies can be produced by expression in a suitable prokaryotic or eukaryotic host system characterized by the production of pharmacologically acceptable antibody molecules. Examples of eukaryotic cells are mammalian cells such as CHO, COS, HEK 293, BHK, SK-Hip and HepG2. Other suitable expression systems are prokaryotic cells (e.g., E. coli with pET / BL21 expression system), yeast (Saccharomyces cerevisiae and / or Pichia pastoris systems) and insect cells.

[0454] A variety of vectors can be used to prepare the antibodies disclosed herein, and are selected from eukaryotic and prokaryotic expression vectors. Examples of vectors for prokaryotic expression include plasmids, such as but not limited to preset, pet and pad, wherein the promoter for the prokaryotic expression vector includes but is not limited to one or more of lac, trc, trp, recA or araBAD. Examples of vectors for eukaryotic expression include: (i) for expression in yeast, vectors such as, but not limited to, pAO, pPIC, pYES or pMET, using promoters such as, but not limited to, AOX1, GAP, GAL1 or AUG1; (ii) for expression in insect cells, vectors such as, but not limited to, pMT, pAc5, pIB, pMIB or pBAC, using promoters such as, but not limited to, PH, p10, MT, Ac5, OpIE2, gp64 or polh, and (iii) for expression in mammalian cells, vectors such as, but not limited to, pSVL, pCMV, pRc / RSV, pcDNA3 or pBPV, and, in one aspect, vectors derived from viral systems, such as, but not limited to, vaccinia virus, adeno-associated virus, herpes virus or retrovirus, using promoters such as, but not limited to, CMV, SV40, EF-1, UbC, RSV, ADV, BPV and β-actin.

[0455] Methods for conjugating proteins to polymers

[0456] In some embodiments, a method for preparing a therapeutic protein-half-life extending moiety conjugate is provided, the method having the step of conjugating a therapeutic protein with a half-life extending moiety to provide a therapeutic protein-half-life extending moiety conjugate, wherein the therapeutic protein has a cysteine ​​residue added by recombinant DNA technology, and the half-life extending moiety has a thiol-specific reactive group selected from the group of maleimide, vinyl sulfone, o-dithiopyridinium and iodoacetamide.

[0457] In some embodiments, a method for preparing an anti-VEGF antibody conjugate (e.g., KSI-301) from OG1950 is provided. The method comprises reducing the OG1950 protein with a 30x molar excess of TCEP reducing agent. After reduction, the antibody is oxidized to produce a deblocked OG1950 antibody, wherein disulfide bonds between and within the light and heavy chains naturally present in the antibody are formed. OG1950 is then conjugated by adding an excipient and adding a 3-10x molar excess of a maleimide biopolymer. The biopolymer is linked to the OG1950 antibody via a covalent thiol ether bond. After conjugation, the anti-VEGF antibody conjugate, e.g., KSI-301, is purified to remove unconjugated antibody and polymer.

[0458] The above proteins and methods may also vary. Therefore, in some embodiments, a method for preparing a conjugated protein (which need not be an antibody or an anti-VEGF antibody) is provided. The method comprises reducing one or more cysteines in a protein to form a deblocked protein in a solution. After reducing the one or more cysteines, the deblocked protein is reoxidized to restore at least one disulfide bond in the reduced protein while ensuring that the engineered cysteine ​​residues in the protein remain in a free thiol form to form a reoxidized deblocked protein in solution. At least one excipient is then added to the solution. The excipient reduces polymer-induced protein precipitation. After the excipient is added, a polymer is added to the solution, which is conjugated to the reoxidized deblocked protein at the engineered cysteine ​​residues to form a conjugated protein.

[0459] In some embodiments, the molar excess of the reducing agent can be changed to any amount that works. In some embodiments, a 10, 20, 30, 40, 50, 60, 70, 80, 90x molar excess of reducing agent can be used (it does not have to be TCEP in all embodiments). In some embodiments, any antibody (therapeutic or other) can be used. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15x molar excess of maleimide biopolymer can be used. In some embodiments, the protein to be blocked is excessive than the polymer. In some embodiments, the amount of the protein to be blocked or the protein to be blocked of the reoxidation is less than the amount of the polymer. In some embodiments, the amount of the protein to be blocked or the protein to be blocked of the reoxidation is 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1% of the amount of the polymer. In some embodiments, the polymer used is 2.5-4.5 times the protein, measured in molar excess. In some embodiments, the polymer used is 10-20 times the protein, measured by mass. In some embodiments, the amount of reduced antibody is greater than the amount of polymer. In some embodiments, the amount of polymer is greater than the amount of reduced antibody.

[0460] In some embodiments, a purification step is optional.

[0461] In some embodiments, the method of preparing an antibody conjugate comprises conjugating an anti-VEGF-A antibody to a polymer containing phosphorylcholine. In some embodiments, the method comprises the step of conjugating an anti-VEGF-A antibody to a polymer containing phosphorylcholine. The anti-VEGF-A antibody comprises an amino acid residue added by recombinant DNA technology. In some embodiments, the added amino acid residue is a cysteine ​​residue. In some embodiments, the cysteine ​​residue is added outside the variable region of the antibody. The cysteine ​​residue can be added to the heavy chain or light chain of the antibody.

[0462] In some embodiments, the polymer comprises or consists of a polymer containing phosphorylcholine. In some embodiments, the polymer containing phosphorylcholine comprises a thiol-specific reactive group selected from the group of maleimide, vinyl sulfone, o-disulfide pyridine and iodoacetamide. In some embodiments, the thiol-specific reactive group on the polymer containing phosphorylcholine reacts with a cysteine ​​residue on an anti-VEGF-A antibody to form an antibody conjugate.

[0463] In some embodiments, the protein to be conjugated can be an antibody, an antibody protein fusion, or a binding fragment thereof. In some embodiments, the protein is not an antibody, but an enzyme, a ligand, a receptor, or other protein, or a mutant or variant thereof. In some embodiments, the native protein contains at least one disulfide bond and at least one non-native cysteine.

[0464] In some embodiments, the excipient can be an acid or a base. In some embodiments, the excipient is a detergent, a sugar, or a charged amino acid. In some embodiments, the excipient helps to keep the protein in solution during conjugation with the polymer. In some embodiments, the excipient is added to the solution containing the protein before the polymer is added to the solution containing the protein.

[0465] In some embodiments, the reaction occurs under aqueous conditions between about pH 5 and about pH 9. In some embodiments, the reaction occurs between pH 6.0 and pH 8.5, between pH 6.5 and pH 8.0, or between pH 7.0 and pH 7.5. In some embodiments, the reaction occurs between pH 8 and pH 9.

[0466] In some embodiments, the polymer is conjugated to the protein at 2-37 degrees C. In some embodiments, the conjugation occurs at 0-40 degrees C, 5-35 degrees C, 10-30 degrees C, and 15-25 degrees C. In some embodiments, the polymer is conjugated at 5-10 degrees Celsius.

[0467] In some embodiments, the conjugated proteins described herein can be contacted with ion exchange media or hydrophobic interaction chromatography or affinity chromatography media for purification (to remove the conjugate from the unconjugated). In some embodiments, the ion exchange media, hydrophobic interaction chromatography and / or affinity chromatography media separate the conjugated protein from the free polymer and the reoxidized deblocked protein.

[0468] In some embodiments, the polymers disclosed herein may comprise one or more of the following: a zwitterion, phosphorylcholine, or a PEG linker that bridges the center of the polymer branch point to a maleimide functional group. In some embodiments, any of the polymers provided herein may be added to a protein by the methods provided herein.

[0469] In some embodiments, any of the proteins provided herein can be conjugated to any of the polymers provided herein by one or more of the methods provided herein.

[0470] In some embodiments, the methods provided herein allow for larger scale processing to manufacture and purify protein and / or antibody conjugates. In some embodiments, the volume employed is at least 1 liter, e.g., 1, 10, 100, 1,000, 5,000, 10,000 liters or more. In some embodiments, the amount of antibody conjugate produced and / or purified can be 0.1, 1, 10, 100, 1000, 2000, 2500, 3000 or more grams.

[0471] In some embodiments, the therapeutic protein can be any of the anti-VEGF-A antibodies described herein, which have a cysteine ​​residue added by recombinant DNA technology. In some embodiments, the anti-VEGF antibody heavy chain has the following CDRs: CDRH1: i.e., CDRH1 in SEQ ID NO: 172, CDRH2: i.e., CDRH2 in SEQ ID NO: 173, and CDRH3: i.e., CDRH3 in SEQ ID NO: 174. The heavy chain may also have a threonine (T) at position 221. In some embodiments, the anti-VEGF light chain has the following CDRs: CDRL1: i.e., CDRL1 in SEQ ID NO: 199, CDRL2: i.e., CDRL2 in SEQ ID NO: 200, and CDRL3: i.e., CDRL3 in SEQ ID NO: 201. The anti-VEGF-A light chain may also have a leucine (L) at Kabat position 4.

[0472] In some embodiments, the anti-VEGF-A antibody is an IgG1. In some embodiments, the heavy chain has one or more mutations to modulate effector function. In some embodiments, the mutation occurs at one or more of the following amino acid positions (EU numbering): E233, L234, L235, G236, G237, A327, A330, and P331. In some embodiments, the mutation is selected from the group consisting of: E233P, L234V, L234A, L235A, G237A, A327G, A330S, and P331S (EU numbering). In some embodiments, the mutation is (EU numbering) L234A, L235A, and G237A.

[0473] In some embodiments, the cysteine ​​residues added to the therapeutic protein by recombinant DNA technology should not participate in Cys-Cys disulfide pairing. In this regard, the therapeutic protein can be dimeric. For example, a complete anti-VEGF-A antibody has two light chains and two heavy chains. For example, if a Cys residue is introduced into the heavy chain, the complete antibody will have two such introduced cysteines at the same position, and there is a possibility that these cysteine ​​residues will form intrachain disulfide bonds. If the introduced cysteine ​​residue forms a Cys-Cys disulfide bond or has a tendency to do so, the introduced Cys residue is useless for conjugation. It is known in the art how to avoid positions in the heavy and light chains that will cause intrachain disulfide pairing. See, for example, U.S. Patent Application No. 2015 / 0158952.

[0474] In some embodiments, the cysteine ​​residue introduced by recombinant DNA technology is selected from the group consisting of (EU numbering) Q347C and L443C. In some embodiments, the cysteine ​​residue is L443C (EU numbering, or 449C). In some embodiments, the heavy chain of the antibody has at least one amino acid sequence in SEQ ID NO: 7-13, 19-27, 89, 90, 256-262; the light chain has at least one amino acid sequence in SEQ ID No: 91-93, 28-30.

[0475] In some embodiments, the thiol-specific reactive group is maleimide.

[0476] In some embodiments, the polymeric half-life extending moiety is selected from the group consisting of polyethylene glycol (PEG), branched PEG, (Warwick Effect Polymers; Coventry, UK), polysialic acid (PSA), starch, hydroxyethyl starch (HES), hydroxyalkyl starch (HAS), carbohydrates, polysaccharides, pullulan, chitosan, hyaluronic acid, chondroitin sulfate, dermatan sulfate, dextran, carboxymethyl dextran, polyalkylene oxides (PAO), polyalkylene glycols (PAG), polypropylene glycol (PPG), polyoxazolines, polyacryloylmorpholine, polyvinyl alcohol (PVA), polycarboxylates, polyvinylpyrrolidone, polyphosphazenes, polyoxazolines, polyethylene-co-maleic anhydride, polystyrene-co-maleic anhydride, poly(1-hydroxymethylethylenehydroxymethylformaldehyde) (PHF), zwitterionic polymers, polymers containing phosphorylcholine, and polymers containing 2-methacryloyloxy-2'-ethyltrimethylammonium phosphate (MPC).

[0477] In some embodiments, the half-life extending moiety is a zwitterionic polymer. In some embodiments, the zwitterion is phosphorylcholine, i.e., a polymer containing phosphorylcholine. In some embodiments, the polymer consists of MPC units.

[0478] In some embodiments, the MPC polymer has three or more arms. In some embodiments, the MPC polymer has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 arms. In some embodiments, the MPC polymer has 3, 6, or 9 arms. In some embodiments, the MPC polymer has 9 arms. In some embodiments, the polymer is synthesized with an initiator comprising 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more polymer initiation sites.

[0479] In some embodiments, the molecular weight of the MPC polymer is between about 300,000 and 1,750,000 Da. In some embodiments, the molecular weight of the MPC polymer is between about 500,000 and 1,000,000 Da or between about 600,000 and 900,000 Da.

[0480] In some embodiments, the method for preparing a therapeutic protein-half-life extension part conjugate has an additional step, namely contacting the therapeutic protein with a thiol reducing agent under conditions that produce reduced cysteine ​​sulfhydryl groups. As described above, it is preferred that the cysteine ​​residues added by recombinant DNA technology are unpaired, that is, they do not participate in Cys-Cys intrachain disulfide bonds or do not substantially participate in such bonding. However, it is known that Cys residues that do not participate in such Cys-Cys disulfide bonding and freely conjugated react with free cysteine ​​in the culture medium to form disulfide adducts. See, for example, WO 2009 / 052249. Cysteine ​​so derived will not be available for conjugation. In order to release the newly added cysteine ​​from the disulfide adduct, the purified protein is treated with a reducing agent (e.g., dithiothreitol). However, such treatment with a reducing agent will reduce all cysteine ​​residues in the therapeutic protein, including many native cysteines that participate in interchain and intrachain Cys-Cys disulfide bonds. Native Cys-Cys disulfides are often critical to protein stability and activity and should be reformed. In some embodiments, all native (eg, interchain and intrachain) Cys-Cys disulfides are reformed.

[0481] In order to reform the native interchain and intrachain disulfide residues, after reduction to remove cysteine ​​disulfide adducts, the therapeutic protein is exposed to oxidative conditions and / or an oxidant for a specified period of time, such as overnight. In some embodiments, exposure to ambient air overnight can be used to achieve the reformation of native disulfide bonds. In some embodiments, an oxidant is used to restore native disulfides. In some embodiments, the oxidant is selected from the group consisting of aqueous CuSO4 and dehydroascorbic acid (DHAA). In some embodiments, the oxidant is DHAA. In some embodiments, the range of DHAA used is within the range of 5-30 equivalents. In some embodiments, the range is 10-20 equivalents. In some embodiments, the range is 15 equivalents.

[0482] In some embodiments, the thiol reducing agent is selected from the group consisting of tris[2-carbonylethyl]phosphine hydrochloride (TCEP), dithiothreitol (DTT), dithioerythritol (DTE), sodium borohydride (NaBH4), sodium cyanoborohydride (NaCNBH3), β-mercaptoethanol (BME), cysteine ​​hydrochloride and cysteine. In some embodiments, the thiol reducing agent is TCEP.

[0483] In some embodiments, the thiol reducing agent concentration is 1 to 100-fold molar excess relative to the therapeutic protein concentration. In some embodiments, the thiol reducing agent concentration is 20 to 50-fold molar excess relative to the therapeutic protein concentration. In some embodiments, after incubation with the therapeutic protein, the thiol reducing agent is removed prior to oxidation of the therapeutic protein.

[0484] In some embodiments, the method of conjugating a therapeutic protein to a half-life extending moiety has a further step of purifying the therapeutic protein conjugate after conjugation. In some embodiments, the therapeutic protein conjugate is purified using a technique selected from ion exchange chromatography, hydrophobic interaction chromatography, size exclusion chromatography, and affinity chromatography, or a combination thereof.

[0485] In some embodiments, the therapeutic protein conjugate retains at least 20% of the biological activity relative to the unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate retains at least 50% of the biological activity relative to the unconjugated therapeutic protein. In some embodiments, the therapeutic protein conjugate retains at least 90% of the biological activity relative to the native therapeutic protein.

[0486] In some embodiments, the therapeutic protein conjugate has an increased half-life relative to the unconjugated therapeutic protein. In some embodiments, the half-life of the therapeutic protein conjugate is increased by at least 1.5 times relative to the unconjugated therapeutic protein. In some embodiments, the half-life of the therapeutic protein conjugate is increased by at least 5 times relative to the unconjugated therapeutic protein.

[0487] In some embodiments, the zwitterionic polymer of the method of conjugating a therapeutic protein to a half-life extending moiety is a free radical polymerizable monomer having a zwitterionic group, and the method has a further step of polymerizing the free radical polymerizable zwitterionic monomer in a polymerization medium to provide a polymer, the medium comprising: a free radical polymerizable zwitterionic monomer; a transition metal catalyst M t (q-1)+ , where M t is a transition metal, q is the higher oxidation state of the metal, and q-1 is the lower oxidation state of the metal, where the metal catalyst is represented by Mt (q-1)+ X' (q-1) The salt is provided in the form of a salt wherein X' is a counterion or group, or by providing an inactive metal salt M in its higher oxidation state t q+ X' q and a reducing agent to provide in situ a transition metal catalyst, the reducing agent being capable of reducing the transition metal from an oxidized inactive state to a reduced active state; a ligand; and an initiator.

[0488] In order to function as an ATRP transition metal catalyst, the transition metal should have at least two readily accessible oxidation states separated by one electron, i.e., a higher oxidation state and a lower oxidation state. In ATRP, a reversible redox reaction causes the transition metal catalyst to cycle between a higher oxidation state and a lower oxidation state, while the polymer chain cycles between having a growing chain end and a dormant chain end. See, e.g., U.S. Pat. No. 7,893,173.

[0489] In some embodiments, the free radical polymerizable zwitterionic monomer is selected from the group consisting of:

[0490]

[0491] Where R1 is H or C 1-6 alkyl, ZW is a zwitterion, and n is an integer of 1-6.

[0492] In some embodiments, the free radical polymerizable monomer is

[0493]

[0494] Where R1 is H or C 1-6 Alkyl, R2, R3, R4 are the same or different and are H or C 1-4 Alkyl, X and Y are the same or different and are integers from 1 to 6. In some embodiments, R1, R2, R3 and R4 are each methyl, and X and Y are each 2.

[0495] In some embodiments, the free radical polymerizable monomer is Where R1 is H or C 1-6 Alkyl, R2 and R3 are the same or different and are H or C 1-4 alkyl, R4 is PO4-, SO3- or CO2-, X and Y are the same or different and are integers from 1 to 6. In some embodiments, R1, R2 and R3 are methyl, R4 is PO4-, and X and Y are each 2.

[0496] In some embodiments, the monomer is

[0497] Where R1 is H or C 1-6 alkyl, R2, R3 and R4 are the same or different and are H or C 1-4 alkyl, R5 is PO4-, SO3- or CO2-, X and Y are the same or different and are integers from 1 to 6. In some embodiments, R1, R2, R3 and R4 are methyl, R5 is PO4-, X and Y are 2.

[0498] In some embodiments, the transition metal Mt is selected from the group consisting of Cu, Fe, Ru, Cr, Mo, W, Mn, Rh, Re, Co, V, Zn, Au and Ag. (q-1)+ X' (q-1) Provided in the form of salt. (q-1)+ Selected from the group consisting of: Cu 1+ , Fe 2+ 、Ru 2+ Cr 2+ 、Mo 2+ , W 2+ , Mn 3+ , Rh 3+ 、Re 2+ 、Co + 、V2 + 、Zn + 、Au + and Ag + , X' is selected from the group consisting of halogen, C 1-6 Alkoxy, (SO4) 1 / 2 、(PO4) 1 / 3 、(R7PO4) 1 / 2 , (R72PO4), trifluoromethanesulfonate, hexafluorophosphate, methanesulfonate, arylsulfonate, CN and R7CO2, wherein R7 is H or a linear or branched C 1-6 Alkyl, which may be substituted 1 to 5 times by halogen. t (q-1)+ It is Cu 1+ , X' is Br.

[0499] In some embodiments, M t (q-1)+ In some embodiments, M t q+ X q In some embodiments, the reducing agent is an inorganic compound. In some embodiments, the reducing agent is selected from the group consisting of: sulfur compounds with low oxidation levels, sodium bisulfite, inorganic salts containing metal ions, metals, hydrazine hydrate, and derivatives of these compounds. In some embodiments, the reducing agent is a metal. In some embodiments, the reducing agent is Cu 0 .

[0500] In some embodiments, the reducing agent is an organic compound. In some embodiments, the organic compound is selected from the group consisting of alkylthiols, mercaptoethanol or carbonyl compounds that can be easily enolized, ascorbic acid, acetylacetonate, camphorsulfonic acid, hydroxyacetone, reducing sugars, monosaccharides, glucose, aldehydes and derivatives of these organic compounds.

[0501] In some embodiments, the ligand is selected from the group consisting of: 2,2'-bipyridine, 4,4'-di-5-nonyl-2,2'-bipyridine, 4,4-dinonyl-2,2'-bipyridine, 4,4',4"-tris(5-nonyl)-2,2':6',2"-terpyridine, N,N,N',N',N"-pentamethyldiethylenetriamine, 1,1,4,7,10,10-hexamethyltriethylenetetramine, tris(2-dimethylaminoethyl)amine, N,N-bis(2-pyridine)- ... In some embodiments, the ligand is 2,2'-bipyridine.

[0502] In some embodiments, the initiator has the following structure:

[0503]

[0504] wherein R1 is a nucleophilic reactive group, R2 comprises a linker, and R3 comprises a polymer synthesis initiator moiety having the structure

[0505]

[0506] wherein R4 and R5 are the same or different and are selected from the group consisting of: alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cycloalkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, aryleneoxy, heteroaryl, amino, amido or any combination thereof; Z is halogen, -OR (wherein R is -H, methyl, ethyl, propyl or isopropyl), -SCN or -NCS; and s is an integer between 1 and 20.

[0507] In some embodiments, Z is Br, R4 and R5 are each methyl. In some embodiments, R1 is selected from the group consisting of -NH2, -OH and -SH.

[0508] In some embodiments, R2 is alkyl, substituted alkyl, alkylene, alkoxy, carboxyalkyl, haloalkyl, cycloalkyl, cycloalkyl ether, alkenyl, alkenylene, alkynyl, alkynylene, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, aryleneoxy, heteroaryl, amino, amido, or any combination thereof. In some embodiments, R2 is

[0509]

[0510] wherein X and Y are the same or different and are an integer from 1 to 20. In some embodiments, X and Y are each 4.

[0511] In some embodiments, R3 is

[0512]

[0513] wherein R6, R7 and R8 are the same or different and are selected from the group consisting of

[0514]

[0515] wherein Z is -OR (wherein R is -H, methyl, ethyl, propyl or isopropyl), -SCN, -NCS, -F, -Cl, -Br or -I. In some embodiments, Z is -Br, R6, R7 and R8 are each

[0516]

[0517] In some embodiments, the initiator has the following structure:

[0518]

[0519] wherein A and B are the same or different and are integers from 2 to 12, and Z is any halogen, such as Br. In some embodiments, A and B are each 4.

[0520] In some embodiments, the method further comprises the step of reacting the polymer with a maleimide reagent to provide a polymer having a terminal maleimide. In some embodiments, the maleimide compound is

[0521]

[0522] Pharmaceutical composition

[0523] The therapeutic protein can be incorporated into a pharmaceutical composition with a pharmaceutically acceptable excipient. Pharmaceutical compositions suitable for oral administration can be in the form of discrete units, such as capsules, solutions, syrups, or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions). Excipients suitable for tablets or hard gelatin capsules include lactose, corn starch or its derivatives, stearic acid or its salts. Excipients suitable for soft gelatin capsules include, for example, vegetable oils, waxes, fats, semisolid or liquid polyols, etc. For the preparation of solutions and syrups, excipients that can be used include, for example, water, polyols, and sugars. For the preparation of suspensions, oils (e.g., vegetable oils) can be used to provide oil-in-water or water-in-oil suspensions.

[0524] The pharmaceutical composition may be adapted for intranasal administration where the excipient is a solid, including coarse powders having a particle size, for example, in the range of 20 to 500 microns, which are administered in the manner of snuff, i.e., by rapid inhalation through the nasal passages from a powder container close to the nose. Suitable compositions for administration as nasal sprays or nose drops where the excipient is a liquid include aqueous or oily solutions of the active ingredient. Pharmaceutical compositions suitable for administration by inhalation include fine particle powders or mists which may be generated by various types of metered dose pressurized aerosols, nebulizers or insufflators.

[0525] Pharmaceutical compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions, which may contain antioxidants, buffers, antibacterial agents, and solutes that make the preparations substantially isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents. Excipients that can be used for injection solutions include, for example, water, alcohols, polyols, glycerol, and vegetable oils. The composition may be present in unit dose or multi-dose containers, such as sealed ampoules and vials, and may be stored under freeze-dried (lyophilized) conditions, requiring only the addition of the carried sterile liquid, such as water for injection, immediately before use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets. The pharmaceutical composition may be substantially isotonic, meaning that the osmotic pressure is about 250-400 mOsm / kg water.

[0526] Pharmaceutical compositions may contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavor enhancers, salts (the substance itself may be provided in the form of a pharmaceutically acceptable salt), buffers, coating agents, or antioxidants. In addition to the substance, they may also contain therapeutically active agents. Pharmaceutical compositions may be used in combination with one or more pharmaceutically acceptable excipients. Such excipients may include, but are not limited to, saline solutions, buffered saline solutions (such as phosphate buffered saline solutions), glucose, liposomes, water, glycerol, ethanol, and combinations thereof.

[0527] Antibodies and pharmaceutical compositions containing them can be administered in an effective regimen for treating or preventing a patient's disease, including, for example, oral, intravitreal, intravenous, subcutaneous, intramuscular, intraosseous, intranasal, topical, intraperitoneal, and intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration or routes, etc. In treatment or prevention, the active agent can be administered to an individual as an injectable composition, for example, as a sterile aqueous dispersion. In some embodiments, the agent is isotonic or substantially isotonic.

[0528] For mammals, especially human administration, the dosage of the expected active agent is 0.01 mg / kg body weight, usually about 1 mg / kg. The doctor can determine the actual dosage that is most suitable for the individual, depending on factors including the age, weight, sex and reaction of the individual, the disease or disorder treated, and the age and condition of the individual treated. The above dosage is an exemplary average situation. Of course, there are also situations where higher or lower dosages are needed. In some embodiments, the dosage can be 0.5 to 20 mg / eye, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 mg.

[0529] The dosage can be repeated as needed (e.g., weekly, biweekly, monthly, once every two months, once a quarter, twice a year, once a year). If side effects occur, the dosage and / or dosage frequency can be reduced according to normal clinical practice. In one embodiment, the pharmaceutical composition can be administered once every to thirty days. In one embodiment, the pharmaceutical composition can be administered twice every thirty days. In one embodiment, the pharmaceutical composition can be administered once a week.

[0530] Antibodies and pharmaceutical compositions can be used alone or in combination with other compounds (such as therapeutic compounds or molecules, such as anti-inflammatory drugs, analgesics or antibiotics). Such administration with other compounds can be simultaneous, separate or sequential. The composition can be prepared in a set form, which can include appropriate instructions.

[0531] The antibodies and pharmaceutical compositions disclosed herein can be used to treat or prevent disease, particularly the ocular diseases or disorders described herein.

[0532] Anti-VEGF antibody conjugates or anti-VEGF protein conjugates and pharmaceutical compositions containing them can be formulated in the form of eye drops and / or ointments and administered by ocular, intraocular and / or intravitreal injections, and / or juxta-scleral injections, and / or subretinal injections, and / or subtenon injections, and / or superchoroidal injections, and / or subconjunctival and / or topical administration. Such antibodies and compositions can be delivered by a variety of methods, such as intravitreal delivery as a device and / or reservoir that allows slow release of the compound into the vitreous, including those described in references such as Intraocular Drug Delivery, Jaffe, Ashton and Pearson, editors, Taylor & Francis (March 2006). In one example, the device may be in the form of a micropump and / or a matrix and / or a passive diffusion system and / or an encapsulated chamber that releases the compound over a prolonged period of time (Intraocular Drug Delivery, Jaffe, Ashton and Pearson, editors, Taylor & Francis (March 2006)).

[0533] Preparations for eye, intraocular or intravitreal administration can be prepared by methods known in the art and the ingredients used. The main requirement for effective treatment is appropriate penetration of the eye. Different from the anterior eye diseases that can be delivered locally, retinal diseases require more site-specific methods. Eye drops and ointments rarely penetrate into the back of the eye, and the blood-eye barrier hinders systemically administered drugs from penetrating into the eye tissue. Therefore, the drug delivery method usually selected for the treatment of retinal diseases (such as AMD and CNV) is direct intravitreal injection. Intravitreal injection is usually repeated at intervals, which depends on the patient's condition and the nature and half-life of the drug delivered.

[0534] Therapeutic antibodies and related conjugates are generally placed in a container having a sterile access port, for example, an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle. Such compositions can also be provided in the form of a pre-filled syringe.

[0535] A "stable" formulation is one in which the protein or protein conjugated to a polymer of another half-life extending moiety substantially maintains its physical stability and / or chemical stability and / or biological activity upon storage. "Stable" also refers to a formulation that exhibits little or no signs of instability, including aggregation and / or deamidation. For example, the provided formulation can remain stable for at least two years when stored at an indicated temperature of 5-8°C. Suitable formulations of the anti-VEGF antibody conjugates of the present disclosure are described, for example, in PCT Publication No. WO2017117464, which is incorporated herein by reference in its entirety.

[0536] There are a variety of analytical techniques for measuring protein stability in the art, for example, reviewed in Peptide and Protein Drug Delivery, 247-301 (Vincent Lee ed., New York, NY, 1991) and Jones, 1993 Adv. Drug Delivery Rev. 10: 29-90. Stability can be measured at a selected temperature over a selected time period. In some embodiments, the storage stability of the formulation is at least 6 months, 12 months, 12-18 months or 2 years or more.

[0537] A protein, such as an antibody or fragment thereof, "maintains its physical stability" in a pharmaceutical formulation if it shows no signs of aggregation, precipitation, deamidation, and / or denaturation when assessed visually for color and / or clarity, or when measured by UV light scattering or by size exclusion chromatography.

[0538] A protein "retains its chemical stability" in a pharmaceutical formulation if the chemical stability at a given time is such that the protein is considered to still retain its biological activity. Chemical stability can be assessed by detecting and quantifying chemically altered forms of the protein. Chemical changes can involve size changes (e.g., shearing), which can be assessed using, for example, size exclusion chromatography, SDS-PAGE, and / or matrix-assisted laser desorption ionization / time-of-flight mass spectrometry (MALDI / TOF MS). Other types of chemical changes include charge changes (e.g., occurring as a result of deamidation), which can be assessed by, for example, ion exchange chromatography. For example, if the biological activity of an antibody at a given time is within about 10% (within the error of the assay) of the biological activity exhibited when the pharmaceutical formulation was prepared, as determined in an antigen binding assay, the antibody "retains its biological activity" in a pharmaceutical formulation.

[0539] A protein-polymer conjugate "retains its chemical stability" if the chemical bond between the protein and the polymer remains intact, e.g., it is not hydrolyzed or otherwise disrupted. As described above, the protein portion of the conjugate retains its chemical stability.

[0540] "Isotonic" means that the target preparation has substantially the same osmotic pressure as human blood or the vitreous body injected intravitreally. The osmotic pressure of an isotonic preparation is generally about 250 to 400 mOsm. For example, isotonicity can be measured using a vapor pressure or freezing type osmometer.

[0541] As used herein, "buffer" refers to a buffered solution that resists changes in pH through the action of its acid-base binding components. In some embodiments, the pH of the buffer is from about 3.0 to about 8.0; for example, from about 4.5 to 8; or from about pH 6 to about 7.5; or from about 6.0 to about 7.0, or about 6.5-7.0, or from about pH 7.0 to about 7.5; or from about 7.1 to about 7.4. pH values ​​at any point between the above ranges are also contemplated.

[0542] In some embodiments, "PBS" phosphate buffered saline, Tris-based buffers, and histidine-based buffers are used. In some embodiments, acetate buffers are used.

[0543] In some embodiments, the PBS buffer is composed of at least Na2HPO4, KH2PO4 and NaCl, adjusted to provide an appropriate pH. In some embodiments, the buffer may contain other pharmaceutical excipients, such as KCl and other salts, detergents and / or preservatives, in order to provide a stable storage solution.

[0544] A "preservative" is a compound that may be included in a formulation to substantially reduce bacterial action therein, thereby facilitating the production of, for example, a multi-purpose formulation. Examples of potential preservatives include octadecyldimethylbenzyl ammonium chloride, hexamethylammonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl group is a long-chain compound), and benzethonium chloride. Other types of preservatives include aromatic alcohols such as phenol, butyl alcohol, and benzyl alcohol, alkyl hydroxybenzoates such as methylparaben or propylparaben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol.

[0545] In some embodiments, for safety in human use or animal testing, the preparation should have sufficiently low endotoxin levels. "Endotoxin" is lipopolysaccharide (LPS) derived from the cell membrane of Gram-negative bacteria. Endotoxin consists of a hydrophilic polysaccharide portion covalently linked to a hydrophobic lipid portion (lipid A). Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF. 1991. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 5 (12): 2652-2660. Lipid A is responsible for most of the biological activity of endotoxins, i.e., its toxicity. Endotoxins are shed in large quantities during bacterial cell death and growth and division. They have a high degree of thermal stability and are not destroyed under conventional sterilization conditions. Extreme treatments with heat or pH are necessary, such as 180-250°C and acids or bases exceeding 0.1 M (Petsch D, Anspach F. 2000. Endotoxin removal from protein solutions. J Biotechnol. 76:97-119). Such conditions are of course very harmful to biopharmaceuticals.

[0546] In the biotechnology and pharmaceutical industries, endotoxins may be found in the production process and in the final product. Because bacteria can grow in nutrient-poor media (including water, saline solutions, and buffers), endotoxins are ubiquitous unless preventive measures are taken. Injection of endotoxins into animals or humans can cause a variety of pathophysiological effects, including endotoxin shock, tissue damage, and even death. Ogikubo Y, Ogikubo Y, Norimatsu M, Noda K, Takahashi J, Inotsume M, Tsuchiya M, Tamura Y. 2004. Evaluation of the bacterial endotoxin test for quantifications of endotoxin contamination of porcinevaccines. Biologics 32: 88-93.

[0547] When low concentrations of endotoxin (1 ng / mL) are injected intravenously, febrile reactions and shock are induced in mammals (Fiske JM, Ross A, Van Der Meid RK, McMichael JC, Arumugham. 2001. Method for reducing endotoxin in Moraxella catarrhalis UspA2 protein preparations. J Chrom B. 753: 269-278). All pharmacopoeias set the maximum level of endotoxin for intravenous use of drugs and biological products at 5 endotoxin units (EU) per kg body weight per hour (Daneshiam M, Guenther A, Wendel A, Hartung T, Von Aulock S. 2006. In vitro pyrogen test for toxic or immunomodulatory drugs. J Immunol Method 313: 169-175). EU is a measure of the biological activity of endotoxin. For example, 100 pg of standard endotoxin EC-5 and 120 pg of endotoxin from Escherichia coli O111: B4 have an activity of 1 EU (Hirayama C, Sakata M. 2002. Chromatographic removal of endotoxin from protein solutions by polymer particles. J Chrom B 781: 419-432). In biological research and the pharmaceutical industry, reaching this threshold level has always been a challenge (Berthold W, Walter J. 1994. Protein Purification: Aspects of Processes for Pharmaceutical Products. Biologicals 22: 135-150; Petsch D, Anspach FB. 2000. Endotoxin removal from protein solutions. J Biotech 76: 97-119).

[0548] The presence of endotoxins in drugs delivered by intravitreal injection is particularly concerning. Rycroft performed the first intravitreal injection of a drug (penicillin) in 1945. Rycroft BW. 1945. Penicillin and the control of deep intra-ocular infection. British J Ophthalmol 29(2):57-87. The vitreous is a chamber into which high levels of drugs can be introduced and maintained for relatively long periods of time. The drug concentrations that can be obtained by intravitreal injection far exceed those produced by topical or systemic administration (e.g., intravenous).

[0549] One of the most dangerous complications that may result from an intravitreal injection is endophthalmitis. Endophthalmitis is divided into two categories: infectious and sterile. Infectious endophthalmitis is usually caused by bacteria, fungi, or parasites. Symptoms of infectious endophthalmitis include severe pain, loss of vision, and redness of the conjunctiva and underlying episclera. Infectious endophthalmitis requires urgent diagnosis and treatment. Possible treatments include intravitreal antibiotics and, in some cases, pars plana vitrectomy. Enucleation surgery may be required to remove the blind and painful eye. See, e.g., Christy NE, Sommer A. 1979. Antibiotic prophylaxis of postoperative endophthalmitis. Ann Ophthalmol 11(8): 1261-1265.

[0550] In contrast, sterile endophthalmitis does not involve an infectious agent and can be defined as acute intraocular inflammation of the vitreous cavity that resolves without intravitreal antibiotics and / or vitreoretinal surgery. If vitreous microbiological studies have been performed, they need to be demonstrated to be culture negative to maintain the diagnosis of sterile endophthalmitis. Marticorena J, Romano V, Gomez-Ulla F. 2012 “Sterile Endophthalmitis after Intravitreal Injections” MedInflam.928123.

[0551] It has been observed that intravitreal injection of biologic drugs contaminated with endotoxins can result in sterile endophthalmitis. Marticorena et al. The Food and Drug Administration has approved bevacizumab (Avastin) for the treatment of glioblastoma and metastatic colorectal cancer, advanced nonsquamous non-small cell lung cancer, and metastatic renal cancer. Bevacizumab is also widely used off-label for the treatment of wet AMD. Bevacizumab is supplied by the manufacturer as 100 mg / 4 ml. This solution is not intended for direct intravitreal injection and should be prepared by a pharmacist. Clusters of sterile endophthalmitis have been observed and are theorized to be caused by inadvertent contamination of bevacizumab with endotoxin by the compounding pharmacist.

[0552] In view of the terrible clinical consequences of intravitreal injection of endotoxin, the total amount of endotoxin that can be given to patients by intravitreal administration is very limited. In some embodiments, a solution of an antibody or antibody conjugate having an endotoxin level of no more than 5.0 EU / ml is provided. In some embodiments, the endotoxin level is no more than 1.0 EU / ml. In some embodiments, the endotoxin level is no more than 0.5 EU / ml. In some embodiments, the endotoxin level is no more than 0.2 EU / ml. In some embodiments, the endotoxin level is no more than 2, 1, 0.5, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, or 0.01 EU / ml.

[0553] Two commonly used FDA-approved tests for the presence of endotoxins are the rabbit pyrogen test and the Limulus amebocyte lysate (LAL) assay (Hoffman S et al. 2005. International validation of novel pyrogen tests based on human monocytoid cells J. Immunol. Methods 298: 161-173; Ding JL, Ho BA. 2001. Newera in pyrogen testing. Biotech. 19: 277-281). The rabbit pyrogen test was developed in the 1920s and involves monitoring the temperature rise of rabbits injected with a test solution. However, due to expense and long turnaround time, the use of the rabbit pyrogen test has been greatly reduced in recent years. More common is the LAL test. LAL is derived from the blood of horseshoe crabs and will coagulate after exposure to endotoxins.

[0554] One of the simplest LAL assays is the LAL gel-clotting assay. Essentially, the LAL clotting assay is combined with a serial dilution of the sample of interest. The formation of a gel is directly proportional to the amount of endotoxin in the sample. A series of dilutions is prepared from the sample and the ability of each dilution to form a LAL gel is determined. At a certain point, a negative reaction is included. The amount of endotoxin in the original sample can be estimated by the dilution assay.

[0555] Other LAL tests have also been developed, including turbidimetric LAL assay (Ong KG, Lelan JM, Zeng KF, Barrett G, Aourob M, Grimes CA. 2006. A rapid highly-sensitive endotoxin detection system. Biosensors and Bioelectronics 21: 2270-2274) chromogenic LAL assay (Haishima Y, Hasegawa C, Yagami T, Tsuchiya T, Matsuda R, Hayashi Y. 2003. Estimation of uncertainty in kinetic-colorimetric assay of bacterial endotoxins. J Pharm Biomed Analysis. 32: 495-503). Turbidimetric and chromogenic assays are much more sensitive and quantitative than simple gel-clotting dilution assays.

[0556] In some embodiments, a method for reducing the amount of endotoxin in a composition having an antibody disclosed herein is provided. The method has the following steps: contacting the composition with an affinity chromatography resin that binds the antibody; eluting the antibody from the affinity chromatography resin to form an affinity chromatography eluate having an antagonist; contacting the affinity chromatography eluate with an ion exchange resin that binds the antibody; and eluting the antibody from the ion exchange resin, wherein the antibody eluted from the ion exchange resin is substantially free of endotoxin.

[0557] The above-mentioned method for reducing the amount of endotoxin or other methods or processes described herein can be carried out in the order described in the above steps, or can be optionally carried out by changing the order of steps or even repeating one or more steps. In one embodiment, the method for reducing the amount of endotoxin in the composition is carried out in the order of the steps. In some embodiments, before the affinity chromatography eluent is contacted with the ion exchange resin, the affinity chromatography resin is contacted, washed and eluted in the same order more than once. The method can also include the filtering step using, for example, 0.1 micron, 0.20 micron or 0.45 micron filter, which can be carried out in one or more eluents removed after each resin binding step.

[0558] In some cases, the steps of contacting the composition with an affinity chromatography resin, washing, and eluting the antibodies from the affinity chromatography resin may be repeated more than once, and then contacting the first eluent with an ion exchange resin. In one embodiment, the affinity chromatography resin comprises a recombinant protein A ("r-Protein A") resin. An example of a suitable recombinant protein A resin is MabSelect Sure and Mabselect Sure LX (Cytiva). In another embodiment, a suitable affinity chromatography resin will comprise a protein G chromatography resin. In other embodiments, a suitable affinity chromatography resin comprises a mixed protein A / protein G resin. In some embodiments, a suitable affinity chromatography resin comprises a protein L resin. In other embodiments, a suitable affinity chromatography resin comprises a hydrophobic charge induction resin comprising a 4-mercaptoethylpyridine ligand, such as MEP resin (BioSepra, Saint-Christophe-Cergy, France).

[0559] In some embodiments, the ion exchange resin comprises an anion exchange resin. As known to those skilled in the art, ion exchangers can be based on various materials related to the matrix and the attached charged groups. For example, the following matrices can be used, wherein the materials mentioned can be more or less cross-linked: POROS XS (ThermoFisher), POROS XQ (ThermoFisher), MacroCap Q (Cytiva, Piscataway, NJ), agarose (e.g., Sepharose Sepharose Fast and Sepharose High ), cellulose-based (such as DEAE ), glucanyl (e.g. ), silica-based and synthetic polymer-based. For anion exchange resins, the charged groups covalently attached to the matrix can be, for example, diethylaminoethyl, quaternary aminoethyl and / or quaternary ammonium. In some embodiments, the anion exchange resin comprises a quaternary amine group. An exemplary anion exchange resin having a quaternary amine group for binding anti-M-CSF antibodies is Q resin (Amersham, Piscataway, NJ).

[0560] In other aspects, if the endotoxin level is higher than the desired level after the composition is subjected to the aforementioned anion exchange chromatography step, the composition may alternatively be subjected to a cation exchange resin treatment. In some embodiments, any endotoxin in the composition should have a different binding to the ion exchange resin than the protein in question to allow the protein to be purified from the endotoxin. In this regard, endotoxin is negatively charged and will typically bind to anion exchange resins. If both protein and endotoxin bind to anion exchange resins, purification of one from the other can be achieved by eluting both into different fractions using a salt gradient. The relative binding of a protein to a specific resin can also be changed by changing the pH of the buffer relative to the pI of the protein. In some embodiments, cation exchange chromatography is the only ion exchange chromatography used.

[0561] In some embodiments, if the endotoxin level after the anion exchange resin is too high, the composition can be further subjected to a second ion exchange step, for example, by contacting the composition with a cation exchange resin, followed by a washing step, and then eluting from the ion exchange resin. In some embodiments, the cation exchange resin comprises sulfonic acid groups for binding. An exemplary cation exchange resin is SP Resin FF (Amersham, Piscataway, NJ) POROS XS (CEX) (ThermoFisher). In some embodiments, removal of endotoxins is accomplished using hydrophobic interaction chromatography. In some embodiments, when the endotoxin and mAb have the same or similar charge, hydrophobic interaction chromatography is used. In some embodiments, hydrophobic interaction chromatography can be performed by an exemplary system, such as using Sartobind Phenyl (Sartorius, Gottingen, Germany).

[0562] In some embodiments, after producing an antibody protein solution with a specific endotoxin level, there are many steps before the final preparation of the protein. In some embodiments, the half-life extension portion is conjugated to the protein. The conjugate is then formulated into a final pharmaceutical preparation for injection into the patient. In some embodiments, the conjugate is purified again on an ion exchange resin, which can be a cation exchange resin. In other embodiments, the protein is formulated. In all cases, normal laboratory procedures should be used to prevent endotoxin contaminants from being introduced into protein samples or protein-polymer conjugates.

[0563] In some embodiments, any of the following arrangements are contemplated herein:

[0564] A method for purifying a product using affinity chromatography, the method comprising loading an eluate onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to a target protein; and washing the affinity chromatography matrix with a buffer solution containing a chaotropic agent.

[0565] A method for purifying a product and reducing impurities from a load fluid comprising a protein and one or more impurities by passing the load fluid through an affinity chromatography matrix, followed by at least one wash solution comprising a chaotropic salt, and collecting the protein using an elution solution.

[0566] A method for separating impurities in an eluate containing a target protein, the method comprising loading the eluate containing the target protein onto an affinity chromatography matrix; and washing the affinity chromatography matrix with one or more buffer solutions, the buffer solution comprising one or more of lithium and lithium salts, magnesium and magnesium salts, calcium and calcium salts, and guanidine and guanidine salts.

[0567] A method for producing a product using affinity chromatography, the method comprising loading an eluate containing a target protein onto an affinity chromatography matrix, performing a first wash on the affinity chromatography matrix with a first buffer containing sodium phosphate and salt, and performing a second wash on the affinity chromatography matrix with a second buffer containing a chaotropic agent.

[0568] A method for producing a product using affinity chromatography, the method comprising loading an eluate containing a target protein onto an affinity chromatography matrix, performing a first wash with a first buffer containing Tris and a salt, and performing a second wash with a second buffer containing Tris and a chaotropic agent, wherein the chaotropic agent in the second buffer is different from the salt contained in the first buffer.

[0569] A method for producing a product, the method comprising collecting a loading fluid, wherein the loading fluid comprises a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting the bound target protein; and collecting an eluate, wherein the eluate comprises the target protein.

[0570] A method for producing a product, the method comprising collecting a loading fluid, wherein the loading fluid contains a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, supplying a buffer solution containing a chaotropic salt to the affinity chromatography matrix, eluting the bound target protein; and collecting an eluate, wherein the eluate contains the target protein.

[0571] A method of producing a product, the method comprising: collecting a conjugated protein, wherein the conjugated protein comprises an antibody conjugated to a conjugated polymer, loading the conjugated protein onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the conjugated protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting the conjugated protein, and collecting an eluate, wherein the eluate contains the conjugated protein.

[0572] A method for producing a product, the method comprising washing an affinity chromatography matrix bound to a target protein of interest with a buffer solution comprising a chaotropic salt, eluting and collecting an eluate, wherein the eluate contains the target protein of interest, and removing viral contaminants from the eluate. The method may also include, wherein removing viral contaminants from the eluate includes one or more of low pH inactivation, detergent inactivation, polishing chromatography steps, virus filtration (VF), ultrafiltration (UF) and / or diafiltration (DF). The method may also include, wherein the eluate is further combined with an acceptable pharmaceutical excipient to form a pharmaceutical composition. The method may also include, wherein a buffer solution is added to the pharmaceutical composition. The method may also include, wherein a preservative solution is added to the pharmaceutical composition. The method may also include, wherein the pharmaceutical composition is further refined for intravitreal injection.

[0573] A method for producing a product, comprising washing an affinity chromatography matrix bound to a target protein with a buffer containing a chaotropic salt, removing the chaotropic salt, eluting and collecting an eluate, wherein the eluate contains the target protein.

[0574] A method for producing a product, the method comprising collecting a loading fluid, wherein the loading fluid comprises a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting and collecting an eluate, wherein the eluate comprises the target protein, and removing viral contaminants from the eluate.

[0575] A method for producing a product, the method comprising loading an eluate onto an affinity chromatography matrix, washing with a first wash buffer, washing with a second wash buffer comprising a chaotropic salt, washing with a third wash buffer, wherein the third wash buffer removes the chaotropic salt, eluting with an elution buffer, wherein the eluate is collected, wherein the eluate comprises a protein product. The method may also include, wherein the first wash buffer comprises 50 mM sodium phosphate. The method may also include, wherein the first wash buffer also comprises 250 mM NaCl. The method may also include, wherein the first wash buffer comprises Tris and salt. The method may also include removing viral contaminants from the eluate. The method may also include, wherein removing viral contaminants comprises: one or more of low pH inactivation, detergent inactivation, polishing chromatography steps, virus filtration (VF), ultrafiltration (UF) or diafiltration (DF). The method may also include, wherein the eluate comprises a target protein. The method may also include, wherein the target protein is an antibody. The method may also include, wherein the antibody is further conjugated to a polymer to form an antibody conjugate. The method may also include, wherein the antibody conjugate comprises a bispecific antibody. The method may also include, wherein the bispecific antibody comprises anti-VEGF and anti-IL-6 binding moieties. The method may also include, wherein the antibody conjugate has the following structure:

[0576] wherein: each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; PC is: wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

[0577] A method for producing a product, the method comprising recovering a cell culture supernatant, wherein the cell culture supernatant comprises a target protein, treating the cell culture supernatant to form an eluate, wherein the eluate comprises the target protein, loading the eluate onto an affinity chromatography matrix, washing with a first wash buffer comprising Tris or sodium phosphate, washing with a second wash buffer comprising a chaotropic salt, eluting with an elution buffer, wherein the eluate is collected, wherein the eluate comprises a protein product, inactivating viral contaminants present in the eluate with a low pH viral buffer to obtain a virus-inactivated eluate, filtering the virus-inactivated eluate, subjecting the virus-inactivated eluate to at least one round of ion exchange chromatography, and filtering the virus-inactivated eluate to obtain a retentate, wherein the retentate comprises the target protein. The method may also include, wherein the cell culture supernatant is produced in a bioreactor using an animal component-free cell culture. The method may also include, wherein treating the cell culture supernatant comprises harvesting a cell product from the cell culture. The method may also include, wherein the cell culture is purified to remove cells and cell debris. The method may also include, wherein the eluent comprises clarified cell culture supernatant. A method for purifying a protein using affinity chromatography, the method comprising contacting a loading fluid with a medium, wherein the medium is an affinity chromatography matrix that binds a target protein, washing the medium with a buffer solution comprising a chaotropic agent, wherein the chaotropic agent is a salt, and contacting the washed medium with an elution solution under conditions suitable for eluting the target protein.

[0578] A method for producing a product, the method comprising applying a solution containing a target protein to an affinity chromatography matrix, washing the affinity chromatography matrix with a first buffer, washing the affinity chromatography matrix with a second buffer containing a chaotropic agent, washing the affinity chromatography matrix with a third buffer to remove the chaotropic agent, eluting with an elution buffer, wherein an eluate is collected, wherein the eluate contains the protein product.

[0579] A protein purification system comprises: a column having a first antigen binding protein bound to the column, a phosphate wash buffer containing sodium phosphate and salt, an intermediate wash buffer containing tris, a second wash buffer containing magnesium chloride and an elution buffer containing sodium formate.

[0580] A protein purification system, the system comprising: a column having a first antigen binding protein bound to the column; a first tris wash buffer comprising tris and salt, an intermediate tris wash buffer, a second wash buffer comprising magnesium chloride, and an elution buffer comprising sodium formate. The system may also include, wherein the column comprises a ligand for affinity chromatography. The system may also include, wherein the ligand comprises protein A or protein G. The system may also include, wherein the first wash buffer comprising sodium phosphate and salt has a pH between 5.5 and 9.5. The system may also include, wherein the phosphate wash buffer comprising sodium phosphate and salt comprises about 50mM sodium phosphate. The system may also include, wherein the phosphate wash buffer comprising sodium phosphate and salt comprises about 250mM NaCl. The system may also include, wherein the first tris wash buffer comprises about 50mMTris. The system may also include, wherein the first tris wash buffer also comprises about 250mM NaCl. The system may also include, wherein the intermediate tris wash buffer comprises about 50mM Tris. The system may also include, wherein the pH of the first tris wash buffer is about 7.2. The system may also include, wherein the pH of the second wash buffer is about 7.8. The system may also include, wherein the concentration of magnesium chloride in the second wash buffer is about 2.8 M. The system may also include, wherein the concentration of sodium formate in the elution buffer comprises 10 mM.

[0581] An antibody purification system comprises a column having a protein A resin bound to an antibody, wherein the antibody comprises a light chain and a heavy chain of at least one of SEQ ID NOs: 91-93, 28-30 and at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262, respectively, a chaotropic wash buffer comprising a chaotropic salt, and an elution buffer comprising sodium formate.

[0582] The methods described herein may also include, wherein the protein of interest is a bispecific antibody. The methods described herein may also include, wherein the bispecific antibody is specific for VEGF and IL-6. The methods described herein may also include, wherein the bispecific antibody is specific for VEGF and IL-6. The methods described herein may also include, wherein the protein of interest is an antibody conjugate. The methods described herein may also include, wherein the affinity chromatography matrix is ​​a protein A chromatography matrix. The methods described herein may also include, wherein the chaotropic agent in the buffer solution consists of a magnesium salt. The methods described herein may also include, wherein the concentration of the magnesium salt is between 1.5-3.5M. The methods described herein may also include, wherein the chaotropic agent in the buffer solution consists of a calcium salt. The methods described herein may also include, wherein the concentration of the calcium salt is between 1-3M. The methods described herein may also include, wherein the chaotropic agent in the buffer solution consists of a guanidine salt. The methods described herein may also include, wherein the concentration of the guanidine salt is between 0.05-3M. The methods described herein may also include, wherein the buffer solution further comprises tris. The methods described herein may also include, wherein the concentration of tris in the buffer solution is at least 5mM. The methods described herein may also include, wherein the pH of the buffer solution is greater than 5.5. The methods described herein may also include, wherein the eluate also contains viral impurities. The methods described herein may also include removing viral impurities. The methods described herein may also include inactivating viral impurities. The methods described herein may also include washing the affinity chromatography matrix loaded with the loading fluid with a pre-wash buffer solution before washing with the buffer solution. The methods described herein may also include, after washing with the buffer solution, washing the affinity chromatography matrix loaded with the eluate with a post-wash buffer solution. The methods described herein may also include, wherein the pre-wash buffer solution comprises sodium phosphate. The methods described herein may also include, wherein the pre-wash buffer solution comprises Tris and salt.

[0583] The methods described herein may also include wherein the antibody conjugate has the structure:

[0584] wherein each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; the polymer is bound to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; PC is:

[0585] wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

[0586] The method described herein may also include, wherein the antibody conjugate comprises an anti-VEGF antibody conjugate comprising an anti-VEGF-A light chain and an anti-VEGF-A heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDRH1: CDRH1 in SEQ ID NO: 172, CDRH2: CDRH2 in SEQ ID NO: 173, and CDRH3: CDRH3 in SEQ ID NO: 174, and the anti-VEGF-A antibody light chain comprises CDRL1: CDRL1 in SEQ ID NO: 199, CDRL2: CDRL2 in SEQ ID NO: 200, and CDRL3: CDRL3 in SEQ ID NO: 201. The methods described herein may also include, wherein the anti-VEGF antibody conjugate comprises: an antibody conjugate comprising an anti-VEGF-A immunoglobulin G (IgG) bound to a polymer, the polymer comprising an MPC monomer, wherein the sequence of the anti-VEGF-A antibody heavy chain is at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262, the sequence of the anti-VEGF-A antibody light chain is at least one of SEQ ID NOs: 91-93, 28-30, and wherein the antibody is bound to the polymer at C449. The methods described herein may also include, wherein the target protein of interest is produced by cell culture. The methods described herein may also include, wherein the cell culture comprises CHO cells. The methods described herein may also include, after washing with a buffer solution, the step of washing the affinity chromatography matrix loaded with the eluate with a post-wash buffer solution. The methods described herein may also include washing the affinity chromatography matrix with a buffer solution to remove nucleic acids, endotoxins, defoaming agents, or other small molecules other than the target protein of interest. The methods described herein may also include washing the affinity chromatography matrix with a buffer solution to remove impurities while keeping the target protein of interest bound to the affinity chromatography matrix. The methods described herein may also include washing the affinity chromatography matrix with a buffer solution to remove host cell proteins other than the target protein of interest. The methods described herein may also include, wherein the addition of a chaotropic agent to the buffer solution does not elute the target protein of interest. The methods described herein may also include one or more of viral inactivation, tangential flow filtration, diafiltration, ultrafiltration, ion exchange chromatography, or viral reduction filtration. The methods described herein may also include, wherein the eluent is produced using a cell culture without animal components in a bioreactor. The methods described herein may also include, wherein the product is the target protein. The methods described herein may also include, wherein the impurities include host cell protein impurities.

[0587] Methods described herein may also include, wherein the first wash buffer comprises salt. Methods described herein may also include, wherein the first wash buffer comprises a type based on phosphate. Methods described herein may also include, wherein the first wash buffer comprises sodium phosphate. Methods described herein may also include, wherein the first wash buffer comprises a phosphate between about 0.1 to about 250mM, including about 0.1mM, about 1mM, about 5mM, about 10mM, about 15mM, about 20mM, about 25mM, about 30mM, about 35mM, about 40mM, about 45mM, about 50mM, about 55mM, about 60mM, about 65mM, about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM, about 100mM, about 150mM, about 200mM, about 250mM, or any integer between 0.1 to 250mM. The methods described herein may also include wherein the first wash buffer comprises 10 mM sodium phosphate.

[0588] Methods described herein may also include, wherein the second wash buffer comprises salt. Methods described herein may also include, wherein the second wash buffer comprises a type based on phosphate. Methods described herein may also include, wherein the second wash buffer comprises sodium phosphate. Methods described herein may also include, wherein the second wash buffer comprises a phosphate between about 0.1 to about 2500mM, including about 0.1mM, about 1mM, about 5mM, about 10mM, about 15mM, about 20mM, about 25mM, about 30mM, about 35mM, about 40mM, about 45mM, about 50mM, about 55mM, about 60mM, about 65mM, about 70mM, about 75mM, about 80mM, about 85mM, about 90mM, about 95mM, about 100mM, about 150mM, about 200mM, about 250mM, or any integer between 0.1 to 250mM. The methods described herein may also include wherein the second wash buffer comprises 10 mM sodium phosphate.

[0589] The methods described herein may also include, wherein the wash buffer comprises salt. The methods described herein may also include, wherein the wash buffer comprises a type based on phosphate. The methods described herein may also include, wherein the wash buffer comprises sodium phosphate. The methods described herein may also include, wherein the wash buffer comprises a phosphate between about 0.1 to about 250 mM, including about 0.1 mM, about 1 mM, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 55 mM, about 60 mM, about 65 mM, about 70 mM, about 75 mM, about 80 mM, about 85 mM, about 90 mM, about 95 mM, about 100 mM, about 150 mM, about 200 mM, about 250 mM, or any integer between 0.1 to 250 mM. The methods described herein may also include, wherein the wash buffer comprises 10 mM sodium phosphate.

[0590] In some embodiments, the buffer system can adopt a ...

Claims

1. A method for purifying a product using affinity chromatography, the method comprising: loading the eluate onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the protein of interest; and washing the affinity chromatography matrix with a buffer solution comprising a chaotropic agent.

2. A method for purifying a product and reducing impurities from a load fluid comprising a protein and one or more impurities, the method comprising passing the load fluid through an affinity chromatography matrix, followed by at least one wash solution comprising a chaotropic salt, and collecting the protein using an elution solution.

3. A method for separating impurities in an eluate containing a target protein, the method comprising: The eluate containing the target protein is loaded onto an affinity chromatography matrix; The affinity chromatography matrix is ​​washed with one or more buffer solutions containing magnesium or a magnesium salt.

4. A method for producing a product using affinity chromatography, the method comprising: The eluate containing the target protein is loaded onto the affinity chromatography matrix. performing a first wash on the affinity chromatography matrix with a first buffer comprising sodium phosphate and salt, and The affinity chromatography matrix is ​​subjected to a second wash with a second buffer comprising a chaotropic agent.

5. A method for producing a product using affinity chromatography, the method comprising: The eluate containing the target protein is loaded onto the affinity chromatography matrix. A first wash is performed with a first buffer containing Tris and salt, A second wash is performed with a second buffer containing Tris and a chaotrope, wherein the second buffer chaotrope contains a different salt than that contained in the first buffer.

6. A method for producing a product, the method comprising: (i) collecting a loading fluid, wherein the loading fluid contains a target protein, (ii) loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, (iii) washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, (iv) eluting the bound target protein; and (v) collecting the eluate, wherein the eluate contains the target protein.

7. A method for producing a product, the method comprising: collecting a loading fluid, wherein the loading fluid contains a target protein, The loading fluid is loaded onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, supplying a buffer solution containing a chaotropic salt to the affinity chromatography matrix, Elute the bound target protein; and The eluate is collected, wherein the eluate contains the protein of interest.

8. A method for producing a product, the method comprising: collecting the conjugated protein, wherein the conjugated protein comprises an antibody bound to a conjugated polymer, loading the conjugated protein onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the conjugated protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, elution of the conjugated protein, and The eluate is collected, wherein the eluate contains the conjugated protein.

9. A method for producing a product, the method comprising: The affinity chromatography matrix bound to the target protein is washed with a buffer containing a chaotropic salt, and the eluate is eluted and collected. wherein the eluate contains the target protein of interest, And remove viral contaminants from the eluate.

10. The method of claim 9, wherein removing viral contaminants from the eluate comprises: One or more of low pH inactivation, detergent inactivation, polishing chromatography steps, viral filtration (VF), ultrafiltration (UF) and / or diafiltration (DF).

11. A method for producing a product, the method comprising: The affinity chromatography matrix bound to the target protein is washed with a buffer containing a chaotropic salt, The chaotropic salt is removed, and the eluate is eluted and collected, wherein the eluate contains the target protein of interest.

12. The method according to 11, wherein the eluate is further combined with an acceptable pharmaceutical excipient to form a pharmaceutical composition.

13. The method according to claim 12, wherein a buffer solution is added to the pharmaceutical composition.

14. The method of claim 12, wherein a preservative solution is added to the pharmaceutical composition.

15. The method of claim 12, wherein the pharmaceutical composition is further refined for intravitreal injection.

16. A method for producing a product, the method comprising: collecting a loading fluid, wherein the loading fluid comprises a target protein, loading the loading fluid onto an affinity chromatography matrix, wherein the affinity chromatography matrix binds to the target protein, washing the affinity chromatography matrix with a buffer solution comprising a chaotropic salt, eluting and collecting the eluate, wherein the eluate contains the target protein of interest, and Viral contaminants were removed from the eluate.

17. A method for producing a product, the method comprising: The eluate was loaded onto the affinity chromatography matrix. Wash with first wash buffer, Wash with a second wash buffer containing a chaotropic salt, washing with a third wash buffer, wherein the third wash buffer removes chaotropic salts, Elution is performed with an elution buffer, wherein the eluate is collected, wherein the eluate contains the protein product.

18. The method of claim 17, wherein the first wash buffer comprises 50 mM sodium phosphate. The method of claim 17 , wherein the first wash buffer further comprises 250 mM NaCl.

20. The method of claim 17, wherein the first wash buffer comprises Tris and salt.

21. The method of claim 17, further comprising removing viral contaminants from the eluate.

22. The method of claim 21, wherein removing viral contaminants comprises: One or more of low pH inactivation, detergent inactivation, polishing chromatography step, virus filtration (VF), ultrafiltration (UF) or diafiltration (DF).

23. The method of claim 17, wherein the eluate comprises a protein of interest.

24. The method of claim 23, wherein the protein of interest is an antibody.

25. The method of claim 24, wherein the antibody is further conjugated to a polymer to form an antibody conjugate.

26. The method of claim 24, wherein the antibody conjugate has the structure of formula (I): in: Each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; The polymer is conjugated to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; The PC is: wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and i) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are an integer from 0 to 3000; or ii) wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different such that the sum of n1, n2, n3, n4, n5, n6, n7, n8 and n9 is 2500 plus or minus 15%.

27. The method of claim 25, wherein the antibody conjugate comprises a bispecific antibody.

28. The method of claim 24, wherein the bispecific antibody comprises anti-VEGF and anti-IL-6 binding portions.

29. A method of producing a product, the method comprising: recovering the cell culture supernatant, wherein the cell culture supernatant contains the protein of interest, treating the cell culture supernatant into an eluate, wherein the eluate contains the target protein, The eluate is loaded onto an affinity chromatography matrix. Wash with a first wash buffer containing Tris or sodium phosphate, Wash with a second wash buffer containing a chaotropic salt, eluting with an elution buffer, wherein an eluate is collected, wherein the eluate contains the protein product, inactivating viral contaminants present in the eluate with a low pH viral buffer to obtain a virus-inactivated eluate, filtering the virus-inactivated eluate, The virus-inactivated eluate is subjected to at least one round of ion exchange chromatography, and The virus-inactivated eluate is filtered to obtain a retentate, wherein the retentate contains the protein of interest.

30. The method of claim 29, wherein the cell culture supernatant is produced in a bioreactor using an animal component-free cell culture.

31. The method of claim 29, wherein processing the cell culture supernatant comprises harvesting a cell product from the cell culture.

32. The method of claim 31 , wherein the cell culture is clarified to remove cells and cell debris.

33. The method of claim 29, wherein the eluate comprises clarified cell culture supernatant.

34. A method for purifying a protein using affinity chromatography, the method comprising: The loading fluid is contacted with a medium, wherein the medium is an affinity chromatography matrix that binds the target protein, the medium is washed with a buffer solution containing a chaotropic agent, wherein the chaotropic agent is a salt, and the washed medium is contacted with an elution solution under conditions suitable for eluting the target protein.

35. A method of producing a product, the method comprising: A solution containing the target protein is applied to the affinity chromatography matrix. washing the affinity chromatography matrix with a first buffer, washing the affinity chromatography matrix with a second buffer containing a chaotropic agent, washing the affinity chromatography matrix with a third buffer to remove the chaotropic agent, Elution is performed with an elution buffer, wherein the eluate is collected, wherein the eluate contains the protein product.

36. A protein purification system, the system comprising: a column having a first antigen binding protein bound to the column, Phosphate wash buffer containing sodium phosphate and salt, Intermediate wash buffer containing tris, a second wash buffer comprising magnesium chloride, and Elution buffer containing sodium formate.

37. A protein purification system, the system comprising: a column having a first antigen binding protein bound to the column, a first tris wash buffer comprising tris and salt, Intermediate tris wash buffer, a second wash buffer comprising magnesium chloride, and Elution buffer containing sodium formate.

38. The system of claim 36, wherein the column comprises a ligand for affinity chromatography.

39. The system of claim 36, wherein the ligand comprises Protein A or Protein G.

40. The system of claim 36, wherein the first wash buffer comprising sodium phosphate and salt has a pH between 5.5 and 9.

5.

41. The system of claim 36, wherein the phosphate wash buffer comprising sodium phosphate and salt comprises about 50 mM sodium phosphate.

42. The system of claim 36, wherein the phosphate wash buffer comprising sodium phosphate and salt comprises about 250 mM NaCl.

43. The system of claim 36, wherein the first tris wash buffer comprises about 50 mM Tris.

44. The system of claim 43, wherein the first tris wash buffer further comprises about 250 mM NaCl.

45. The system of claim 36, wherein the intermediate tris wash buffer comprises about 50 mM Tris.

46. ​​The system of claim 36, wherein the pH of the first tris wash buffer is about 7.

2.

47. The system of claim 36, wherein the pH of the second wash buffer is about 7.

8.

48. The system of claim 36, wherein the concentration of magnesium chloride in the second wash buffer is about 2.8 M.

49. The system of claim 36, wherein the concentration of sodium formate in the elution buffer comprises 10 mM.

50. An antibody purification system, comprising: A column having a protein A resin bound to an antibody, wherein the antibody comprises a light chain and a heavy chain of at least one of SEQ ID NOs: 91-93, 28-30 and at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262, respectively, and A chaotropic wash buffer comprises a chaotropic salt, and an elution buffer comprises sodium formate.

51. The method of claim 1, wherein the protein of interest is a bispecific antibody.

52. The method of claim 51, wherein the bispecific antibody is specific for VEGF and IL-6.

53. The method of claim 51, wherein the bispecific antibody is OG2072.

54. The method of claim 1, wherein the protein of interest is an antibody conjugate.

55. The method of claim 1, wherein the affinity chromatography matrix is ​​a Protein A chromatography matrix.

56. The method of claim 1, wherein the chaotropic agent in the buffer solution comprises one or more of lithium, lithium salts, magnesium, magnesium salts, calcium, calcium salts, guanidine and / or guanidine salts.

57. The method of claim 56, wherein the concentration of one or more of lithium, lithium salts, magnesium, magnesium salts, calcium, calcium salts, guanidine and / or guanidine salts is between 0.05-3.5 M, respectively.

58. The method of claim 1, wherein the buffer solution further comprises tris.

59. The method of claim 58, wherein the concentration of tris in the buffer solution is at least 5 mM.

60. The method of claim 1, wherein the pH of the buffer solution is greater than 5.

5.

61. The method of claim 3, wherein the eluate further contains viral impurities.

62. The method of claim 61, further comprising removing the viral impurities.

63. The method of claim 62, further comprising inactivating the viral impurities.

64. The method of claim 3, further comprising the step of washing the affinity chromatography matrix loaded with the loading fluid with a pre-wash buffer solution before washing with the buffer solution.

65. The method according to 64, further comprising the step of washing the affinity chromatography matrix loaded with the eluate with a post-wash buffer solution after washing with the buffer solution.

66. A method according to 64, wherein the pre-wash buffer solution comprises sodium phosphate.

67. The method of claim 64, wherein the pre-wash buffer solution comprises Tris and salt.

68. The method of claim 25, wherein the antibody conjugate has a structure of Formula (I), in: Each heavy chain of the anti-VEGF-A antibody is represented by the letter H, and each light chain of the anti-VEGF-A antibody is represented by the letter L; The polymer is conjugated to the anti-VEGF-A antibody via the sulfhydryl group of C443 (EU numbering), which is depicted on one of the heavy chains; The PC is: wherein the curved line represents the point of attachment to the rest of the polymer, wherein X is a) —OR, wherein R is —H, methyl, ethyl, propyl, isopropyl, b) —H, c) any halogen, including —Br, —Cl or —I, d) —SCN, or e) —NCS; and wherein n1, n2, n3, n4, n5, n6, n7, n8 and n9 are the same or different and are integers from 0 to 3000.

69. The method of claim 68, wherein the antibody conjugate comprises an anti-VEGF antibody conjugate comprising an anti-VEGF-A light chain and an anti-VEGF-A heavy chain, wherein the anti-VEGF-A antibody heavy chain comprises CDRH1: CDRH1 in SEQ ID NO: 172, CDRH2: CDRH2 in SEQ ID NO: 173, and CDRH3: CDRH3 in SEQ ID NO: 174, and the anti-VEGF-A antibody light chain comprises CDRL1: CDRL1 in SEQ ID NO: 199, CDRL2: CDRL2 in SEQ ID NO: 200, and CDRL3: CDRL3 in SEQ ID NO:

201.

70. The method of claim 69, wherein the anti-VEGF antibody conjugate comprises: an antibody conjugate comprising anti-VEGF-A immunoglobulin G (IgG) bound to a polymer, the polymer comprising an MPC monomer, wherein the sequence of the anti-VEGF-A antibody heavy chain is at least one of SEQ ID NOs: 7-13, 19-27, 89, 90, 256-262, and the sequence of the anti-VEGF-A antibody light chain is at least one of SEQ ID NOs: 91-93, 28-30, and wherein the antibody is bound to the polymer at C449.

71. The method of claim 1, wherein the target protein of interest is produced by cell culture.

72. The method of claim 71, wherein the cell culture comprises CHO cells.

73. The method according to claim 3, further comprising the step of washing the affinity chromatography matrix loaded with the eluate with a post-wash buffer solution after washing with the buffer solution.

74. The method of claim 3, wherein the affinity chromatography matrix is ​​washed with a buffer solution to remove nucleic acids, endotoxins, antifoaming agents, or other small molecules other than the target protein of interest.

75. The method of claim 3, wherein the affinity chromatography matrix is ​​washed with a buffer solution to remove impurities while maintaining the target protein of interest bound to the affinity chromatography matrix.

76. The method of claim 3, wherein washing the affinity chromatography matrix with a buffer solution removes host cell proteins other than the target protein of interest.

77. The method of claim 4, wherein the addition of a chaotropic agent to a buffer solution does not elute the target protein of interest.

78. The method of claim 3, further comprising one or more of viral inactivation, tangential flow filtration, diafiltration, ultrafiltration, ion exchange chromatography, or viral reduction filtration.

79. The method of claim 3, wherein the eluate is produced in a bioreactor using animal component-free cell culture.

80. The method of claim 3, wherein the product is a protein of interest.

81. The method of claim 3, wherein the impurities comprise host cell protein impurities.

82. The method of claim 17, wherein the first wash buffer comprises 10 mM sodium phosphate.

83. The method of claim 17, wherein the first wash buffer comprises a phosphate-based species.

84. The method of claim 17, wherein the first wash buffer further comprises 50 mM NaCl.

85. A method of processing a product, the method comprising: The eluate is loaded onto an affinity chromatography matrix; and Washing with a wash buffer comprising a chaotropic salt to collect an eluate, wherein the concentration of the chaotropic salt increases from a first concentration to a second concentration, wherein the eluate is collected in at least one fraction, wherein the at least one fraction comprises the product of interest.

86. The method of claim 85, wherein the concentration of the first concentration of the chaotropic salt is 0 M, wherein the concentration of the second concentration of the chaotropic salt is 4.0 M.

87. The method of claim 85, wherein the chaotropic salt is one or more of lithium, a lithium salt, magnesium, a magnesium salt, calcium, a calcium salt, guanidine, and / or a guanidine salt.

88. The method of claim 87, wherein the chaotropic salt is selected from the group consisting of magnesium chloride, calcium chloride, lithium chloride, and guanidine hydrochloride.

89. The method of claim 1, wherein the buffer solution further comprises one or more of acetate, citrate, ACES, BES, Bicine, HEPES, MES, MOPS, MOPSO, TAPS, Tricine, Bis-Tris, Bis-Tris propane, arsenate, CAPS, CAPSO, CHES, glycine, bisglycine, imidazole, PIPES, TEA, or TES.

Citation Information

Cited By

  • Omoflaibro antigen stock solution and preparation method of Omoflaibro antigen stock solution

    CN119454939A

  • Production method of Oumoprayer's monoclonal antibody stock solution and Oumoprayer's monoclonal antibody stock solution

    CN119524125A